[0001] This application claims the benefits of U.S. Provisional Application No. 62/833,965, filed April 15, 2019 and U.S. Provisional Application No. 62/912,219, filed October 8, 2019, the entire contents of which are incorporated herein by reference.

1 FIELD

[0002] Provided herein are compositions, devices and methods for modifying skin function and appearance and protecting skin by the formation of a layer over the skin of a subject that forms quickly and that is thin, durable, non-invasive, easy to use, and with skin-like properties.

2 BACKGROUND

[0003] International Application Publication Nos. WO2012/030984, W02012/030993, WO2013/044098 and WO2017/083398 disclosed compositions and polymer materials suitable for skincare products for cosmetic and therapeutic applications. The synthesis and application of an elastic, wearable crosslinked polymer layer (XPL) that mimics the properties of normal, youthful skin have been described in Yu, Betty, et al.“An elastic second skin,” Nature materials 15.8 (2016): 911.

[0004] Current methods for reducing the appearance of skin imperfections, for example wrinkles, fine lines, age spots, enlarged pores or scars, include invasive and non-invasive methods and compositions. Invasive techniques, such as surgery, fillers {e.g., Restylane, Juvederm), laser resurfacing or Botox®, may provide longer-lasting effects and can treat prominent imperfections. However, many consumers either cannot afford or do not wish undergo such drastic cosmetic treatments.

[0005] Examples of non-invasive methods include hiding imperfections by applying a foundation-type make-up to the skin or applying a cosmetic composition that includes an ingredient that may reduce the appearance of the imperfections over time {e g·, an anti-wrinkle cream). Unfortunately, foundation make-up is not durable and cannot reduce the appearance of pronounced skin imperfections, such as deep wrinkles or scars, while cosmetic compositions containing ingredients that may reduce the appearance of an imperfection take time to produce an effect, and also may not reduce the appearance of a pronounced imperfection. In particular, many current cosmetic compositions do not have the required mechanical properties to reduce the appearance of pronounced imperfections.

[0006] High molecular weight polymers, including proteins and polysaccharides, have been used in attempts to develop anti-aging skin care cosmetic compositions (Jachowicz et al, Skin Res. and Tech., 2008, 14:312-319). While these polymers change the physical properties (e.g., elasticity and stiffness) of the skin upon application to the skin, they did not provide the durability to enable natural, repeated facial motion for extended wear. The commercially available polymer materials used in skincare products today do not necessarily provide the elasticity, environmental resistance and skin adhesion for long lasting product performance nor do they provide the aesthetic feel and appearance required by the consumer of cosmetic products.

[0007] The skin acts as a protective barrier from the external environment. When damaged, a cascade of events is triggered to repair to the damaged tissue. Wound healing is a complex process, progressing through four stages (inflammation, proliferation, remodeling, and epithelialization) to repair the damaged area. Although wound healing is a natural process, disruption of the events involved may lead to incomplete healing and further damage to the tissue. Current methods of treating wounds include applying a dressing to the wound to stem bleeding, prevent infection and encourage healing. Wound dressings are often made from breathable material (for example, gauze). Occlusive dressings have been used on wounds, but the effects of occlusion on wounded skin are not completely understood ( see e.g., Leow and

Maibach; J Dermatol Treat, (1997) 8, 139-142). However, current methods of using occlusion on wounded skin is unsatisfactory because current occlusive dressings are not durable, convenient, or long lasting. Moreover, some current occlusive coverings require subjects to wrap plastic around the area to be treated, lowering subject compliance because the treatment is cumbersome and uncomfortable. Lastly, current occlusive coverings do not permit the exposure of the wound to the environment to be modulated based upon the nature of the wound. For example, current occlusive dressings are designed to exclude both air and water, and generally it is not possible to permit exposure to one and not the other. The commercially available polymer materials used in therapeutic products today do not necessarily provide the elasticity,

environmental resistance and skin adhesion for long lasting product performance nor do they provide the aesthetic feel and appearance required by the consumer of therapeutic products. [0008] Accordingly, there remains a need for compositions, devices and methods for modifying skin function and appearance and protecting skin.

[0009] Microencapsulation is a technique by which solid, liquid or gaseous active ingredients are packaged within a second material for the purpose of shielding the active ingredient from the surrounding environment. Thus the active ingredient is designated as the core material whereas the surrounding material forms the shell. This technique has been employed in a diverse range of fields from chemicals and pharmaceuticals to cosmetics and printing. Casanova et at., Journal of microencapsulation 33.1 (2016): 1-17 and Dubey etal, Defence Science Journal 59.1 (2009): 82-95.

3 SUMMARY

[0010] The composition provided herein can be used to create a thin film on the skin of a subject in a single application step to the skin of the subject More specifically, a composition provided herein does not have to be stored in multiple compartments, nor mixed with another composition or component before application to the skin. Instead, a single composition can be manufactured, stored in a single compartment, and then applied to the skin of a subject to create a film on the skin of the subject. In certain embodiments, because there is no need to mix a composition provided herein prior to application to the skin, the container comprising a composition provided herein may also include an applicator suitable for application of the composition to the skin. Without being bound by theory, a ligand (see Section 6.1.1) slows down or prevents the cross-linking reaction between the other components of such a single- component formulation. Without being bound by theory, an encapsulating agent (see Section 6.1.2) slows down or prevents the cross-linking reaction between the other components of such a single-component formulation.

[0011] Provided herein is a composition, comprising (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the one unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking.

[0012] Provided herein is a composition, comprising (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking.

[0013] Provided herein is a composition, comprising (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent, wherein the encapsulating agent slows down or prohibits cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane by forming physical or chemical barriers such as microcapsules between the transition metal and hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking.

[0014] Provided herein is a composition, comprising (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent, wherein the encapsulating agent slows down or prohibits cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane by forming physical or chemical barriers such as microcapsules between the transition metal and hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross- linking.

[0015] In one embodiment, the components provided herein are mixed and stored together as a homogeneous mixture. In one embodiment, the components provided herein are mixed and stored together as a heterogeneous mixture, e.g., a suspension or an emulsion.

[0016] In one embodiment, the composition provided herein can be stored at about -5, 0, 5, 10, 15, 25, 30, 35 or 40 °C without visible changes. In one embodiment, the composition provided herein can be stored for about 30, 60, 90, 120 or 180 days or for about 1, 2 or 3 years without visible changes. In one embodiment, the composition provided herein can be stored with light. In one embodiment, the composition provided herein is stored without light In one embodiment, the composition provided herein is stored in a light-proof container. In one embodiment, the composition provided herein is stored in a sound-proof container. In one embodiment, the composition provided herein is stored in a shock-proof container. In one embodiment, the composition provided herein is stored in a thermo-insulated container. In one embodiment, the composition provided herein is stored in an electromagnetically shielded container.

[0017] In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 60 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 90 days.

In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 120 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 180 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 365 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 730 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 3 years. [0018] In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized

polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 60 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 90 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 120 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 180 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 365 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 730 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 3 years. [0019] In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 60 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 90 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 120 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 180 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 365 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 730 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 3 years.

[0020] In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 60 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 90 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 120 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 180 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 365 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 730 days. In certain embodiments, the encapsulating agent forms physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 3 years.

[0021] In one embodiment, the transition metal is capable of cross-linking the unsaturated organopolymer and the hydride functionalized polysiloxane thereby forming a film over the skin of a subject. In one embodiment, the transition metal is capable of cross-linking the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane thereby forming a film over the skin of a subject. In one embodiment, the composition is configured such that the transition metal is prevented from catalyzing the cross-linking reaction before film-formation is desired (e.g., before application to the skin of a subject) thereby allowing formulation of the catalyst and the functional components in a single composition.

[0022] In one embodiment, the ligand slows down the cross-linking reaction. In one embodiment, the ligand slows down the cross-linking reaction via complexation, or coordination. In one embodiment, the ligand is divinyltetramethyldisilane, linear vinyl siloxane, cyclic vinyl siloxane, tris (vinylsiloxy) siloxane, tetrakis (vinylsiloxy) silane, vinyl ketone, vinyl ester, acetylenic alcohol, sulfide, mercaptan, divinyl disiloxane, divinyl trisiloxane, divinyl tetrasiloxane, divinyl dimethicone, l,5-divinyl-3-phenylpentamethyltrisilxoane, 1,1, 5,5- tetramethyl-3,3-diphenyl-l,5-divinyltrisiloxane, trivinyl trimethylcyclotrisiloxane, tetravinyl tetramethylcyclotetrasiloxane, pentavinyl pentamethylcyclopentasiloxane, hexavinyl

hexamethylcyclohexasiloxane, tris (vinyldimethylsiloxy) silane, tetrakis (vinyldimethylsiloxy) silane, methacryloxypropyl tris(vinyldimethylsiloxy) silane, dimethyl fumarate, dimethyl maleate, methyl vinyl ketone, methoxy butanone, methyl isobutynol, ethyl mercaptan, diethyl sulfide, hydrogen sulfide, or dimethyl disulfide. In one embodiment, the ligand is

divinyltetramethyldisilane, linear vinyl siloxane, cyclic vinyl siloxane, tris (vinylsiloxy) siloxane, or tetrakis (vinylsiloxy) silane. In one embodiment, the ligand is vinyl ketone, vinyl ester, acetylenic alcohol, sulfide, or mercaptan. In one embodiment, the ligand is divinyl disiloxane, divinyl trisiloxane, divinyl tetrasiloxane, or divinyl dimethicone. In one embodiment, the ligand is l,5-divinyl-3-phenylpentamethyltrisilxoane or 1,1, 5,5-tetramethyl-3,3-diphenyl-l,5- divinyltrisiloxane. In one embodiment, the ligand is trivinyl trimethylcyclotrisiloxane, tetravinyl tetramethylcyclotetrasiloxane, pentavinyl pentamethylcyclopentasiloxane, or hexavinyl hexamethylcyclohexasiloxane. In one embodiment, the ligand is tris (vinyldimethylsiloxy) silane, tetrakis (vinyldimethylsiloxy) silane, or methacryloxypropyl tris(vinyldimethylsiloxy) silane. In one embodiment, the ligand is dimethyl fumarate, dimethyl maleate, methyl vinyl ketone or methoxy butanone. In one embodiment, the ligand is methyl isobutynol. In one embodiment, the ligand is ethyl mercaptan, diethyl sulfide, hydrogen sulfide or dimethyl disulfide. In one embodiment, the ligand is butadiene, pentadiene, hexadiene, heptadiene, octadiene. In one embodiment, the ligand is methylbutadiene, methylpentadiene,

methylhexadiene, methylheptadience, methyloctadiene. In one embodiment, the ligand is ethylbutadiene, ethylpentadiene, ethylhexadiene, ethylheptadience, ethyloctadiene. In one embodiment, the ligand is dimethylbutadiene, dimethylpentadiene, dimethylhexadiene, dimethylheptadience, dimethyloctadiene, or xylene.

[0023] In one embodiment, the encapsulating agent slows down or prohibits the cross-linking reaction. In one embodiment, the encapsulating agent slows down or prohibits the cross-linking reaction by forming physical or chemical barriers between the transition metal and the hydride functionalized polysiloxane. In one embodiment, the encapsulating agent slows down or prohibit the cross-linking reaction by physical or chemical barriers such as microcapsules between the transition metal and the hydride functionalized polysiloxane, wherein the microcapsules have shells formed by the encapsulating agent and cores formed by the transition metal or by the hydride functionalized polysiloxane. In one embodiment, the encapsulating agent is a polysaccharide, protein, lipid or synthetic polymer. In one embodiment, the encapsulating agent is a polysaccharide, wherein the polysaccharide is gum, starch, cellulose, cyclodextrine or chitosan. In one embodiment, the encapsulating agent is a protein, wherein the protein is gelatin, casein or soy protein. In one embodiment, the encapsulating agent is a lipid, wherein the lipid is wax, paraffin or oil. In one embodiment, the encapsulating agent is a synthetic polymer, wherein the synthetic polymer is an acrylic polymer, polyvinyl alcohol or polyvinylpyrrolidone), polyester, polyether, polyurethane, polyurea, polyimide, polyamide, polysulfone, polycarbonate, polyphosphate, or their copolymers. In one embodiment, the encapsulating agent is an inorganic material. In one embodiment, the encapsulating agent is an inorganic material, wherein the inorganic material is a silicate, clay or polyphosphate. In one embodiment, the encapsulating agent is a biopolymer or biodegradable polymer. In one embodiment, the encapsulating agent is a biopolymer, wherein the biopolymer is starch. In one embodiment, the encapsulating agent is a biodegradable polymer, wherein the biodegradable polymer is chitosan, hyaluronic acid, cyclodextrin, alginate, an aliphatic polyester or a copolymer of lactic and glycolic acids. In one embodiment, the encapsulating agent is an aliphatic polyester, wherein the aliphatic polyester is poly(lactic acid). In one embodiment, the encapsulating agent is a copolymer of lactic and glycolic acids, wherein the copolymer of lactic and glycolic acids is poly(lactic co-glycolic acid). In one embodiment, the encapsulating agent is polyurethane- 1, polyurethane-11, polyurethane- 14, polyurethane-6, polyurethane-2, polyurethane- 18 or their mixtures thereof. In one embodiment, the encapsulating agent is polyurethane- 1. In one embodiment, the encapsulating agent is a self-assembled polymer. In one embodiment, the encapsulating agent is a network- forming inorganic dispersion system. In one embodiment, the encapsulating agent is a network- forming inorganic-organic hybrid system.

[0024] In one embodiment, the activity of the ligand to slow down the cross-linking reaction can be reduced or eliminated by evaporation of the ligand, degradation of the ligand, phase transformation of the ligand, chemical degradation of ligand, deactivation of ligand, use of vibrational energy, or use of electromagnetic waves. In one embodiment, the deactivation of the ligand can be triggered by exposure to a chemical, heat or light. In one embodiment, the chemical is an oxidative agent In one embodiment, the chemical is a reducing agent. In one embodiment, the oxidative agent is oxygen.

[0025] In one embodiment, the activity of the encapsulating agent to slow down or prohibit the cross-linking reaction can be reduced or eliminated by disassembly of the physical or chemical barriers such as microcapsules. In one embodiment, the activity of the encapsulating agent to slow down or prohibit the cross-linking reaction can be reduced or eliminated by mechanical action, acoustic, heat, light, dissolution, diffusion, degradation, use of solvents, pH changes, temperature changes, pressure or a combination thereof. In one embodiment, the mechanical action is rubbing. In one embodiment, the heat causes the evaporation of the encapsulating agent.

[0026] In one embodiment, the activity of the encapsulating agent to slow down or prohibit the cross-linking reaction can be reduced or eliminated by phase transformation of the encapsulating agent, chemical degradation of the encapsulating agent, deactivation of the encapsulating agent, use of vibrational energy, or use of electromagnetic waves. In one embodiment, the deactivation of the encapsulating agent can be triggered by exposure to a sound, chemical, heat or light In one embodiment, the chemical is an oxidative agent In one embodiment, the chemical is a reducing agent In one embodiment, the oxidative agent is oxygen.

[002h In one embodiment, the ligand is a volatile ligand. In one embodiment, the ligand is volatile at about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or 70 °C. In one embodiment, the ligand is volatile at about 20, 25, 30, 35, 40, 45 or 50 °C. In one embodiment, the ligand is volatile at about 20, 25, 30, 35, or 40 °C. In one embodiment, the ligand is volatile at about 35 °C. In one embodiment, the ligand is volatile at about 25 °C.

[0028] In one embodiment, the encapsulating agent is a volatile agent. In one embodiment, the encapsulating agent is volatile at about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or

70 °C. In one embodiment, the encapsulating agent is volatile at about 20, 25, 30, 35, 40, 45 or 50 °C. In one embodiment, the encapsulating agent is volatile at about 20, 25, 30, 35, or 40 °C. In one embodiment, the encapsulating agent is volatile at about 35 °C. In one embodiment, the encapsulating agent is volatile at about 25 °C. [0029] In one embodiment, the volatile ligand is divinyltetramethyldisilane, divinyldisiloxane , divinyltrisiloxane, trivinyl trimethylcyclotrisiloxane, tetravinyl

tetramethylcyclotetrasiloxane, tris (vinyldimethylsiloxy) silane, tetrakis (vinyldimethylsiloxy) silane, butadiene, pentadiene, hexadiene, heptadiene, octadiene, xylene, dimethyl hexadiene, methylbutadiene, dimethyl maleate, methyl vinyl ketone, methyl isobutynol, ethyl mercaptan, diethyl sulfide, hydrogen sulfide, or dimethyl disulfide.

[0030] In one embodiment, the ligand is an electromagnetic-driven ligand. In one embodiment, the electromagnetic-driven ligand is a platinum complex of triazine. In one embodiment, the platinum complex of triazine is tetrakis ( 1 -phenyl- 3 -hexy 1-triazenido) Pt (IV), Pt(II)-phosphine complex, platinum/oxalate complexs, Pt(II)-bis-(diketonates), dicarbonyl- Pt(IV)R3 complex, or sulfoxide-Pt(II) complex.

[0031] In one embodiment, the ligand is a heat-sensitive ligand. In one embodiment, the heat-sensitive ligand is a platinum complex of triazine. In one embodiment, the platinum complex of triazine is tetrakis ( 1 -phenyl-3 -hexyl-triazeni do) Pt (TV), or Pt(II)-phosphine complex. In one embodiment, the ligand is a cold-sensitive ligand.

[0032] In one embodiment, the ligand is an acoustic-driven ligand. In one embodiment, the ligand is an acoustic-driven ligand, wherein the energy from the acoustic wave is capable to release the catalyst (e.g, platinum) out of the ligand complex.

[0033] In one embodiment, the ligand is 1,3-divinyltetramethyldisiloxane. In one embodiment, the ligand is 1,1,3,3,5,5-hexamethyl-l,5-divinyltrisiloxane. In one embodiment, the ligand is l,5-divinyl-3-phenylpentamethyltrisiloxane. In one embodiment, the ligand is 1,1,5,5-tetramethyl-3,3-diphenyl-l,5-divinyltrisiloxane. In one embodiment, the ligand is 1,3,5- trivinyl-l,3,5-trimethylcyclotrisiloxane. In one embodiment, the ligand is 2, 4,6,8- tetramethyltetravinylcyclotetrasiloxane. In one embodiment, the ligand is 1,3,5,7,9-pentamethyl- 1,3,5,7,9-pentavinylcyclopentasiloxane. In one embodiment, the ligand is

tris(vinyldimethylsiloxy)methylsilane. In one embodiment, the ligand is

tetrakis(vinyldimethylsiloxy)silane. In one embodiment, the ligand is

methacryloxypropyltris(vinyldimethylsiloxy)silane. In one embodiment, the ligand is 1,2- divinyltetramethyldisilane. In one embodiment, the ligand is methyl vinyl ketone. In one embodiment, the ligand is dimethyl maleate. In one embodiment, the ligand is dimethyl fumarate. In one embodiment, the ligand is (3E)-4-methoxy-3-buten-2-one. In one embodiment, the ligand is (E)-2-ethylhex-2-enal. In one embodiment, the ligand is pent-l-en-3-one. In one embodiment, the ligand is maleic acid. In one embodiment, the ligand is 1,5-hexadiene, 1,4- hexadiene, 2,4-hexadiene.

[0034] In one embodiment, in the ligand is a polymer having at least one unsaturated group, a function group with one lone-pair electrons or a function group with ability to function as an electron donor. In one embodiment, the ligand is divinyldisiloxane.

[0035] In one embodiment, in the ligand is a platinum poison.

[0036] In one embodiment, the ligand is a siloxane polymer having at least one unsaturated group. In one embodiment, in the ligand is a vinyl-containing siloxane polymer. In one embodiment, the ligand is a divinyl-containing siloxane polymer. In one embodiment, the ligand is a divinyl-containing disiloxane. In one embodiment, the ligand is divinyl trisiloxane or divinyl tetrasilxoane.

[0037] In one embodiment, the transition metal is platinum.

[0038] In one embodiment, the molar ratio of transition metal to ligand is between about 10:1 to about 1:10000. In one embodiment, the molar ratio of transition metal to ligand is between about 1 :250 to about 1:750. In one embodiment, the molar ratio of transition metal to ligand is between about 1 : 500. In one embodiment, the vinyl to functional hydride molar ratio is between about 1:10 and about 1:100. In one embodiment, the vinyl to functional hydride molar ratio is between about 1:15 and about 1:90. In one embodiment, the vinyl to functional hydride molar ratio is between about 1 :25 and about 1 :70. In one embodiment, the vinyl to functional hydride molar ratio is between about 1:30 and about 1 :60. In one embodiment, the composition has a viscosity of between about 5,000 and 700,000 cSt or cP at about 25°C. In one

embodiment, the molar ratio of hydride functionalized polysiloxane to ligand is between about 10:1 to about 1 : 10000. In one embodiment, the molar ratio of hydride functionalized

polysiloxane to ligand is between about 1 :250 to about 1:750. In one embodiment, the molar ratio of hydride functionalized polysiloxane to ligand is between about 1:500.

[0039] In one embodiment, the molar ratio of transition metal or hydride functionalized polysiloxane to encapsulating agent is between about 10:1 to about 1 : 10000. In one

embodiment, the molar ratio of transition metal to encapsulating agent is between about 1 :250 to about 1:750. In one embodiment, the molar ratio of transition metal to encapsulating agent is between about 1 : 500. In one embodiment, the molar ratio of hydride functionalized polysiloxane to encapsulating agent is between about 1 :250 to about 1:750. In one embodiment, the molar ratio of hydride functionalized polysiloxane encapsulating agent is between about 1:500.

[0040] In one embodiment, the unsaturated organopolymer is vinyl functionalized organopolymer. In one embodiment, the unsaturated organopolymer is alkene functionalized organopolymer. In one embodiment, the unsaturated organopolymer is alkyne functionalized organopolymer. In one embodiment, the vinyl functionalized organopolymer is acrylate organopolymer. In one embodiment, the vinyl functionalized organopolymer is methacrylate organopolymer. In one embodiment, the vinyl functionalized organopolymer is acrylic organopolymer. In one embodiment, the vinyl functionalized organopolymer is methacrylic organopolymer. In one embodiment, the alkene functionalized organopolymer is organopolymer with diene. In one embodiment, the alkene functionalized organopolymer is organopolymer with polyene. In one embodiment, the alkyne functionalized organopolymer is organopolymer with polyyne. In one embodiment, the unsaturated organopolymer is vinyl functionalized

organopolysiloxane.

[0041] In one embodiment, the vinyl functionalized organopolysiloxane is vinyl terminated. In one embodiment, the vinyl functionalized organopolysiloxane is selected from the group consisting of vinyl terminated polydimethylsiloxane; vinyl terminated diphenylsiloxane- dimethylsiloxane copolymers; vinyl terminated polypheny lmethylsiloxane, vinylphenylmethyl terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer; vinyl terminated

trifluoropropylmethylsiloxane-dimethylsiloxane copolymer; vinyl terminated diethylsiloxane- dimethylsiloxane copolymer; vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy terminated; vinylmethylsiloxane-dimethylsiloxane copolymers, silanol terminated;

vinylmethylsiloxane-dimethylsiloxane copolymers, vinyl gums; viny lmethylsiloxane

homopolymers; vinyl T-structure polymers; vinyl Q-structure polymers; monovinyl terminated polydimethylsiloxanes; vinylmethylsiloxane terpolymers; vinylmethoxysilane homopolymers and combinations thereof. In one embodiment, the hydride functionalized polysiloxane is alkyl terminated. In one embodiment, the hydride functionalized polysiloxane is selected from the group consisting of hydride terminated polydimethylsiloxane; polypheny 1- (dimethylhydrosiloxy)siloxane, hydride terminated; methylhydrosiloxane-pheny lmethylsiloxane copolymer, hydride terminated; methylhydrosiloxane-dimethylsiloxane copolymers, trimethylsiloxy terminated; polymethylhydrosiloxanes, trimethylsiloxy terminated; polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer; methylhydrosiloxane-phenyloctylmethylsiloxane terpolymer and combinations thereof. In one embodiment, the hydride functionalized polysiloxane comprises trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymers. In one embodiment, the hydride functionalized polysiloxane has a percent SiH content of between about 3 and about 45%; or a SiH content of between about 0.5 and about 10 mmol/g; or a combination of both. In one embodiment, the hydride functionalized polysiloxane has a viscosity of about 5 to about 11,000 cSt or cP at about 25°C. In one embodiment, the hydride functionalized polysiloxane has at least 2 Si-H units on average.

[0042] In one embodiment, the vinyl functionalized organopolysiloxane is a polymer of formula IIa and the hydride functionalized polysiloxane is a polymer of formula III:

wherein:

R ^1a' , R ^3a' , R ^4a' , R ^5a' , R ^6a' , R ^8a' , R ^9a' and R ^10a ’ ^' are each independently C _1-20 alkyl,

C2-20 alkenyl, C5-10 aryl, hydroxyl or C1-20 alkoxyl;

p and q are each independently an integer from between 10 and 6000;

R ^1b , R ^a , R ^3b , R ^6b , R ^7b and R ^8b are C1-20 alkyl;

R ^4b , R ^5b , R ^9b , R ^10b , R ^7b are each independently selected from the group consisting of hydrogen, C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl and C1-20 alkoxyl, wherein at least two of _R 4b _R 5b _R » _R iob are hydrogen; and

m and n are each independently an integer from between 10 and 6000.

[0043] In one embodiment, the composition further comprises an agent selected from the group consisting of sunscreens, anti-aging agents, anti-acne agents, anti-wrinkle agents, spot reducers, anti-oxidants, and vitamins. In one embodiment, the composition further comprises one or more feel modifiers, tack modifiers, spreadability enhancers, diluents, adhesion modifiers, optics modifiers, particles, volatile siloxanes, emulsifiers, emollients, surfactants, thickeners, solvents, film formers, humectants, preservatives, or pigments. [0044] In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity between about 500 and about 500,000 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity between about 150,000 and about 185,000 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 10,000 cSt or cP at about 25 °C.

[0045] In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity between about 150,000 and about 185,000 cSt or cP at about 25 °C, and the hydride

functionalized polysiloxane has a viscosity of between about 30 and about 100 cSt or cP at about 25°C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of about 45 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized

organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of about 50 cSt or cP at about 25 °C.

[0046] In one embodiment, the composition further comprises a reinforcing constituent In one embodiment, the reinforcing constituent is selected from the group consisting of mica, zinc oxide, titanium dioxide, aluminum oxide, clay, silica, surface treated mica, surface treated zinc oxide, surface treated titanium dioxide, surface treated aluminum oxide, surface treated clay and surface treated silica.

[0047] Provided herein is a method of using a composition provided herein as a single formulation in a one-step method without the need to formulate and store the catalyst separately from other components that form the thin film. Instead, a single formulation can be applied to the skin of a subject. Without being bound by theory, during the application to the skin the ligand is separated from the catalyst (e.g., the transition metal) or from the hydride

functionalized polysiloxane. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by evaporating the ligand. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by absorbing the ligand into another phase. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by absorbing the ligand into the skin of a subject. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by absorbing the ligand into another ingredients forming a complex. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by transforming the ligand into non-complex with the transition metal or from the hydride functionalized polysiloxane. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by using heat. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by cooling the composition. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by using heat generated with a blow-dry. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by using ultrasound. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by using electromagnetic waves. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by using visible light In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by using ultraviolet light. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by using infrared radiation.

[0048] Provided herein is a method of using a composition provided herein as a single formulation in a one-step method without the need to formulate and store the catalyst and the hydride functionalized polysiloxane separately from other components that form the thin film. Instead, a single formulation can be applied to the skin of a subject Without being bound by theory, during the application to the skin the encapsulating agent is separated from the catalyst (e.g., the transition metal) or from the hydride functionalized polysiloxane. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by evaporating the encapsulating agent In one

embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by absorbing the encapsulating agent into another phase. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by absorbing the encapsulating agent into the skin of a subject In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by absorbing the encapsulating agent into other ingredients forming a complex. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by transforming the encapsulating agent into non-microcapsule. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by using heat. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by cooling the composition. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by using heat generated with a blow-dry. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by using ultrasound. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by using electromagnetic waves. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by using visible light. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by using ultraviolet light In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by using infrared radiation.

[0049] In one embodiment, the composition forms a film over the skin of a subject In one embodiment, the composition forms a film over the kerationous substrates of a subject In one embodiment, the composition forms a film over the hair of a subject In one embodiment, the composition forms a film over the mucous membrane surfaces of a subject. In one embodiment, the composition forms a film over a medical device on the skin of a subject. In one embodiment, the composition forms a film over a wearable device on the skin of a subject In one

embodiment, the composition forms a film over the epithelial layers of a subject. In one embodiment, the method comprises decomposing the ligand using visible light and freeing the transition metal. In one embodiment, the method comprises decomposing the ligand using visible light and freeing the hydride functionalized polysiloxane. In one embodiment, the method comprises decomposing the encapsulating agent using visible light and freeing the transition metal. In one embodiment, the method comprises decomposing the encapsulating agent using visible light and freeing the hydride functionalized polysiloxane.

[0050] In one embodiment, the composition provided herein is a single formulation that enables one-step room temperature vulcanizing (RTV). In one embodiment, the formulation provided herein is capable of vulcanizing at room temperature in one-step.

[0051] Provided herein is a method of using a composition provided herein as a single formulation in a one-step method without the need to separate the silane or hydride

functionalized polysiloxane and the catalyst complex from each other before application to the skin of a subject

[0052] Provided herein is a method of using a composition provided herein to form a thin film on the skin of a subject In certain embodiments, such a method comprises applying a composition provided herein to the skin of a subject and separating the ligand from the catalyst (e.g., at least one transition metal) or from the hydride functionalized polysiloxane in the composition such that the cross-linking reaction is accelerated. In certain embodiments, such a composition comprises (a) at least one transition metal; (b) at least one unsaturated

organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, such a composition comprises (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized

polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the separating step involves evaporating the ligand, absorbing the ligand into another phase, absorbing the ligand into the skin of a subject, absorbing the ligand into another ingredients forming a complex, transforming the ligand into non-complex with the transition metal or with the hydride functionalized polysiloxane, heating the composition, cooling the composition, applying ultrasound on the composition, applying electromagnetic waves on the composition, applying visible light on the composition, applying ultraviolet light on the composition, or applying infrared radiation on the composition. Provided herein is a method of using a composition provided herein as a single formulation in a one-step method, comprising separating at least one divinyl disiloxane from platinum in a composition provided herein, such as a composition that comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the divinyl disiloxane at a concentration sufficient to slow down cross- linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. Provided herein is a method of using a composition provided herein as a single formulation in a one-step method, comprising separating at least one divinyl disiloxane from platinum in a composition provided herein, such as a composition that comprises

(a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the divinyl disiloxane at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by evaporating the ligand with or without using heat

[0053] Provided herein is a method of using a composition provided herein to form a thin film on the skin of a subject In certain embodiments, such a method comprises applying a composition provided herein to the skin of a subject and separating the encapsulating agent from the catalyst (e.g, at least one transition metal) or from the hydride functionalized polysiloxane in the composition such that the cross-linking reaction is accelerated. In certain embodiments, such a composition comprises (a) at least one transition metal; (b) at least one unsaturated

organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down or prohibit cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross- linking. In certain embodiments, such a composition comprises (a) at least one transition metal;

(b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down or prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the separating step involves evaporating the encapsulating agent, absorbing the encapsulating agent into another phase, absorbing the encapsulating agent into the skin of a subject, absorbing the encapsulating agent into another ingredients forming a complex, transforming the encapsulating agent into non- microencapsulate with the transition metal or with the hydride functionalized polysiloxane, heating the composition, cooling the composition, applying ultrasound on the composition, applying electromagnetic waves on the composition, applying visible light on the composition, applying ultraviolet light on the composition, or applying infrared radiation on the composition. Provided herein is a method of using a composition provided herein as a single formulation in a one-step method, comprising separating at least polyurethane- 1 from platinum in a composition provided herein, such as a composition that comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the polyurethane- 1 at a concentration sufficient to slow down or prohibit cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross- linking. Provided herein is a method of using a composition provided herein as a single formulation in a one-step method, comprising separating at least polyurethane- 1 from platinum in a composition provided herein, such as a composition that comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the polyurethane- 1 at a concentration sufficient to slow down or prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by evaporating the encapsulating agent with or without using heat.

4 BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 depicts a scheme of a microcapsule.

[0055] Figure 2 depicts the morphology of microcapsules. [0056] Figure 3 depicts a schematic overview over the four principal process steps in microsphere preparation by solvent extraction/evaporation.

[0057] Figure 4 depicts a schematic illustration of the process of micro-encapsulation by spray-drying.

5 TERMINOLOGY, ABBREVIATIONS AND CONVENTIONS

[0058] As used herein, the term“skin” includes body surfaces where normal skin is intact, compromised, or partially or completely lost or removed. Skin further includes skin

imperfections that are commonly considered to be part of“skin.” Examples of skin

imperfections include wrinkles, blemishes, freckles, acne, moles, warts, lesions, scars, tattoos, bruises, skin disfigurements, birth marks, sun damage, age damage, spots (e.g., aging spots), uneven skin tone, sagging skin, cellulite, stretch marks, loss of skin elasticity, skin roughness, enlarged pores, hyperpigmentation, telangiectasia, redness, shine, port wine stain (or nevus flammeus, e.g., nevus fiammeus nuchae or midline nevus fiammeus), and melasma. Skin further includes skin area over which any cosmetic, personal care, medical, paint, or any other foreign material, or a combination thereof, is applied.

[0059] As used herein, the term“layer” includes a covering, film, sheet, barrier, coating, membrane, device or prosthetic skin formed on, sprayed on, or spread over a surface. A layer may be, but is not necessarily, continuous. A layer may, but does not necessarily, have substantially even and/or uniform thickness.

[0060] As used herein, the terms“compromised skin barrier function,”“compromised skin barrier,” or“compromised skin condition” include conditions such as dermatological disorders, skin conditions, and wounds.

[0061] As used herein, the term“dermatological disorders” include disorders that cause at least one symptom on the skin of a subject that may require medical treatment Dermatological disorders may be caused by, among other things, autoimmune disorders and/or environmental factors, such as allergens or chemicals. Examples of symptoms of dermatological disorders include, but are not limited to, itchy skin, dry skin, crusting, blistering, or cracking skin, dermatitis, skin edema, or skin lesion formation. Dermatological disorders include, but are not limited to, eczema, psoriasis, ichthyosis, rosacea, chronic dry skin, cutaneous lupus, lichen simplex chronicus, xeroderma, acne, disease-driven secondary dermatological disorder, and ulcer.

[0062] As used herein, the term“skin conditions” include, but are not limited to, itchy skin, raw skin, dry skin, flaking or peeling skin, blisters on the skin, redness, swelling or inflammation of the skin, and oozing, scabbing or scaling skin. Skin conditions also include compromised skin barrier conditions caused by laser, light or chemical peel treatment

[0063] As used herein, the term“wounds” include injuries to the skin wherein the skin is tom, cut or punctured. Wounds include open wounds, for example, abrasions, lacerations, incisions, punctures, avulsions, or amputations. Wounds also include bum wounds, a type of injury to skin and/or flesh caused by heat, electricity, wind, chemicals, light, radiation or friction.

[0064] As used herein, the terms“treat,”“treating” and“treatment” include both therapeutic and prophylactic / preventative measures.“Treat,”“treating” and“treatment” further include both disorder modifying treatment and symptomatic treatment. Treatment may ameliorate or cause a reduction in the severity and/or duration of at least one symptom of the conditions of compromised skin barrier function. Treatment may also cause a complete recovery from the conditions of compromised skin barrier function.

[0065] As used herein, the terms“apply,”“applied” and“application” includes any and all known methods of contacting or administering compositions provided herein to a subject’s skin or body. The application may be by finger, hand, brush, cotton ball, cotton swab, tissue, pad, sponge, roll-on, spatula, dispenser, drops, spray, splash, foam, mousse, serum, spritz, and other appropriate methods.

[0066] As used herein, the term“subject” includes subjects in which the compositions disclosed herein would be appropriate for use, particularly animals (e.g, a human). Subjects may further include plants, wherein skin refers to the surface over portions of the plant that may benefit from application of the composition, such as flowers, leaves, fruits, stems, branches, bark, and roots.

[006h As used herein, the term“In vitro” means tested or formed not on, in, or over a subject’s skin or body.

[0068] As used herein, the term“routine daily activities” includes instrumental activities of daily living, such as feeding (e.g., eating, drinking, taking medications), continence (e.g., urination and defecation), toileting, dressing, bathing (e.g., shower, bath), grooming, physical ambulation (e.g., walking, using transportation), talking (e.g., using the telephone), preparing food, housekeeping, doing laundry, shopping, and handling finances. Examples of such daily activities are described in Lawton and Brody, Assessment of older people: self-maintaining and instrumental activities of daily living, Gerontologist 1969 Autumn;9(3): 179-86 and Katz et al., Studies of Illness in the Aged. The Index of ADL: A Standardized Measure of Biological and Psychosocial Function, JAMA 1963 Sep 21; 185:914-9.

[0069] As used herein, the term“demanding activities” includes activities that generate elevated level of strain and/or stress on the skin of a subject as compared to the strain or stress generated by routine daily activities. Examples of such demanding activities include exercising, swimming (in sea- water, fresh water or chlorinated water), steam room (heat at high humidity), sauna (heat at low humidity), and other like activities.

[0070] Unless otherwise stated, descriptions of any material used as part of any composition disclosed herein are of such material as an ingredient of the composition prior to mixing, combination and/or reaction of such material with other ingredients) of the composition.

[0071] As used herein, the term“crosslinkable polymer” refers to a polymer that can physically or chemically interact, or both physically and chemically interact, with itself or with other polymers to form a layer on a surface (e.g., skin, leather, glass, plastic, metal) to which it is applied.“Physically interact” refers to the formation of non-covalent interaction (e.g., hydrogen bonds, or electrostatic, polar, ionic, van der Waals, or London forces) between two or more polymer chains.“Chemically interact” refers to the formation of covalent bonds between two or more polymer chains. Covalent bonds may be formed through chemical reactions that occur spontaneously or are initiated by, for example, catalyst, moisture, heat, pressure, change in pH, or radiation. The crosslinkable polymer(s) may be homopolymer or copolymer, for example, random copolymer, alternating copolymer, periodic copolymer, statistical copolymer, block copolymer, graft or grafted copolymer, or a combination thereof. The crosslinkable polymer(s) may be a linear polymer, a branched polymer, a star polymer, a loop polymer, or a combination thereof.

[0072] In preferred embodiments, the composition comprises one or more organopolymer(s).

An“organopolymef” refers to a polymer that includes carbon. In preferred embodiments, the organopolymer is a organopolysiloxane polymer. In preferred embodiments, the organopolysiloxane polymer is a linear siloxane polymer. In preferred embodiments, the organopolysiloxane polymer is a branched siloxane polymer.

[0073] The term“viscosity” refers to the measure of the resistance of a fluid which is being deformed by either shear stress or tensile stress. The viscosity of the composition affects the thickness, spreadability, and evenness and/or uniformity of the layer formed on a substrate. Viscosity may be reported as either dynamic viscosity (also known as absolute viscosity, typical units Pa s, Poise, P, cP) or kinematic viscosity (typical units cm ² /s, Stokes, St, cSt), which is the dynamic viscosity divided by density of the fluid measured. Viscosity ranges of the ingredients disclosed herein are commonly provided by the supplier of the ingredients in units of kinematic viscosity (e.g., cSt), as measured using a Rheometer or a Cannon-Fenske Tube Viscometer.

[0074] Viscosity of a fluid can be measured in vitro, for example, using a rheometer (e.g., linear shear rheometer or dynamic shear rheometer) or a viscometer (also called viscosimeter, e.g., capillary viscometer or rotational viscometer), at an instrument specific strain. For example, Thomas G. Mezger, The Rheology Handbook: For Users of Rotational and Oscillatory Rheometers (2nd Ed.), Vincentz Network, 2006, and American Society for Testing and Materials (ASTM) standards such as ASTM D3835-08, ASTM D2857-95, ASTM D2196-10, and ASTM D2983-09 provide instructions on how to measure the viscosity of a fluid. Viscosity of a fluid is preferably measured in vitro using the Rheometer Viscosity Measurement Test described herein. Density of the fluid may vary with temperature or pressure. Unless otherwise specified, all properties of compositions, layers and/or devices disclosed herein, including viscosity, are measured at room temperature (about 25 °C) and about 1 atmosphere air pressure.

[0075] Anhydrous compositions generally have longer shelf-life than emulsions with similar ingredients, without the need for preservatives against bacteria or mold.“Anhydrous” as used herein refers to containing as an ingredient less than about 10%, less than about 5%, less than about 2%, less than about 1%, or less than about 0.1% water. In some embodiments, the composition is anhydrous. In some embodiments, the composition is an emulsion. In some embodiments, the composition is a dispersion. In some embodiments, the composition is a suspension. In some embodiments, the composition is a paste. In some embodiments, the composition is a semi-solid. In some embodiments, the composition is an ointment. In some embodiments, the composition is a cream. In some embodiments, the composition is a serum. In some embodiments, the composition is a lotion. In some embodiments, the composition is a patch. In certain embodiments, the composition can be spread, sprayed, stenciled stamped, pattered, patched, transferred, layered, covered or spritzed over skin.

[0076] The term“glass transition temperature” refers to the temperature at a transition from the solid state to the liquid state occurs. A glass transition temperature may be reported as a temperature (°C, °F or K). Glass transition temperature can be measured in vitro, for example, using thermal analysis instruments such as a Differential Scanning Calorimeter (DSC) or a Thermogravimetric Analysis (TGA).

[0077] The term“tack-free time” refers to the time when the layer has solidified sufficiently that it no longer sticks to a finger or a substrate that lightly touches it under normal force less than 0.15 Newtons, incurring stickiness to the film.

[0078] The term“adhesive force” refers to the force per unit length required to separate the materials adhered to a standard substrate such as leather or polypropylene or polyurethane. In certain embodiments, the adhesive force of the layer on polypropylene substrate is greater than about 2 N/m.

[0079] The terms“tensile strength,” or“ultimate tensile strength,” or“fracture stress,” or “stress at break,” or“maximum tensile stress,” or“ultimate tensile stress,” or“fracture strength,” or“breaking strength” refer to stress at which a specimen fails via fracture. Tensile strength can be measured on a specimen formed from the composition in vitro, for example, using the Cyclic and Extension Pull Test as described herein.

[0080] The terms“fracture strain,” or“elongation at break,” or“stretchiness at break,” or “strain at break,” or“maximum elongation,” or“maximum strain,” or“maximum stretchiness” or“extension at break” or“maximum extension” refer to strain at which a specimen fails via fracture. Fracture strain can be measured on a specimen formed from the composition in vitro, for example, using the Cyclic and Extension Pull Test as described herein.

[0081] The terms“tensile modulus,” or“Young’s modulus,” or“modulus of elasticity,” or

“stiffness,” or“tensile stiffness,” or“elastic modulus” refer to the force per unit area that is needed to stretch and deform a material beyond the initial length. Tensile modulus is an inverse of compliance, relating to flexibility or deformability of a material beyond the initial length. Tensile modulus can be measured on a specimen formed from the composition in vitro, for example, using the Cyclic and Extension Pull Test as described herein. Tensile modulus can also be measured using the ASTM D5083 Tensile Properties of Reinforced Thermosetting Plastics Using Straight-Sided Specimens standard test.

[0082] The terms“shear modulus” or“modulus of rigidity” or“shear stiffness” refer to the force per unit area that is needed to shear and deform a material beyond the initial length. Shear modulus is be measured on a specimen formed from the composition in vitro by using the ASTM D7175 Determining the Rheological Properties of Asphalt Binder using a Dynamic Shear Rheometer.

[0083] The term“cyclic tensile residual strain” refers to tensile residual strain after cyclic tensile deformation. The term“residual strain” refers to strain that remains in a material after the original cause of stress has been removed. Residual strain may be reported as plastic strain, inelastic strain, non-elastic strain, or viscoelastic strain. The cyclic tensile residual strain can be measured on a specimen formed from the composition in vitro, for example, using the Cyclic and Extension Pull Test as described herein.

[0084] The terms“cyclic tensile hysteresis loss energy” or“cyclic hysteresis strain energy” refer to the excess energy being dissipated as heat when the specimen is subjected to cyclic tensile deformation. Cyclic tensile hysteresis loss energy can be measured on a specimen formed from the composition in vitro, for example, using the Cyclic and Extension Pull Test as described herein.

[0085] The terms“fracture toughness,” or“toughness,” or“tensile toughness,” or “deformation energy,” or“failure energy,” or“fracture energy” refer to the ability to absorb energy of mechanical deformation per unit volume up to the point of failure. Fracture toughness can be measured on a specimen formed from the composition in vitro, for example, using the Cyclic and Extension Pull Test as described herein.

[0086] The term“oxygen transmission rate” or OTR refers to the permeation flux of oxygen through a membrane with certain thickness. Oxygen transmission rate can be measured on a specimen formed from the composition in vitro, for example, using the ASTM F2622 Oxygen Gas Transmission Rate Through Plastic Film and Sheeting Using Various Sensors test.

[0087] The term“oxygen permeance” refers to the permeation flux of oxygen through a membrane with certain thickness, per unit oxygen vapor pressure difference between the membrane (typically in cmHg). Oxygen permeance can be measured on a specimen formed from the composition in vitro, for example, using the ASTM F2622 Oxygen Gas Transmission Rate Through Plastic Film and Sheeting Using Various Sensors test

[0088] The terms“oxygen permeability coefficient” or“intrinsic oxygen permeability” refer to a measure of how fast the oxygen can move through a membrane, which involves a successive process of oxygen sorption into a membrane then followed by oxygen diffusion through the membrane. Oxygen permeability coefficient can be measured on a specimen formed from the composition in vitro, for example, using the ASTM F2622 Oxygen Gas Transmission Rate Through Plastic Film and Sheeting Using Various Sensors test.

[0089] The term“water vapor transmission rate” or WVTR refers to the permeation flux of water vapor through a membrane with certain thickness. Water vapor transmission rate can be measured on a specimen formed from the composition in vitro, for example, using the ASTM F1249 Water Vapor Transmission Rate Through Plastic Film and Sheeting Using a Modulated Infrared Sensor test

[0090] The term“water vapor permeance” refers to the permeation flux of water vapor through a barrier with certain thickness, per unit water vapor pressure difference between one side and the other side of the barrier (typically in cmHg). Water vapor permeance can be measured on a specimen formed from the composition in vitro, for example, using the ASTM F1249 Water Vapor Transmission Rate Through Plastic Film and Sheeting Using a Modulated Infrared Sensor test

[0091] The terms“water vapor permeability coefficient” or“intrinsic water vapor permeability” refer to a measure of how fast water vapor can move through a barrier, which involves a successive process of water vapor sorption into a barrier, followed by water vapor diffusion through the barrier. Water vapor permeability coefficient can be measured on a specimen formed from the composition in vitro, for example, using the ASTM FI 249 Water Vapor Transmission Rate Through Plastic Film and Sheeting Using a Modulated Infrared Sensor test

[0092] The term“transepidermal water loss” refers to the measurement of the quantity of water that passes from inside a body through the epidermal layer to the surrounding atmosphere via diffusion and evaporation processes. Transepidermal water loss is measured by using the Transepidermal Water Loss (TEWL) Measurement Test as described herein. Differences in TEWL measurements caused by age, race, gender, and/or area of the skin of the subject tested are generally less than the standard error in the TEWL measurements.

[0093] The term“skin hydration” refers to the measure of water content of the skin, typically through a Corneometer which is based on capacitance measurement of a dielectric medium near skin surface.

[0094] The term“retraction time” refers to the time taken for the skin to return to its original state after initial deformation by the Suction Cup device. Skin retraction time can be measured, for example, using a cutometer/suction cup pursuant to the procedure as described in H. Dobrev, “Use of Cutometer to assess epidermal hydration,” Skin Research and Technology 2000,

6(4):239-244.

[0095] As used herein, and unless otherwise specified, the term“about,” when used in connection with doses, amounts, or weight percent of ingredients of a composition or a dosage form, means dose, amount, or weight percent that is recognized by those of ordinary skill in the art. Specifically, the term“abouf’ contemplates a dose, amount, or weight percent within 30 %, 25%, 20%, 15%, 10%, or 5% of the specified dose, amount, or weight percent is encompassed.

[0096] The term“encapsulation” refers to a process of encapsulating a material (core) in a shell of a second material (shell/wall material), permanently or temporarily. In some

embodiments, the second material is called“encapsulating agent.” The process results in small capsules as described in Figure 1, termed microcapsules. Microcapsules may be classified as mononuclear, polynuclear or matrix type as described in Figure 2. In some embodiments, the microcapsules have diameters between one micron and a few millimeters. In some embodiments, the microcapsules whose diameters are between about 50 nm to about 2 mm. In some embodiments, the microcapsules whose diameters are between about 2 mm to about 2000 mm. In some embodiments, the microcapsules whose diameters are between about 50 nm to about 1000 nm. In some embodiments, the microcapsules whose diameters are between about 100 nm to about 500 nm. In some embodiments, the microcapsules whose diameters are in the nanometer range are referred to as nanocapsules.

6 DETAILED DESCRIPTION

[0097] A composition provided herein can be used to create a thin film on the skin of a subject in a single application step to the skin of the subject More specifically, a composition provided herein does not have to be mixed with another composition, component, or formulation before application to the skin. Instead, a single composition can be manufactured, stored, and then applied to the skin of a subject to create a film on the skin of the subject. In certain embodiments, because there is no need to mix a composition provided herein prior to application to the skin, the container comprising a composition provided herein may also include an applicator suitable for application of the composition to the skin. Without being bound by theory, a ligand (see Section 6.1) slows down or prevents the cross-linking reaction between the other components of such a single-component formulation. Without being bound by theory, an encapsulating agent slows down or prevents the cross-linking reaction between the other components of such a single-component formulation.

[0098] In certain embodiments, provided herein is a composition comprising (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride

functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking.

[0099] In certain embodiments, provided herein is a composition comprising (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking.

[0100] In certain embodiments, provided herein is a composition comprising (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride

functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down or prohibit cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking.

[0101] In certain embodiments, provided herein is a composition comprising (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down or prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking.

[0102] In one embodiment, the components provided herein are mixed and stored together as a homogeneous mixture. In one embodiment, the components provided herein are mixed and stored together as a heterogeneous mixture, e.g., a suspension or an emulsion.

[0103] In one embodiment, the composition provided herein can be stored at about -5, 0, 5, 10, 15, 25, 30, 35 or 40 °C without visible changes. In one embodiment, the composition provided herein can be stored for about 30, 60, 90, 120 or 180 days or for about 1, 2 or 3 years without visible changes. In one embodiment, the composition provided herein can be stored with light. In one embodiment, the composition provided herein is stored without light In one embodiment, the composition provided herein is stored in a light-proof container. In one embodiment, the composition provided herein is stored in a sound-proof container. In one embodiment, the composition provided herein is stored in a shock-proof container. In one embodiment, the composition provided herein is stored in a thermo-insulated container. In one embodiment, the composition provided herein is stored in an electromagnetically shielded container.

[0104] Provided herein are compositions that can be used to form a film over the skin of a subject. In certain embodiments, the resulting film has certain properties that are described herein. In certain embodiments, the film can be used for cosmetic and therapeutic applications.

[0105] More specifically, provided herein is a composition that can be used as a single formulation to be applied to, e.g., the skin of a subject where it forms a film over the skin of the subject. In certain embodiments, a formulation provided herein comprises at least one transition metal capable of catalyzing the cross-linking reaction between an unsaturated organopolymer and a hydride functionalized polysiloxane. In certain embodiments, a formulation provided herein comprises at least one transition metal capable of catalyzing the cross-linking reaction between a vinyl functionalized organopolysiloxane and a hydride functionalized polysiloxane. Such a formulation can be configured such that the transition metal is prevented from catalyzing the cross-linking reaction before film-formation is desired (e.g., before application to the skin of a subject) thereby allowing formulation of the catalyst and the monomers in a single

composition. In certain embodiments, the formulation can comprise at least one ligand that prevents the transition metal from catalyzing the cross-linking reaction. Once film formation is desired, the activity of the ligand to prevent the cross-linking reaction can be reduced or eliminated by different means depending on the nature of the ligand as described hereinbelow.

In certain embodiments, the formulation can comprise at least one encapsulating agent that prevents the transition metal from catalyzing the cross-linking reaction or the hydride functionalized polysiloxane from freely interacting with unsaturated organopolymer in the vicinity of the transition metal. In certain embodiments, the formulation can comprise at least one encapsulating agent that prevents the transition metal from catalyzing the cross-linking reaction or the hydride functionalized polysiloxane from freely interacting with vinyl functionalized organopolysiloxane in the vicinity of the transition metal. Once film formation is desired, the activity of the encapsulating agent to prevent the cross-linking reaction can be reduced or eliminated by different means depending on the nature of the encapsulating agent as described hereinbelow.

6.1 Compositions For Use With The Methods Provided Herein

[0106] In certain embodiments, the compositions for use with the methods provided herein comprise a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane. In certain embodiments, the compositions for use with the methods provided herein comprise a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane.

[0107] In certain embodiments, the compositions for use with the methods provided herein comprise a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane. In certain embodiments, the compositions for use with the methods provided herein comprise a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane. More detailed information regarding these components is provided in the sections below.

6.1.1 Ligand

[0108] In certain embodiments, the ligand is a chemical or a functional group that binds to a catalyst to form a ligand-catalyst complex. [0109] The following chemicals may be used as the ligand for use with the compositions and methods provided herein: divinyltetramethyldisilane, linear vinyl siloxanes, cyclic vinyl siloxanes, tris (vinylsiloxy) silanes, tetrakis (vinylsiloxy) silanes and beyond, vinyl ketones and vinyl esters, acetylenic alcohols, sulfides and mercaptans including all their derivatives.

Examples of linear vinyl siloxanes include divinyl disiloxane, divinyl trisiloxane, divinyl tetrasiloxane, and beyond (divinyl dimethicone) - including derivatives as examples in divinyl trisiloxane derivatives: l,5-divinyl-3-phenylpentamethyltrisilxoane; 1,1, 5,5-tetramethyl-3,3- diphenyl-l,5-divinyltrisiloxane. Examples of cyclic vinyl siloxanes include trivinyl

trimethylcyclotrisiloxane, tetravinyl tetramethylcyclotetrasiloxane, pentavinyl

pentamethylcyclopentasiloxane, hexavinyl hexamethylcyclohexasiloxane, and beyond - including derivatives as examples in substitution of methyl to alkyl or alkoxyl such as ethyl or ethoxy. Examples of branched (vinylsiloxy) silanes and their derivatives include tris

(vinyldimethylsiloxy) silane, tetrakis (vinyldimethylsiloxy) silane, methacryloxypropyl tris(vinyldimethylsiloxy) silane. Examples of vinyl ketones and vinyl esters and their derivatives include dimethyl fumarate, dimethyl maleate, methyl vinyl ketone, methoxy butanone. Examples of acetylenic alcohols and their derivatives include methyl isobutynol. Examples of sulfides, mercaptans and their derivatives include ethyl mercaptan, diethyl sulfide, hydrogen sulfide, dimethyl disulfide.

[0110] In certain embodiments, the ligand is capable of slowing down the catalytic activity for hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network.

[0111] In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to 99 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to 50 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to 25 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to 10 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 1 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.1 % of the reaction rate without the ligand.

In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.01 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.001 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.0001 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.00001 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.000001 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.0000001 % of the reaction rate without the ligand.

[0112] In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to 99 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to 50 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to 25 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to 10 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 1 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.1 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.01 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.001 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.0001 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.00001 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.000001 % of the reaction rate without the ligand. In certain embodiments, the ligand is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.0000001 % of the reaction rate without the ligand.

[0113] In certain embodiments, the ligand is capable of delaying the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to 99 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to 50 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to 25 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to 10 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 1 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.1 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.01 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.001 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.0001 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.00001 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.000001 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.0000001 % of the reaction rate without the ligand.

[0114] In certain embodiments, the ligand is capable of delaying the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to 99 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to 50 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to 25 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to 10 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 1 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.1 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.01 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.001 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.0001 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.00001 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.000001 % of the reaction rate without the ligand. In certain embodiments, the ligand is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.0000001 % of the reaction rate without the ligand.

[0115] In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 60 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 90 days.

In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 120 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 180 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 365 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 730 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 3 years.

[0116] In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized

polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 60 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 90 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 120 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 180 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 365 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 730 days. In certain embodiments, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 3 years.

[0117] In certain embodiments, the ligand is at a concentration of about 1 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 10 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 20 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 30 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 40 % by weight of the composition. In certain embodiments, the ligand is at a

concentration of about 50 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 60 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 70 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 80 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 90 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 95 % by weight of the

composition. In certain embodiments, the ligand is at a concentration of about 99 % by weight of the composition. In certain embodiments, the ligand is at a concentration of about 99.9 % by weight of the composition.

[0118] In one embodiment, the molar ratio between the ligand and the transition metal is about 10 ⁷ : 1. In one embodiment, the molar ratio between the ligand and the transition metal is about 10 ⁶ : 1. In one embodiment, the molar ratio between the ligand and transition metal is about 10 ⁵ :1. In one embodiment, the molar ratio between the ligand and the transition metal is about 10 ⁴ : 1. In one embodiment, the molar ratio between the ligand and the transition metal is about 10 ³ :1. In one embodiment, the molar ratio between the ligand and the transition metal is about 10 ² : 1. In one embodiment, the molar ratio between the ligand and the transition metal is about 10:1. In one embodiment, the molar ratio between the ligand and the transition metal is about 1:1. In one embodiment, the molar ratio between the ligand and the transition metal is about 1:2. In one embodiment, the molar ratio between the ligand and the transition metal is about 1:5. In one embodiment, the molar ratio between the ligand and the transition metal is about 500: 1. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 10 ⁷ : 1. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 10 ⁶ :1. In one embodiment, the molar ratio between the ligand and hydride functionalized polysiloxane is about 10 ⁵ :1. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 10 ⁴ : 1. In one embodiment, the molar ratio between the ligand and the hydride

functionalized polysiloxane is about 10 ³ :1. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 10 ² : 1. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 10:1. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 1:1. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 1:2. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 1:5. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 500: 1.

[0119] In one embodiment, the ligand is a moderator delaying the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In one embodiment, the ligand is a moderator delaying the hydrosilylation reaction by complexing with the catalyst. In one embodiment, the ligand is a moderator that complexing with the catalyst reversibly. In one embodiment, the ligand is a moderator that dissociates with the catalyst at higher

temperatures, e.g., about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C. In one embodiment, the ligand is a moderator that dissociates with the catalyst by evaporation. In one embodiment, the ligand is a moderator that dissociates with the catalyst by solvent extraction. In one embodiment, the ligand is a moderator that dissociates with the catalyst under acoustic wave. In one embodiment, the ligand is a moderator that dissociates with the catalyst under electromagnetic wave. In one embodiment, the ligand is

divinyltetramethyldisiloxane, trivinyltetramethyltrisiloxane, trimethylcyclotrisiloxane, tetravinyl tetramethylcyclotetrasiloxane, or dimethyl fumarate. Without being bound by theory, upon dissociation of the ligand from the catalyst, the hydrosilylation reaction is no longer delayed.

[0120] In one embodiment, the ligand is a retarder delaying the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In one embodiment, the ligand is a retarder delaying the hydrosilylation reaction by complexing with the catalyst. In one embodiment, the ligand is a retarder that complexing with the catalyst reversibly. In one embodiment, the ligand is a retarder that dissociates with the catalyst at higher temperatures, e.g., about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C. In one embodiment, the ligand is a retarder that dissociates with the catalyst under acoustic wave.

In one embodiment, the ligand is a retarder that dissociates with the catalyst under

electromagnetic wave. In one embodiment, the ligand is divinyltetramethyldisiloxane, trivinyltetramethyltrisiloxane, trimethylcyclotrisiloxane, tetravinyl

tetramethylcyclotetrasiloxanedivinyltetramethyldisiloxane , or dimethyl fumarate. Without being bound by theory, upon dissociation of the ligand from the catalyst, the hydrosilylation reaction is no longer delayed.

[0121] In one embodiment, the ligand is an inhibitor preventing the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In one embodiment, the ligand is an inhibitor preventing the hydrosilylation reaction by complexing with the catalyst In one embodiment, the ligand is an inhibitor that can be removed to reactivate with the catalyst In one embodiment, the ligand is an inhibitor that can be removed at higher temperatures, e.g., about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C. In one embodiment, the ligand is an inhibitor that can be removed with acoustic wave. In one embodiment, the ligand is an inhibitor that can be removed with electromagnetic wave. In one embodiment, the ligand is a low boiling acetylenic alcohol. In one embodiment, the ligand is methyl-isobutanol.

[0122] In certain embodiments, the ligand is capable of slowing down the catalytic activity for hydrosilylation reaction by providing stronger binding interaction to the catalyst, in comparison to other functional moieties, relevant for hydrosilylation.

[0123] In certain embodiments, the ligand is capable of slowing down the catalytic activity for hydrosilylation reaction such that at most about 0.1%, 0.5%, 1%, 2%, 5%, 8% or 10% of the functional moieties are reacted over the period of a day, a week, a month, or a year.

[0124] In certain embodiments, the ligand is capable of stabilization of the catalyst and spatially separation of the catalyst away from one another. This way, the ligand prevents the catalyst to form larger structure, modifying its catalytic activity.

[0125] In certain embodiments, the ligand is capable of stabilization of the catalyst and spatially separation of the catalyst away from hydride functional organopolysiloxanes. This way, the ligand prevents the initiation of intermediate state for hydrosilylation, modifying the catalytic activity of the catalyst

[0126] In certain embodiments, the ligand is capable of stabilization of the catalyst such that at most about 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 5%, 10% or 50% of the catalyst catalyzing the hydrosilylation reaction.

[0127] In certain embodiments, the ligand is capable of slowing down the catalytic activity for hydrosilylation reaction by forming a ligand-catalyst complex.

[0128] In certain embodiments, the ligand is capable of forming a ligand-catalyst complex such that at least about 99.9 %, 99.5 %, 99 %, 98 %, 95 %, 92 %, 90 %, 70 %, 50 %, 25 %, 10% or 5 % of the catalyst forms a ligand-catalyst complex.

[0129] In certain embodiments, the ligand is capable of forming a ligand-catalyst complex such that at least about 99.9 %, 99.5 %, 99 %, 98 %, 95 %, 92 %, 90 %, 70 %, 50 %, 25 %, 10% or 5 % of the ligand forms a ligand-catalyst complex.

[0130] In certain embodiments, at least about 5 % of the ligand forms a ligand-catalyst complex; whereas at least about 99% of the catalyst forms a ligand-catalyst complex.

[0131] In one embodiment, the amount of ligand is sufficient to form a ligand-catalyst complex with about 100 % of the catalyst In certain embodiments, the amount of ligand is about 1.1, 1.2, 1.3, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.4, 3.6, 3.9, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90 or 100 times by mole of the amount required to form a ligand-catalyst complex with about 100 % of the catalyst.

[0132] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by decreasing the concentration of the ligand.

[0133] In certain embodiments, the activity of the ligand to prevent the slow down the catalytic activity for hydrosilylation reaction can be reduced by decreasing the concentration of the ligand by means of evaporation.

[0134] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by decreasing the concentration of the ligand by means of sorption, including physisorption and chemisorption; or adsorption and absorption.

[0135] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by decreasing the concentration of the ligand by means of phase separation including solidification, crystallization, precipitation, surface self- segregation, interface self-segregation, phase extraction, phase inversion, or coacervation.

[0136] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by decreasing the concentration of the ligand by means of ligand migration such as solvent extraction.

[0137] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by decreasing the concentration of the ligand by means of ligand degradation such as chemical oxidation, optical degradation by UV and such.

[0138] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by decreasing the concentration of the ligand by means of ligand reconfiguration such as complexation, charge transfer, electron transfer, proton transfer, radical transfer and else.

[0139] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by the use of ultrasound to supply vibrational energy to knock the catalyst out of the ligand-catalyst complex.

[0140] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by the use of electromagnetic waves that free the catalyst out of the ligand-catalyst complex.

[0141] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by the use of temperature as a form of heat or cold that reduces the interactive strength of the ligand-catalyst complex.

[0142] In certain embodiments, the activity of the ligand to slow down the catalytic activity for hydrosilylation reaction can be reduced by the use of environments that trigger a phase transition in ligand, impacting the stability of ligand-catalyst complex.

[0143] In certain embodiments, the ligand is a volatile ligand, such that its vapor pressure at about 25C is above 0.1 mm Hg. In one embodiment, the volatile ligand is volatile at about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or 70 °C. In one embodiment, the ligand is volatile at about 20, 25, 30, 35, 40, 45 or 50 °C. In one embodiment, the volatile ligand is volatile at about 20, 25, 30, 35, or 40 °C. In one embodiment, the volatile ligand is volatile at about 35 °C. In one embodiment, the volatile ligand is volatile at about 25 °C. [0144] In one embodiment, the volatile ligand provided herein is or includes at least one or more compounds of Formula (la):

wherein

A is R1R2SiO-, -OR ⁴ , -NR ⁵ R ⁶ , -CR ⁷ R ⁸ R ⁹ or C5-io aryl;

B is absent, -R ¹¹ R ¹² Si-0-, -OCONR ¹³ -, -NR ¹⁴ CONR ¹⁵ -, -CO-, -NR ¹⁶ CO-, -SO2- , -0-, -S- or -NR ¹⁷ -;

C is absent, C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, -0-, -NR ¹⁰ - or -S-;

D is absent, -R ¹⁸ R ¹⁹ Si-0-, -OCONR ²⁰ -, -NR ²¹ CONR ²² -, -C0-, -NR ²³ CO-, -SO2- , -0-, -S- or -NR ²⁴ ;

E is C1-20 alkyl, -SiR ²⁵ R ²⁶ R ²⁷ , -OR ²⁸ , -NR ²⁹ R ³⁰ , -CR ³¹ R ³² R ³³ or C5-10 aryl;

R ¹ , R ² , R ³ , R ⁷ , R ⁸ , R ⁹ . R ¹⁰ , R ¹¹ , R ¹² , R ¹⁸ R ¹⁹ , R ²⁵ , R ²⁶ , R ²⁷ , R ³¹ , R ³² and R ³³ are each independently hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or Ci-20 alkoxyl;

R ⁴ , R ⁵ , R ⁶ , R ¹³ , R ¹⁴ , R ¹⁵ , R ¹⁶ , R ¹⁷ , R ²⁰ , R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁸ , R ²⁹ and R ³⁰ are each independently hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl; and

f and g are each independently an integer from about 0 to about 6000.

[0145] In certain embodiments, the volatile ligand can be divinyltetramethyldisilane, divinyldisiloxane, divinyltrisiloxane, trivinyl trimethylcyclotrisiloxane, tetravinyl

tetramethylcyclotetrasiloxane, tris (vinyldimethylsiloxy) silane, tetrakis (vinyldimethylsiloxy) silane, dimethyl maleate, methyl vinyl ketone, methyl isobutynol, ethyl mercaptan, diethyl sulfide, hydrogen sulfide, dimethyl disulfide. Without being bound by theory, the activity of the volatile ligand is reduced by exposure to air, wherein the ligand evaporates and the catalyst is set free to catalyze.

[0146] In certain embodiments, the ligand is an acoustic-driven ligand. In certain embodiments, the acoustic-driven ligand can be any of the above ligands. Without being bound by theory, the activity of the acoustic-driven ligand is reduced by exposure to ultrasound, wherein the ultrasound supplies vibrational energy to knock the catalyst out of the ligand-catalyst complex. Selection of ultrasound ranges of frequency would regulate the rate of hydrosilylation. In certain embodiment, the catalyst and the ligand may not be necessary for hydrosilylation to proceed, as energy from acoustic cavitation may be sufficient to activate free radicals to initiate the hydrosilylation. In one embodiment, acoustic cavitation activates the hydrogen-terminated silicon surfaces for hydrosilylation.

[0147] In certain embodiments, the ligand is an electromagnetic-driven ligand. In certain embodiments, the electromagnetic-driven ligand can be platinum complex of triazine such as tetrakis ( 1 -phenyl-3 -hexyl-triazeni do) Pt (TV), Pt(II)-phosphine complex, platinum/oxalate complexs, Rt(II)-bis-(diketonates), dicarbonyl-Pt(TV)R3 complex, sulfoxide-Pt(II) complex. Without being bound by theory, the activity of the electromagnetic-driven ligand is reduced by exposure to electromagnetic wave, wherein the electromagnetic wave such as light, UV, infrared wave, microwave supplies electromagnetic energy to knock the catalyst out of the ligand-catalyst complex.

[0148] In certain embodiments, the ligand is a heat-sensitive ligand. In certain embodiments, the heat-sensitive ligand can be platinum complex of triazine such as tetrakis (1 -phenyl-3-hexyl- triazenido) Pt (IV), Pt(II)-phosphine complex. Without being bound by theory, the activity of the heat-sensitive ligand is reduced by exposure to direct heat source or heat as a by-product of chemical reaction, microwave, and else; wherein the heat helps release the catalyst out of the ligand-catalyst complex.

[0149] In certain embodiments, the volatile ligand is used in combination with an acoustic- driven ligand, an electromagnetic-driven ligand, or a heat-sensitive ligand. In certain

embodiments, the volatile ligand is used in combination with an acoustic-driven encapsulating agent, an electromagnetic-driven encapsulating agent, or a heat-sensitive encapsulating agent. In certain embodiments, the volatile ligand is divinyldisiloxane.

[0150] In certain embodiments, the volatile ligand is used in combination with non-volatile ligands such as vinyl dimethicone vinyl cyclodimethicone. In certain embodiments, the volatile ligand is divinyldisiloxane.

[0151] In certain embodiments, the volatile ligand is used in combination with volatile ingredients; either miscible with volatile ligand such as disiloxane, trisiloxane, isododecane, xylene, octene, isopropanol, ethanol or immiscible with volatile ligand such as water, esters. [0152] In certain embodiments, examples of the light-sensitive ligand can be found and prepared according to the disclosures of Wadge, Soizic,“Progressing towards a photoswitchable

Karstedfs catalyst,” Diss. Dept of Chemistry-Simon Fraser University, 2009 and Kaur,

Brahmjot, et al,“Using light to control the inhibition of Karstedfs catalyst,” Organic Chemistry Frontiers 6.8 (2019): 1253-1256, the disclosures of which are incorporated herein by reference in their entireties.

6.1.2 Encapsulating agent

[0153] In certain embodiments, the encapsulating agent is a chemical or a functional group that forms a physical or chemical barrier such as a microcapsule or a self-assembled structure or a network structure with a catalyst or with the hydride functionalized polysiloxane.

[0154] In one embodiment, the encapsulating agent is a polysaccharide, protein, lipid or synthetic polymer. In one embodiment, the encapsulating agent is a polysaccharide, wherein the polysaccharide is gum, starch, cellulose, cyclodextrine or chitosan. In one embodiment, the encapsulating agent is a protein, wherein the protein is gelatin, casein or soy protein. In one embodiment, the encapsulating agent is a lipid, wherein the lipid is wax, paraffin or oil. In one embodiment, the encapsulating agent is a synthetic polymer, wherein the synthetic polymer is an acrylic polymer, polyvinyl alcohol or polyvinylpyrrolidone). In one embodiment, the encapsulating agent is an inorganic material. In one embodiment, the encapsulating agent is an inorganic material, wherein the inorganic material is a silicate, clay or polyphosphate. In one embodiment, the encapsulating agent is a biopolymer or biodegradable polymer. In one embodiment, the encapsulating agent is a biopolymer, wherein the biopolymer is starch. In one embodiment, the encapsulating agent is a biodegradable polymer, wherein the biodegradable polymer is chitosan, hyaluronic acid, a cyclodextrin, alginate, aliphatic polyester or copolymer of lactic and glycolic acids. In one embodiment, the encapsulating agent is an aliphatic polyester, wherein the aliphatic polyester is poly(lactic acid). In one embodiment, the encapsulating agent is a copolymer of lactic and glycolic acids, wherein the copolymer of lactic and glycolic acids is poly(lactic co-glycolic acid). In one embodiment, the encapsulating agent is polyurethane- 1, polyurethane-11, polyurethane- 14, polyurethane-6, polyurethane-2, polyurethane- 18 or their mixtures thereof. In one embodiment, the encapsulating agent is polyurethane- 1. In one embodiment, the encapsulating agent is a self-assembled polymer. In one embodiment, the encapsulating agent is a network-forming inorganic dispersion system. In one embodiment, the encapsulating agent is a network-forming inorganic-organic hybrid system.

[0155] In certain embodiments, the encapsulating agent is capable of slowing down or prohibiting the catalytic activity for hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network.

[0156] In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibiting the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibiting the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to 99 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross- linking reaction at about 25 °C to 50 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to 25 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to 10 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 1 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.1 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.01 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross- linking reaction at about 25 °C to about 0.001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.0001 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.00001 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.000001 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 25 °C to about 0.0000001 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to prohibit the reaction rate of the cross- linking reaction at about 25 oC to 0 % of the reaction rate without the encapsulating agent

[0157] In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to 99 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to 50 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to 25 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross- linking reaction at about 5 °C to 10 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 1 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.1 % of the reaction rate without the encapsulating agent. In certain embodiments, the

encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross- linking reaction at about 5 °C to about 0.01 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.0001 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.00001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross-linking reaction at about 5 °C to about 0.000001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down the reaction rate of the cross- linking reaction at about 5 °C to about 0.0000001 % of the reaction rate without the

encapsulating agent. In certain embodiments, the encapsulating agent is at a concentration sufficient to prohibit the reaction rate of the cross-linking reaction at about 25 °C to 0 % of the reaction rate without the encapsulating agent

[0158] In certain embodiments, the encapsulating agent is capable of delaying or prohibiting the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to 99 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to 50 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to 25 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to 10 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 1 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.1 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.01 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the

hydrosilylation reaction at about 25 °C to about 0.0001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.00001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.000001 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 25 °C to about 0.0000001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of prohibiting the reaction rate of the hydrosilylation reaction at about 25 °C to about 0% of the reaction rate without the encapsulating agent.

[0159] In certain embodiments, the encapsulating agent is capable of delaying or prohibiting the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to 99 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to 50 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to 25 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to 10 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 1 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.1 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.01 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.001 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.0001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the

hydrosilylation reaction at about 5 °C to about 0.00001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.000001 % of the reaction rate without the encapsulating agent. In certain embodiments, the encapsulating agent is capable of lowering the reaction rate of the hydrosilylation reaction at about 5 °C to about 0.0000001 % of the reaction rate without the encapsulating agent In certain embodiments, the encapsulating agent is capable of prohibiting the reaction rate of the hydrosilylation reaction at about 25 °C to about 0 % of the reaction rate without the encapsulating agent.

[0160] In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 60 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 90 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 120 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 180 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 365 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 730 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 3 years.

[0161] In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 60 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 90 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 120 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 180 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 365 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 730 days. In certain embodiments, the encapsulating agent is at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 3 years.

[0162] In certain embodiments, the encapsulating agent is at a concentration of about 1 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 10 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 20 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 30 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 40 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 50 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 60 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 70 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 80 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 90 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 95 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 99 % by weight of the composition. In certain embodiments, the encapsulating agent is at a concentration of about 99.9 % by weight of the composition.

[0163] In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 10 ⁷ :1. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 10 ⁶ : 1. In one embodiment, the molar ratio between the encapsulating agent and transition metal or hydride functionalized polysiloxane is about 10 ⁵ :1. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 10 ⁴ : 1. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 10 ³ :1. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 10 ² : 1. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 10:1. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 1:1. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 1:2. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 1:5. In one embodiment, the molar ratio between the encapsulating agent and the transition metal is about 500:1.

[0164] In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 10 ⁷ : 1. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 10 ⁶ : 1. In one embodiment, the molar ratio between the encapsulating agent and transition metal or hydride functionalized polysiloxane is about 10 ⁵ : 1. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 10 ⁴ : 1. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 10 ³ :1. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 10 ² :1. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 10:1. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 1:1. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 1:2. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 1:5. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 500: 1.

[0165] In one embodiment, the encapsulating agent is a moderator delaying or prohibiting the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In one embodiment, the encapsulating agent is a moderator delaying or prohibiting the hydrosilylation reaction by forming microcapsules with the catalyst or hydride functionalized polysiloxane. In one embodiment, the encapsulating agent is a moderator that forms microcapsules with the catalyst or hydride functionalized polysiloxane reversibly. In one embodiment, the encapsulating agent is a moderator that dissociates with the catalyst or hydride functionalized polysiloxane at higher temperatures, e.g., about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C. In one embodiment, the encapsulating agent is a moderator that dissociates with the catalyst or hydride functionalized polysiloxane by evaporation. In one embodiment, the encapsulating agent is a moderator that dissociates with the catalyst or hydride functionalized polysiloxane by solvent extraction. In one embodiment, the encapsulating agent is a moderator that dissociates with the catalyst or hydride functionalized polysiloxane under acoustic wave. In one embodiment, the encapsulating agent is a moderator that dissociates with the catalyst or hydride functionalized polysiloxane under electromagnetic wave. Without being bound by theory, upon dissociation of the encapsulating agent from the catalyst or hydride functionalized polysiloxane, the hydrosilylation reaction is no longer delayed.

[0166] In one embodiment, the encapsulating agent is a retarder delaying the hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In one embodiment, the encapsulating agent is a retarder delaying the hydrosilylation reaction by complexing with the catalyst or hydride functionalized polysiloxane. In one embodiment, the encapsulating agent is a retarder that forms microcapsules with the catalyst or hydride functionalized polysiloxane reversibly. In one embodiment, the encapsulating agent is a retarder that dissociates with the catalyst or hydride functionalized polysiloxane at higher temperatures, e.g., about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C. In one embodiment, the encapsulating agent is a retarder that dissociates with the catalyst or hydride functionalized polysiloxane under acoustic wave. In one embodiment, the encapsulating agent is a retarder that dissociates with the catalyst or hydride functionalized polysiloxane under electromagnetic wave. Without being bound by theory, upon dissociation of the encapsulating agent from the catalyst or hydride functionalized polysiloxane, the hydrosilylation reaction is no longer delayed.

[0167] In one embodiment, the encapsulating agent is an inhibitor preventing the

hydrosilylation reaction by which the compositions provided herein form a chemical crosslink network. In one embodiment, the encapsulating agent is an inhibitor preventing the

hydrosilylation reaction by forming physical or chemical barriers such as microcapsules with the catalyst or hydride functionalized polysiloxane. In one embodiment, the encapsulating agent is an inhibitor that can be removed to reactivate with the catalyst or hydride functionalized polysiloxane. In one embodiment, the encapsulating agent is an inhibitor that can be removed at higher temperatures, e.g., about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C. In one embodiment, the encapsulating agent is an inhibitor that can be removed with acoustic wave. In one embodiment, the encapsulating agent is an inhibitor that can be removed with electromagnetic wave.

[0168] In certain embodiments, the encapsulating agent is capable of slowing down or prohibiting the catalytic activity for hydrosilylation reaction such that at most about 0.1%, 0.5%, 1%, 2%, 5%, 8% or 10% of the functional moieties are reacted over the period of a day, a week, a month, or a year.

[0169] In certain embodiments, the encapsulating agent is capable of stabilization of the catalyst or hydride functionalized polysiloxane and spatially separation of the catalyst or hydride functionalized polysiloxane away from one another. This way, the encapsulating agent prevents the catalyst to form larger structure, modifying its catalytic activity.

[0170] In certain embodiments, the encapsulating agent is capable of stabilization of the catalyst or hydride functionalized polysiloxane and spatially separation of the catalyst away from hydride functional organopolysiloxanes and vice versa. This way, the encapsulating agent prevents the initiation of intermediate state for hydrosilylation, modifying the catalytic activity of the catalyst.

[0171] In certain embodiments, the encapsulating agent is capable of stabilization of the catalyst such that at most about 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 5%, 10% or 50% of the catalyst catalyzing the hydrosilylation reaction. [0172] In certain embodiments, the encapsulating agent is capable of stabilization of the hydride functionalized polysiloxane such that at most about 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%,

5%, 10% or 50% of the hydride functionalized polysiloxane remains accessible for the hydrosilylation reaction.

[0173] In certain embodiments, the encapsulating agent is capable of slowing down the catalytic activity for hydrosilylation reaction by forming physical or chemical barriers such as microcapsules with the catalyst or hydride functionalized polysiloxane.

[0174] In certain embodiments, the encapsulating agent is capable of forming physical or chemical barriers such as microcapsules with the catalyst such that at least about 99.9 %, 99.5 %, 99 %, 98 %, 95 %, 92 %, 90 %, 70 %, 50 %, 25 %, 10% or 5 % of the catalyst or hydride functionalized polysiloxane forms microcapsules with the encapsulating agent

[0175] In certain embodiments, the encapsulating agent is capable of forming physical or chemical barriers such as microcapsules with the catalyst such that at least about 99.9 %, 99.5 %, 99 ¾, 98 %, 95 %, 92 %, 90 %, 70 %, 50 %, 25 %, 10% or 5 % of the encapsulating agent forms microcapsules with the catalyst or hydride functionalized polysiloxane.

[0176] In certain embodiments, at least about 5 % of the encapsulating agent forms encapsulating agent-catalyst microcapsules; whereas at least about 99% of the catalyst forms encapsulating agent-catalyst microcapsules.

[0177] In one embodiment, the amount of encapsulating agent is sufficient to form encapsulating agent-catalyst microcapsules with about 100 % of the catalyst. In certain embodiments, the amount of encapsulating agent is about 1.1, 1.2, 1.3, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.4, 3.6, 3.9, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90 or 100 times by mole of the amount required to form encapsulating agent-catalyst microcapsules with about 100 % of the catalyst.

[0178] In certain embodiments, at least about 5 % of the encapsulating agent forms encapsulating agent-hydride functionalized polysiloxane microcapsules; whereas at least about 99% of the catalyst forms encapsulating agent-hydride functionalized polysiloxane

microcapsules.

[0179] In one embodiment, the amount of encapsulating agent is sufficient to form encapsulating agent- hydride functionalized polysiloxane microcapsules with about 100 % of the hydride functionalized polysiloxane. In certain embodiments, the amount of encapsulating agent is about 1.1, 1.2, 1.3, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.4, 3.6, 3.9, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90 or 100 times by mole of the amount required to form encapsulating agent-hydride functionalized polysiloxane microcapsules with about 100 % of the hydride functionalized polysiloxane.

[0180] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by decreasing the concentration of the encapsulating agent

[0181] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by decreasing the concentration of the encapsulating agent by means of evaporation. In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by decreasing the concentration of the encapsulating agent by means of sorption, including physisorption and chemisorption; or adsorption and absorption.

[0182] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by decreasing the concentration of the encapsulating agent by means of phase separation including solidification, crystallization, precipitation, surface self-segregation, interface self-segregation, phase extraction, phase inversion, or coacervation.

[0183] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by decreasing the concentration of the encapsulating agent by means of encapsulating agent migration such as solvent extraction.

[0184] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by decreasing the concentration of the encapsulating agent by means of encapsulating agent degradation such as chemical oxidation, optical degradation by UV and such.

[0185] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by decreasing the concentration of the encapsulating agent by means of encapsulating agent reconfiguration, such as charge transfer, electron transfer, proton transfer, radical transfer and else. [0186] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by the use of ultrasound to supply vibrational energy to knock the catalyst or hydride functionalized polysiloxane out of the microcapsules containing encapsulating agent-catalyst or encapsulating agent-hydride functionalized polysiloxane.

[0187] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by the use of electromagnetic waves that free the catalyst or hydride functionalized polysiloxane out of the microcapsules containing encapsulating agent-catalyst or encapsulating agent-hydride functionalized polysiloxane.

[0188] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by the use of temperature as a form of heat or cold that reduces the interactive strength of the encapsulating agent-catalyst or encapsulating agent-hydride functionalized polysiloxane microcapsules.

[0189] In certain embodiments, the activity of the encapsulating agent to slow down or prohibit the activity for hydrosilylation reaction can be reduced by the use of environments that trigger a phase transition in encapsulating agent, impacting the stability of encapsulating agent- catalyst or encapsulating agent-hydride functionalized polysiloxane microcapsules.

[0190] In certain embodiments, the encapsulating agent is a volatile encapsulating agent, such that its vapor pressure at about 25 °C is above 0.1 mm Hg. In one embodiment, the encapsulating agent is a volatile encapsulating agent. In one embodiment, the encapsulating agent is volatile at about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or 70 °C. In one embodiment, the encapsulating agent is volatile at about 20, 25, 30, 35, 40, 45 or 50 °C. In one embodiment, the encapsulating agent is volatile at about 20, 25, 30, 35, or 40 °C. In one embodiment, the encapsulating agent is volatile at about 35 °C. In one embodiment, the encapsulating agent is volatile at about 25 °C. Without being bound by theory, the activity of the volatile encapsulating agent is reduced by exposure to air, wherein the encapsulating agent evaporates and the catalyst is set free to catalyze.

[0191] In certain embodiments, the encapsulating agent is an acoustic-driven encapsulating agent In certain embodiments, the acoustic-driven encapsulating agent can be any of the above encapsulating agents. Without being bound by theory, the activity of the acoustic-driven encapsulating agent is reduced by exposure to ultrasound, wherein the ultrasound supplies vibrational energy to knock the catalyst or hydride functionalized polysiloxane out of the encapsulating agent-catalyst or encapsulating agent-hydride functionalized polysiloxane microcapsules. Selection of ultrasound ranges of frequency would regulate the rate of hydrosilylation. In certain embodiment, the catalyst and the encapsulating agent may not be necessary for hydrosilylation to proceed, as energy from acoustic cavitation may be sufficient to activate free radicals to initiate the hydrosilylation. In one embodiment, acoustic cavitation activates the hydrogen-terminated silicon surfaces for hydrosilylation.

[0192] In certain embodiments, the encapsulating agent is an electromagnetic-driven encapsulating agent. Without being bound by theory, the activity of the electromagnetic-driven encapsulating agent is reduced by exposure to electromagnetic wave, wherein the

electromagnetic wave such as light, UV, infrared wave, microwave supplies electromagnetic energy to knock the catalyst or hydride functionalized polysiloxane out of the microcapsules containing encapsulating agent-catalyst or encapsulating agent-hydride functionalized polysiloxane.

[0193] In certain embodiments, the encapsulating agent is a heat-sensitive encapsulating agent. Without being bound by theory, the activity of the heat-sensitive encapsulating agent is reduced by exposure to direct heat source or heat as a by-product of chemical reaction, microwave, and else; wherein the heat helps release the catalyst or hydride functionalized polysiloxane out of the microcapsules containing encapsulating agent-catalyst or encapsulating agent-hydride functionalized polysiloxane.

[0194] In certain embodiments, the volatile encapsulating agent is used in combination with an acoustic-driven encapsulating agent, an electromagnetic-driven encapsulating agent, or a heat- sensitive encapsulating agent. In certain embodiments, the volatile encapsulating agent is used in combination with an acoustic-driven ligand, an electromagnetic-driven ligand, or a heat- sensitive ligand.

[0195] In certain embodiments, the volatile encapsulating agent is used in combination with volatile ingredients; either miscible with volatile encapsulating agent such as disiloxane, trisiloxane, isododecane, xylene, octene, isopropanol, ethanol or immiscible with volatile encapsulating agent such as water, esters. 6.1.3 Catalyst

[0196] In certain embodiments, the composition further comprises a catalyst that facilitates hydrosilylation of the one or more crosslinkable polymers.“Catalyst’ includes any substance that causes, facilitates, or initiates a physical and/or chemical hydrosilylation reaction. The catalyst may or may not undergo permanent physical and/or chemical changes during or at the end of the process. In preferred embodiments, the catalyst is a metal catalyst capable of initiating and/or facilitating the hydrosilylation at or below body temperature, for example,

Group Vni metal catalysts, such as platinum, rhodium, palladium, cobalt, nickel, ruthenium, osmium and iridium catalysts, and Group IVA metal catalysts, such as germanium and tin. In further preferred embodiments, the catalyst is a platinum catalyst, a rhodium catalyst or a tin catalyst Examples of platinum catalysts include, for example, platinum carbonyl

cyclovinylmethylsiloxane complexes, platinum divinyltetramethyldisiloxane complexes, platinum cyclovinylmethylsiloxane complexes, platinum octanaldehyde/octanol complexes, and other Pt(0) catalysts such as Karstedt’s catalyst, platinum-alcohol complexes, platinum-alkoxide complexes, platinum-ether complexes, platinum-aldehyde complexes, platinum-ketone complexes, platinum-halogen complexes, platinum-sulfur complexes, platinum-nitrogen complexes, platinum-phophorus complexes, platinum-carbon double-bond complexes, platinum carbon triple-bond complexes, platinum-imide complexes, platinum-amide complexes, platinum- ester complexes, platinum-phosphate ester complexes, platinum-thiol ester complexes, platinum lone-pair-electron complexes, platinum-aromatic complexes, platinum p-electron complexes, and combinations thereof. Examples of rhodium catalyst include tris (dibutylsulfide) rhodium trichloride and rhodium trichloride hydrate. Examples of tin catalysts include tin P octoate, tin P neodecanoate, dibutyltin diisooctylmaleate, Di-n-butylbis(2,4 pentanedionate)tin, di-n- butylbutoxychlorotin, dibutyltin dilaurate, dimethyltin dineodecanoate,

dimethylhydroxy(oleate)tin and tin P oleate. In preferred embodiments, the catalyst is platinum catalyst In further preferred embodiments, the catalyst is platinum divinyltetramethyldisiloxane complexes.

[0197] In preferred embodiments, the composition comprises about 0.001 to about 1% by weight (i.e., about 10 ppm to about 1,000 ppm), preferably about 0.005 to about 0.05% by weight (i.e., about 50 ppm to about 500 ppm) catalyst. In further preferred embodiments, the composition comprises about 0.01 to about 0.03% by weight catalyst 6.1.4 Ligand-Catalyst Complex

[0198] In one embodiment, the ligand-catalyst complex is Karstedf s catalyst In one embodiment, the ligand in the ligand-catalyst complex is 1 ,3-divinyltetramethyldisiloxane. In one embodiment, the ligand-catalyst complex has the chemical formula of C24H5403Pt2Si6. In one embodiment, the ligand-catalyst complex has the following structure:

[0199] In one embodiment, the preferred ligand in the ligand-catalyst complex is 1,3- divinyltetramethyldisiloxane or divinyldisiloxane. In one embodiment, the most preferred ligand in the ligand-catalyst complex is 1 ,3-divinyltetramethyldisiloxane. In one embodiment, the ligand has the chemical formula of C8H18OSi2. In one embodiment, the ligand has the following structure:

[0200] In one embodiment, the ligand in the ligand-catalyst complex is 1, 1,3, 3,5,5- hexamethyl-1 ,5-divinyltrisiloxane. In one embodiment, the ligand has the chemical formula of C10H24O2S13. In one embodiment, the ligand has the following structure:

[0201] In one embodiment, the ligand in the ligand-catalyst complex is 1,5 -divinyl-3 - phenylpentamethyltrisiloxane. In one embodiment, the ligand has the chemical formula of C15H2602Si3. In one embodiment, the ligand has the following structure:

[0202] In one embodiment, the ligand in the ligand-catalyst complex is 1, 1,5,5 -tetramethyl- 3,3-diphenyl-1,5-divinyltrisiloxane. In one embodiment, the ligand has the chemical formula of C20H28O2S13. In one embodiment, the ligand has the following structure:

[0203] In one embodiment, the ligand in the ligand-catalyst complex is 1,3,5-trivinyl-1,3,5- trimethylcyclotrisiloxane. In one embodiment, the ligand has the chemical formula of

C9H18C3Si3. In one embodiment, the ligand has the following structure:

[0204] In one embodiment, the ligand in the ligand-catalyst complex is 2, 4,6,8- tetramethyltetravinylcyclotetrasiloxane. In one embodiment, the ligand has the chemical formula of C12H24O4S14. In one embodiment, the ligand has the following structure:

[0205] In one embodiment, the ligand in the ligand-catalyst complex is 1,3, 5, 7, 9- pentamethyl-1,3,5,7,9-pentavinylcyclopentasiloxane. In one embodiment, the ligand has the chemical formula of C15H30O5S15. In one embodiment, the ligand has the following structure:

[0206] In one embodiment, the ligand in the ligand-catalyst complex is

tris(vinyldimethylsiloxy)methylsilane. In one embodiment, the ligand has the chemical formula of C13H30O3S14. In one embodiment, the ligand has the following structure:

[0207] In one embodiment, the ligand in the ligand-catalyst complex is

tetrakis(vinyldimethylsiloxy)silane. In one embodiment, the ligand has the chemical formula of C16H36O4S15. In one embodiment, the ligand has the following structure:

[0208] In one embodiment, the ligand in the ligand-catalyst complex is

methacryloxypropyltris(vinyldimethylsiloxy)silane. In one embodiment, the ligand has the chemical formula of C19H38O5S14. In one embodiment, the ligand has the following structure:

[0209] In one embodiment, the ligand in the ligand-catalyst complex is 1,2- divinyltetramethyldisilane. In one embodiment, the ligand has the chemical formula of C8H18O5Si2. In one embodiment, the ligand has the following structure:

[0210] In one embodiment, the ligand in the ligand-catalyst complex is 1 ,5-hexadiene. In one embodiment, the ligand has the chemical formula of C6H10. In one embodiment, the ligand has the following structure:

[0211 ] In one embodiment, the ligand in the ligand-catalyst complex is 1,4-hexadiene. In one embodiment, the ligand has the chemical formula of C6H10. In one embodiment, the ligand has the following structure:

[0212] In one embodiment, the ligand in the ligand-catalyst complex is Octadiene. In one embodiment, the ligand has the chemical formula of C8H14. In one embodiment, the ligand has one of the following structures:

, and

[0213] In one embodiment, the ligand in the ligand-catalyst complex is Dimethylbutadiene. In one embodiment, the ligand has the chemical formula of C6H10. In one embodiment, the ligand has the following structure:

[0214] In one embodiment, the ligand in the ligand-catalyst complex is Dimethylhexadiene. In one embodiment, the ligand has the chemical formula of C8H14. In one embodiment, the ligand has the following structure:

[0215] In one embodiment, the ligand in the ligand-catalyst complex is Dimethyloctadiene. In one embodiment, the ligand has the chemical formula of CioH18. In one embodiment, the ligand has the following structure:

or

[0216] In one embodiment, the ligand in the ligand-catalyst complex is methyl vinyl ketone. In one embodiment, the ligand has the chemical formula of C4H6O. In one embodiment, the ligand has the following structure:

[0217] In one embodiment, the ligand in the ligand-catalyst complex is dimethyl maleate. In one embodiment, the ligand has the chemical formula of C6H8O4. In one embodiment, the ligand has the following structure:

[0218] In one embodiment, the ligand in the ligand-catalyst complex is dimethyl fumarate. In one embodiment, the ligand has the chemical formula of C6H8O4. In one embodiment, the ligand has the following structure:

[0219] In one embodiment, the ligand in the ligand-catalyst complex is (3E)-4-methoxy-3- buten-2-one. In one embodiment, the ligand has the chemical formula of C5H8O2. In one embodiment, the ligand has the following structure:

[0220] In one embodiment, the ligand in the ligand-catalyst complex is (E)-2-ethylhex-2- enal. In one embodiment, the ligand has the chemical formula of C8H14O. In one embodiment, the ligand has the following structure:

[0221] In one embodiment, the ligand in the ligand-catalyst complex is pent- l-en-3 -one. In one embodiment, the ligand has the chemical formula of C5H8O. In one embodiment, the ligand has the following structure:

[0222] In one embodiments, the ligand is used in combination with 1,3- divinyltetramethyldisiloxane, 1,1,3,3,5,5-hexamethyl-1,5-divinyltrisiloxane, 1,5-divinyl-3- phenylpentamethyltrisiloxane, 1,1,5,5-tetramethyl-3,3-diphenyl-1,5-divinyltrisiloxane, 1,3,5- trivinyl-1 ,3,5-trimethylcyclotrisiloxane, 2,4,6,8-tetramethyltetravinylcyclotetrasiloxane, 1,3,5,7,9-pentamethyl-1,3,5,7,9-pentavinylcyclopentasiloxane ,

tris(vinyldimethylsiloxy)methylsilane, tetrakis(vinyldimethylsiloxy)silane,

methacryloxypropyltris(vinyldimethylsiloxy)silane, 1,2-divinyltetramethyldisilane, methyl vinyl ketone, dimethyl maleate, dimethyl fumarate, (3E)-4-methoxy-3-buten-2-one, (E)-2-ethylhex-2- enal, pent-1-en-3-one, or maleic acid. In one embodiments, the ligand is used in combination with divinyldisiloxane.

6.1.5 Encapsulating agent-Catalyst Microcapsules

[0223] In one embodiment, the encapsulating agent-catalyst microcapsules are prepared by emulsion polymerization, suspension polymerization, interfacial polymerization,

coacervation/phase separation, solvent evaporation/extraction, sol-gel encapsulation, supercritical fluid-assisted microencapsulation, layer-by-layer assembly, spray-drying, spray- cooling, co-extrusion, spinning disk, fluidized-bed coating, melt solidification, or polymer precipitation. In one embodiment, the encapsulating agent-catalyst microcapsules are prepared by solvent evaporation/extraction or spray-drying. In one embodiment, the encapsulating agent- catalyst microcapsules are prepared by solvent evaporation/extraction. In one embodiment, the encapsulating agent-catalyst microcapsules are prepared by spray-drying. 6.1.6 Vinyl fimctionalized Organopolysiloxanes

[0224] In one embodiment, the vinyl functionalized organopolysiloxanes provided herein is or includes at least one or more compounds of Formula I:

wherein

W is R1R3 O-, -OR ⁴ , -NR ⁵ R ⁶ , -CR ⁷ R ⁸ R ⁹ or Cs-io aryl;

X is absent, -R ^u R ¹² Si-0-, -OCONR ¹³ -, -NR ¹⁴ CONR ¹⁵ -, -CO-, -NR ¹⁶ CO-, -SO2- , -0-, -S- or -NR ¹⁷ -;

V is absent, C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, -0-, -NR ¹⁰ - or -S-;

Y is absent, -R ¹⁸ R ¹⁹ Si-0-, -OCONR ²⁰ -, -NR ²¹ CONR ²² -, -CO-, -NR ²³ CO-, -SO2- , -0-, -S- or -NR ²⁴ ;

Z is C1-20 alkyl, -SiR ²⁵ R ²⁶ R ²⁷ , -OR ²⁸ , -NR ²⁹ R ³⁰ , -CR ³¹ R ³² R ³³ or C5-10 aryl;

R ¹ , R ² , R ³ , R ⁷ , R ⁸ , R ⁹ . R ¹⁰ , R ¹¹ , R ¹² , R ¹⁸ R ¹⁹ , R ²⁵ , R ²⁶ , R ²⁷ , R ³¹ , R ³² and R ³³ are each independently hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or Ci-20 alkoxyl;

R ⁴ , R ⁵ , R ⁶ , R ¹³ , R ¹⁴ , R ¹⁵ , R ¹⁶ , R ¹⁷ , R ²⁰ , R ²¹ , R ²² , R ²³ , R ²⁴ , R ²⁸ , R ²⁹ and R ³⁰ are each independently hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl; and

s and t are each independently an integer from about 0 to about 6000.

[0225] In some embodiments, the composition includes more than one compound of formula I and the compounds of formula once may be the same or different.

[0226] X and Y of formula I represent an independent“monomer unit” The number of X and Y monomer units present in formula I is provided by the value of s and t, respectively. Representative monomer units include:

where R is

as for defined for R ¹ , R ² , R ³ , etc, above. [0227] It is understood that when more than one X (or Y) monomer unit is present (e.g. s (or t) is more than one), the values for R ¹¹ , R ¹² , R ¹³ , R ¹⁴ , R ¹⁵ , R ¹⁶ , R ¹⁷ , R ¹⁸ R ¹⁹ , R ²⁰ , R ²¹ , R ²² , R ²³ , and R ²⁴ are selected independently for each individual monomer unit described by -[X] _s - (or - [Y]t-). For example, if the value of the monomer unit X is -R ¹¹ R ¹² Si-0- and the value of s is 3, then -[X]s- is:

In this example, it is understood that the three R ¹¹ groups present in may be the same or different from each other, for example, one R ¹¹ may be hydrogen, and the two other R ¹¹ groups may be methyl.

[0228] W and Z of formula I represent independent terminal caps, one on each end of the polymer. For example, terminal caps include:

wherein denotes

attachment to a monomer unit and wherein R is as for defined for R ¹ , R ² , R ³ , etc, above.

In one embodiment,

are each independently hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or Ci-20 alkoxyl;

R ⁴ , R ⁵ , R ⁶ , R ¹⁴ , R ¹⁵ , R ²¹ , R ²² , R ²⁸ , R ²⁹ and R ³⁰ are each independently hydrogen, C1-20 alkyl, C2-20 alkenyl, C5-10 aryl; and s and t are each independently an integer from about 0 to about 6000, wherein the sum of s and t is not 0.

[0229] In one embodiment,

R ¹ , R ² , R ³ , R ⁷ , R ⁸ , R ⁹ .R ¹¹ , R ¹² , R ¹⁸ R ¹⁹ , R ²⁵ , R ²⁶ , R ²⁷ , R ³¹ , R ³² and R ³³ are each independently hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or Ci-20 alkoxyl;

R ¹⁴ , R ¹⁵ , R ²¹ , and R ²² are each independently hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl; and

s and t are each independently an integer from about 0 to about 6000, wherein the sum of s and t is not 0.

[0230] In one embodiment, V is absent, W is R1R2R3SiO-; X is -R ¹¹ R ¹² Si-0-; Y is -R ¹⁸ R ¹⁹ Si- 0-; Z is -SiR ²⁵ R ²⁶ R ²⁷ ; and R ¹ , R ² , R ³ , R ¹¹ , R ¹² , R ¹⁸ , R ¹⁹ , R ²⁵ , R ²⁶ and R ²⁷ are each independently selected from Ci-20 alkyl (e.g., Ci alkyl, such as methyl) or C2-20 alkenyl (e.g, C2 alkenyl, such as vinyl). In one embodiment, at least one of R ¹ , R ² , R ³ , R ¹¹ , R ¹² , R ¹⁸ , R ¹⁹ , R ²⁵ , R ²⁶ and R ²⁷ is C2-20 alkenyl, for example, C2 alkenyl (e.g., vinyl). In another embodiment, at least two of R ¹ , R ² , R ³ , R ¹¹ , R ¹² , R ¹⁸ , R ¹⁹ , R ²⁵ , R ²⁶ and R ²⁷ are C2-20 alkenyl, for example, C2 alkenyl (e.g., vinyl). In some embodiments, at least one of R ¹ , R ² , R ³ , R ²⁵ , R ²⁶ and R ²⁷ are each C2-20 alkenyl, for example, C2 alkenyl (e.g., vinyl).

[0231] In one embodiment, V is absent, W is R1R2iO-; X is -R ¹¹ R ¹² Si-0-; Y is -R ¹⁸ R ¹⁹ Si- 0-; Z is -SiR ²⁵ R ²⁶ R ²⁷ ; and R ¹ , R ² , R ³ , R ²⁵ , R ²⁶ and R ²⁷ are each independently selected from Ci-20 alkyl (e.g., Ci alkyl, such as methyl) or C2-20 alkenyl (e.g., C2 alkenyl, such as vinyl); and R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ are each independently selected from Ci-20 alkyl (e.g., Ci alkyl, such as methyl). In one embodiment, at least one of R ¹ , R ² , R ³ , and at least one of R ²⁵ , R ²⁶ and R ²⁷ is C2-20 alkenyl, for example, C2 alkenyl (e.g., vinyl). In one embodiment, one of R ¹ , R ² , R ³ is C2 alkenyl (e.g., vinyl) and the others are C1-20 alkyl (e.g., Ci alkyl, such as methyl), and at least one of R ²⁵ , R ²⁶ and R ²⁷ is C2-20 alkenyl, for example, C2 alkenyl (e.g., vinyl)and the others are Ci-20 alkyl (e.g., Ci alkyl, such as methyl). In one embodiment, at least one of R ¹¹ or R ¹² and at least one of R ¹⁸ or R ¹⁹ is C2-20 alkenyl, for example, C2 alkenyl {e.g, vinyl) for at least one monomer unit In one embodiment, one of R ¹¹ or R ¹² is C2 alkenyl {e.g., vinyl) and the others are Ci-20 alkyl {e.g., Ci alkyl, such as methyl), and at least one of R ¹⁸ or R ¹⁹ is C2-20 alkenyl, for example, C2 alkenyl {e.g., vinyl)and the others are Ci-20 alkyl {e.g., Ci alkyl, such as methyl) for at least one monomer unit.

[0232] In some embodiments, the organopolysiloxane includes unsaturated moieties only at the terminal caps of the polymer. In some embodiments, the organopolysiloxane is substantially unsaturated functionalized. In some embodiments, the organopolysiloxane includes vinyl moieties only at the terminal caps of the polymer. In some embodiments, the

organopolysiloxane is substantially vinyl functionalized. In some embodiments, the

organopolysiloxane include vinyl moieties only in the monomer units, but not at the terminal cap of the polymer. In other embodiments, the organopolysiloxane includes vinyl moieties at both the terminal cap or in the monomer unit of the polymer. In one embodiment, the polymer includes two vinyl moieties located either at the terminal cap, or within the monomer unit, or a combination thereof. In at least one embodiment, the organopolysiloxane includes vinyl moieties only at the terminal caps of the polymer and contains Si-H units only within the monomer units and not at the terminal caps.

[0233] In one embodiment, on average at least two vinyl moieties are present in the polymer. In a specific embodiment, at least two vinyl moieties are present in the polymer and at least two vinyl moieties are present on the two terminal caps of the polymer. In a specific embodiment, only two vinyl moieties are present in the polymer. In a specific embodiment, only two vinyl moieties are present in the polymer and are located on each of the terminal caps. In a specific embodiment, on average at least two vinyl moieties are present in the polymer and at least two vinyl moieties are present in one or more monomer units of the polymer. In a specific embodiment, at least two vinyl moieties are present anywhere in the polymer, but separated from another vinyl moiety by about 2000 monomer units, for example, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 monomer units. In a specific embodiment, on average at least two vinyl moieties are present anywhere in the polymer, but separated from another vinyl moiety by about 850 monomer units, for example, 350, 450, 550, 650, 750, 850, 950, 1050,

1150, 1250, or 1350 monomer units. In a specific embodiment, on average greater two vinyl moieties are present anywhere in the polymer, but separated from another vinyl moiety by about 40 monomer units, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 monomer units. In a specific embodiment, one or more Si-H units are present in addition to the vinyl moiety. Alternatively, in one embodiment, if a vinyl moiety is present then a Si-H is not present

[0234] In one embodiment, V is absent, W is R1R2iO-; X is -R ¹¹ R ¹² Si-0-; Y is -R ¹⁸ R ¹⁹ Si-

0-; Z is -SiR ²⁵ R ²⁶ R ²⁷ ; R ¹ , R ² , R ³ , R ¹¹ , R ¹² , R ¹⁸ , R ¹⁹ , R ²⁵ , R ²⁶ and R ²⁷ are each independently selected from hydrogen or C1-20 alkyl (e.g, Ci alkyl, such as methyl). In one embodiment, R ¹ ,

R ² , R ³ , R ²⁵ , R ²⁶ and R ²⁷ are each independently selected from C1-20 alkyl (e.g., Ci alkyl, such as methyl); and R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ are each independently selected from hydrogen or C1-20 alkyl (e.g., Ci alkyl, such as methyl), wherein at least one of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ are hydrogen for at least one monomer unit In one embodiment, on average greater than two Si-H units (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen) are present in the polymer, for example 3- 15 Si-H units may be present In a specific embodiment, 8 Si-H units are present on average. In one embodiment, one or more Si-H units (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen) are present in the polymer. In one embodiment, at least two monomer units on average include a - Si-H unit (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen). In one embodiment, at least three monomer units on average include a -Si-H unit (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen). In one embodiment, at least four monomer units on average include a -Si-H unit (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen). In one embodiment, at least five monomer units on average include a -Si-H unit (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen). In one embodiment, at least six monomer units on average include a -Si-H unit (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen). In one embodiment, at least seven monomer units on average include a -Si-H unit (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen). In one embodiment, at least eight monomer units on average include a -Si-H unit (e.g. one or more of R ¹¹ , R ¹² , R ¹⁸ , and R ¹⁹ is hydrogen). In one embodiment, a Si-H unit may be present in one or both the terminal caps in addition to being present in a monomer unit as described above. In one embodiment, one or more Si-H units may be present only in a monomer unit as described above, and not present in either of the terminal caps. In a specific embodiment, Si-(alkyl) or Si-(vinyl) units may also be present in the polymer. In a specific embodiment, only S1-CH3 and Si-H units are present In a specific embodiment, monomer units or terminal caps include Ci-C2oalkyl, specifically methyl groups, for the non-Si-H positions of the polymer. [0235] In a specific embodiment, on average at least two Si-H units are present in the polymer. In a specific embodiment, on average at least two Si-H moieties are present anywhere in the polymer, but separated from another Si-H moiety by about 2000 monomer units, for example, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 monomer units. In a specific embodiment, on average at least two Si-H moieties are present only in the monomer units of the polymer and not the terminal cap, and are separated from another Si-H moiety by about 2000 monomer units, for example, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 monomer units. In a specific embodiment, on average at least two Si-H units are present anywhere in the polymer, but separated from another Si-H moiety by about 850 monomer units, for example, 350, 450, 550, 650, 750, 800, 850, 950, 1050, 1150, 1250, or 1350 monomer units. In a specific embodiment, on average at least two Si-H moieties are present only in the monomer units of the polymer and not the terminal caps, and are separated from another Si-H moiety by about 2000 monomer units, for example, 350, 450, 550, 650, 750, 800, 850, 950, 1050, 1150, 1250, or 1350 monomer units. In a specific embodiment, on average greater than two Si-H units are present anywhere in the polymer, but separated from another Si-H moiety by about 40 monomer units, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 monomer units. In a specific embodiment, on average at least two Si-H moieties are present only in the monomer units of the polymer and not the terminal caps, and are separated from another Si-H moiety by about 2000 monomer units, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 monomer units.

[0236] In one aspect of any one of the above embodiments, the sum of s and t is an integer from about 1000 to about 8000; from about 1300 to about 2700; from about 1500 to about 2700; from about 1600 to about 2600; from about 1600 to about 2500; from about 1700 to about 2500; from about 1800 to about 2400; from about 1800 to about 2300; from about 1900 to about 2300; from about 2000 to about 2200; from about 2050 to about 2150; from about 2100.

[0237] In one aspect of any one of the above embodiments, the sum of s and t is an integer from about 200 to about 1100; from about 600 to about 1100; from about 700 to about 1000; from about 800 to about 900; from about 825 to about 875; from about 850; from about 200 to about 800; from about 225 to about 700; from about 250 to about 600; from about 275 to about 500; from about 300 to about 400; from about 350 to about 400; from about 375. In a specific embodiment, the sum of s and t is an integer from about 850. [0238] In one aspect of any one of the above embodiments, the sum of s and t is an integer from about 5 to about 1300; from about 10 to about 1100; from about 10 to about 600; from about 15 to about 500; from about 15 to about 400; from about 20 to about 300; from about 20 to about 200; from about 25 to about 100; from about 25 to about 75; from about 30 to about 50; from about 40.

[0239] In some embodiments, the composition includes compounds of formula P:

wherein R ^1a , R ^2a , R ^3a , R ^4a , R ^5a , R ^6a , R ^7a , R ^8a , R ^9a and R ^10a are each independently selected from hydrogen, C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or C1-20 alkoxyl and p and q are each independently an integer from between 10 and about 6000.

[0240] In some embodiments, the organopolysiloxane is a compound of formula Ha:

wherein R ^1a ,’ R ^3a ’ ^'' , R ^4a ’ ^' , R ^5a ’ ^' , R ^6a ’ ^' , R ^8a ’ ^' , R ^9a ’ ^' and R ^10a' are each independently selected from hydrogen, C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or C1--0 alkoxyl and p and q are each independently an integer from between 10 and about 6000. In one embodiment, R ^1a , R ^3a' , R ^4a' , R ^5a' , R ^6a ’ ^'' , R ^8a ’ ^' , R ^9a ’ ^' and R ^10a' are alkyl (e.g., Ci alkyl, such as methyl).

[0241] In some embodiments, the unsaturated organopolymer is an organopolysiloxane. In some embodiments, the organopolysiloxane is vinyl functionalized. In some embodiments, the organopolysiloxane is substantially vinyl functionalized. The language“vinyl functionalized organopolysiloxane” includes organopolysiloxanes that have at least one vinyl group at both terminal ends of the polymer. Specifically, the language“vinyl functionalized

organopolysiloxane” includes organopolysiloxanes of formula HI in which one or both of R ^2a and R ^7a are substituted with a C2 alkyl moiety, for example, a vinyl moiety (e.g., -CH0=CH2). In a specific embodiment, a“vinyl functionalized organopolysiloxane” includes

organopolysiloxanes of formula HI in which one or both of R ^2a and R ^7a are substituted with a C2 alkyl moiety, for example, a vinyl moiety {e.g, -CH=CH2), and R ^1a , R ^3a , R ^4a , R ^5a , R ^6a , R ^8a , R ^9a and R ^10a are independently selected from Ci-20 alkyl, for example, methyl.

[0242] In some embodiments, the organopolysiloxane is a compound of formula nb:

wherein R ^1c , R ^3c , R ^4c , R ^5c , R ^6c , R ^te , R ^9c and R ^10c are each independently selected from hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or Ci-20 alkoxyl and e and f are each independently an integer from between 10 and about 6000. In one embodiment, R ^lc , R ^3c , R ^4c , R ^5c , R ^6c , R ^8c , R ^9c and R ^10c are alkyl {e.g., Ci alkyl, such as methyl). In some embodiments, the sum of e and f is an integer from about 1000 to about 8000; from about 1300 to about 2700; from about 1500 to about 2700; from about 1600 to about 2600; from about 1600 to about 2500; from about 1700 to about 2500; from about 1800 to about 2400; from about 1800 to about 2300; from about 1900 to about 2300; from about 2000 to about 2200; from about 2050 to about 2150; from about 2100.

[0243] In some embodiments, the organopolysiloxane is a compound of formula He:

wherein R ^1d , R ^3d , R ⁴⁰ , R ^M , R ⁶⁰ , R ^M , R ^9d and R ^10d are each independently selected from hydrogen, Ci-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or Ci-20 alkoxyl and g and j are each independently an integer from between 10 and about 6000. In one embodiment, R ^1d , R ^3d , R ^4d , R ^5d , R ^M , R ^M , R ^9d and R ^10d are alkyl {e.g., Ci alkyl, such as methyl). In some embodiments, the sum of g and j is an integer from about 200 to about 1100; from about 600 to about 1100; from about 700 to about 1000; from about 800 to about 900; from about 825 to about 875; from about 850; from about 200 to about 800; from about 225 to about 700; from about 250 to about 600; from about 275 to about 500; from about 300 to about 400; from about 350 to about 400; from about 375. In some embodiments, the sum of g and j is an integer from about 850.

[0244] In some embodiments, the organopolysiloxane is an alkenyl-functionalized organopolysiloxane. In one embodiment, the alkenyl-functionalized polymer comprises one or more alkenyl-functionalized side chains. In this embodiment, any of R1, Ra, R3, R4, Rs and R6 may independently be the fragment:

wherein Z is as defined above for Z1 and Z2 and Ra, Rb, and Rc are independently selected from hydrogen, substituted or unsubstituted branched or straight chain C1-C10 alkyl, alkenyl, or alkynyl group, including without limitation methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t- butyl, pentyl, hexyl, vinyl, allyl, butenyl, pentenyl, hexenyl, propynyl, butynyl, n-pentyl, iso- pentyl, neo-pentyl, tert-pentyl; cycloalkyl, heterocycloalkyl, haloalkyl, benzyl, alkyl-aryl;

substituted or unsubstituted aryl or heteroaryl groups; C1-C6 alkoxy, amino, alkyl amino, dialkyl amino, hydroxyl, carboxy, cyano, or halogen. Preferably R4 is methyl. Exemplary alkenyl- functionalized organopolysiloxanes include without limitation methylvinylsiloxanes, methylvinylsiloxane-dimethylsiloxane copolymers, dimethylvinylsiloxy -terminated

dimethylpolysiloxanes, dimethylvinylsiloxy-terminated dimethylsiloxane-methylphenylsiloxane copolymers, dimethylvinylsiloxy-terminated dimethylsiloxane-diphenylsiloxane- methylvinylsiloxane copolymers, trimethylsiloxy-terminated dimethylsiloxane- methylvinylsiloxane copolymers, trimethylsiloxy-terminated dimethylsiloxane- methylphenylsiloxane-methylvinylsiloxane copolymers, dimethylvinylsiloxy-terminated methyl(3,3,3-trifluoropropyl) polysiloxanes, and dimethylvinylsiloxy-terminated

dimethylsiloxane-methyl-(3,3,-trifluoropropyl)siloxane copolymers.

[0245] In one embodiment, provided herein is a composition comprising a curable silicone formulation containing: components (a), (d) and at least one of (b) or (c): [0246] a. a polyorganosiloxane resin, composed of M and Q units having at least 3 alkenyl groups per molecule, herein after called“SiVi” groups,

[0247] b. a polyorganosiloxane compound having at least 2 Si-bonded hydrogen groups on the polysiloxane chain, hereinafter called“SiH” groups,

[0248] c. a telechelic polyorganosiloxane compound having terminal Si— H groups, and

[0249] d. a hydrosilylation catalyst for the reaction of SiH groups with SiVi groups,

[0250] e. a liquid diluent in an amount of from 0% to maximum 40% by weight of the composition said components reacting together by hydrosilylation at a temperature below 40° C. when they cure to form a continuous film on the substrate.

[0251] In one embodiment, a formulation meeting these requirements is able to cure quickly at room temperature/ambient as a film on a substrate and can provide good balance between adhesion and tackiness requirements; the film can show good adhesion to the substrate while the surface opposite to the substrate shows low tack.

[0252] In one embodiment, the organopolysiloxane is a polydiorganosiloxane resin having at least 3 silicon-bonded alkenyl groups per molecule, with preferably the remaining silicon-bonded organic groups being selected from alkyl and aryl groups, said polydiorganosiloxane resin preferably has a molecular weight from 1,500 daltons to 50,000 daltons.

Suitable polyorganosiloxane resins having silicon bonded unsaturated groups (a) are those with sufficient unsaturated groups for formation of the polymer network. The functional siloxane resin structure may comprise R3S1O1/2 units (M units) and S1O4/2 units (Q units) wherein each R is independently a linear, branched or cyclic hydrocarbon group having 1-20 carbon atoms. Each R can be identical or different, as desired. The hydrocarbon group of R can be exemplified by alkyl groups such as methyl, ethyl, propyl, butyl, hexyl, octyl, vinyl, hexenyl and aryl groups such as phenyl.

6.1.7 Hydride Functionalized Polysiloxane

[0253] In some embodiments, the composition comprises at least one hydride functionalized polysiloxane. The language“hydride functionalized polysiloxane” includes compounds of formula IP:

wherein R ^1b , R ^2b , R ^3b , R ^4b , R ^5b , R ^6b , R ^7b , R ^8b , R ^9b and R ^10b are each independently selected from hydrogen, C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or C1-20 alkoxy and m and n are each independently an integer from between 10 and about 6000, provided that at least one of R ^1b , R ^2b , R ^3b , R ^4b , R ^5b , R ⁶⁶ , R ⁷⁶ , R ^to , R ^9b and R ^10b is hydrogen. In some embodiments, at least one of R ^1b , R ^2b , R ^3b , R ^4b , R ^5b , R ^6b , R ^7b , R ^8b , R ^9b and R ^10b is hydrogen and the remainder are C1-20 alkyl. In some embodiments, at least two of R ^1b , R ^2b , R ^3b , R ^4b , R ^5b , R ^6b , R ^7b , R ^8b , R ^9b and R ^10b are hydrogen (e.g., two Si-H units per functionalized hydride polysiloxane molecule). In other embodiments, at least three of R ^1b , R ^a , R ^3b , R ^4b , R ^5b , R ^6b , R ^7b , R ^8b , R ^9b and R ^10b are hydrogen (e.g., three Si-H units per functionalized hydride polysiloxane molecule). In some embodiments, at least two of R ^1b , R ^2b , R ^3b , R ^4b , R ^5b , R ^6b , R ^7b , R ^8b , R ^9b and R ^10b are hydrogen (e.g., two Si-H units per functionalized hydride polysiloxane molecule) and the remainder are C1-20 alkyl. In other embodiments, at least three of R ^1b , R ^2b , R ^3b , R ^4b , R ^5b , R ^6b , R ^7b , R ^8b , R ^9b and R ^10b are hydrogen (e.g., three Si-H units per functionalized hydride polysiloxane molecule) and the remainder are C1-20 alkyl. In some embodiments, at least two of R ^4b , R ^5b , R ^9b and R ^10b are hydrogen (e.g., two Si-H units per functionalized hydride polysiloxane molecule) and the remainder are C1-20 alkyl. In other embodiments, at least three of R ^4b , R ^5b , R ^9b and R ^10b are hydrogen (e.g., three Si-H units per functionalized hydride polysiloxane molecule) and the remainder are C1-20 alkyl. In some embodiments, at least two of R ^4b , R ^5b , R ^9b and R ^10b are hydrogen (e.g., two Si-H units per functionalized hydride polysiloxane molecule) and the remainder and R ^1b , R ^2b , R ^3b , R ^6b , R ^7b , and R ^8b are C1-20 alkyl. In other embodiments, at least three of R ^4b , R ^5b , R ^9b and R ^10b are hydrogen (e.g., three Si-H units per functionalized hydride polysiloxane molecule) and the remainder and R ^1b , R ^2b , R ^3b , R ^6b , R ^7b , and R ^8b are C1-20 alkyl.

[0254] In one embodiment, at least greater than two monomer units of formula IP include a -

Si-H unit (e.g. one or more of R ⁴⁶ , R ^5b , R ^9b and R ^10b is hydrogen). In one embodiment, at least greater than two monomer units of formula IP include a -Si-H unit (e.g. one or more of R ^4b , R ^5b , R ^9b and R ^10b is hydrogen) and the remaining non-Si-H monomer units are S1-CH3. For example, on average 2 to 15 monomer units of formula IP include a Si-H unit. In one embodiment, at least two monomer units of formula IP include a -Si-H unit (e.g. one or more of R ^4b , R ^5b , R ^9b and R ^10b is hydrogen). In one embodiment, at least three monomer units of formula IP include a -Si- ll unit (e.g. one or more of R ^4b , R ^5b , R ^9b and R ^10b is hydrogen). In one embodiment, at least four monomer units of formula III include a -Si-H unit (e.g. one or more of R ^4b , R ^5b , R ^9b and R ^10b is hydrogen). In one embodiment, at least five monomer units of formula IP include a -Si-H unit (e.g. one or more of R ^4b , R ^5b , R ^9b and R ^10b is hydrogen). In one embodiment, at least six monomer units of formula IP include a -Si-H unit (e.g. one or more of R ^4b , R ^5b , R ^9b and R ^10b is hydrogen). In one embodiment, at least seven monomer units of formula IP include a -Si-H unit (e.g. one or more of R ^4b , R ^5b , R ^9b and R ^10b is hydrogen). In one embodiment, at least eight monomer units of formula IP include a -Si-H unit (e.g. one or more of R ^4b , R ^5b , R ^9b and R ^10b is hydrogen). In a specific embodiment, the non Si-H positions may include a Si-(alkyl) or Si- (vinyl) unit. In a specific embodiment, the non-Si-H positions are S1-CH3. In some of the embodiments, R ^1b , R ^a , R ^3b , R ^6b , R ^7b , and R ^8b are Ci-20 alkyl. In a specific embodiment, the Si-H positions are not present in the terminal caps. In some embodiments, the compound of formula IP is substantially alkyl-terminated. In some embodiments, the compound of formula IP is alkyl-terminated. In one embodiment, the Si-H units in the hydride-functionalized

organopolysiloxanes are separated by 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 65, 70, 75, 80, 85, 90, 100, 125, 150, or 200 monomer units.

[0255] In one aspect of any one of the above embodiments, the sum of m and n is an integer from about 10 to about 1300; from about 10 to about 1100; from about 10 to about 600; from about 15 to about 500; from about 15 to about 400; from about 20 to about 300; from about 20 to about 200; from about 25 to about 100; from about 25 to about 75; from about 30 to about 50; from about 40.

[0256] In some embodiments, the hydride functionalized polysiloxane includes Si-H units only at the terminal caps of the polymer. In some embodiments, the polysiloxane include Si-H units only in the monomer units, but not at the terminal caps of the polymer. In other embodiments, the polysiloxane includes Si-H units at both the terminal cap or in the monomer unit of the polymer. In one embodiment, the polysiloxane includes two to twelve Si-H units on average located either at the terminal cap, or within the monomer unit, or a combination thereof. In one embodiment, the polysiloxane includes four to fifteen Si-H units on average located either at the terminal cap, or within the monomer unit, or a combination thereof. In one embodiment, the polysiloxane includes eight Si-H units on average located either at the terminal cap, or within the monomer unit, or a combination thereof. In one embodiment, the polysiloxane includes two to twelve Si-H units on average located within the monomer unit, and not at the terminal caps. In one embodiment, the polysiloxane includes four to fifteen Si-H units on average located within the monomer unit, and not at the terminal caps. In one embodiment, the polysiloxane includes eight Si-H units on average located within the monomer unit, and not at the terminal caps. In some embodiments, the hydride functionalized polysiloxane is substantially alkyl terminated.

[0257] In other embodiments, the hydride functionalized polysiloxane is alkyl terminated. In other embodiments, the hydride functionalized polysiloxane is substantially alkyl terminated. The language“alkyl terminated” includes hydride functionalized polysiloxanes of formula III in which one or both of R ^2b and R ^7b are Ci-20 alkyl. In some embodiments,“alkyl terminated” includes hydride functionalized polysiloxanes of formula IP in which one, two, three, four , five or six of R ^1b , R ^2b , R ^3b , R ^6b , R ^7b and R ^8b are Ci-20 alkyl. In one embodiment, R

each Ci-20 alkyl, for example, Ci alkyl (e.g., methyl) and R ^9b is

hydrogen. In one embodiment, are each Ci-20 alkyl, for example, C1 alkyl (e.g., methyl) and R ^10b is hydrogen.

[0258] In certain embodiments, the organopolysiloxane having carbon double bonds has a weight percent of carbon double bond-containing monomer units of between about 0.01 and about 2%, and preferably, between about 0.03 and about 0.6%. In certain embodiments, the organopolysiloxane having carbon double bonds has a vinyl equivalent per kilogram of between about 0.005 and about 0.5, and preferably, between about 0.01 and about 0.25. An approximate molar amount of the carbon double bonds in the organopolysiloxane can be calculated based on the average molecular weight of the organopolysiloxane.

[0259] In certain embodiments, the vinyl functionalized organopolysiloxane has a viscosity above about 100 cP and below about 1,000,000 cP at about 25 °C. In certain embodiments, the vinyl functionalized organopolysiloxane has a viscosity below about 750,000 cP, below about 500,000 cP, or below about 250,000 cP at about 25 °C. In preferred embodiments, the vinyl functionalized organopolysiloxane has a viscosity below about 200,000 cP, below about 175,000 cP, below about 150,000 cP, below about 125,000 cP, below about 100,000 cP, or below about 80,000 cP at about 25 °C. In certain embodiments, the vinyl functionalized organopolysiloxane has a viscosity above about 100 cP, above about 500 cP, or above about 1000 cP at about 25 °C. In preferred embodiments, the vinyl functionalized organopolysiloxane has a viscosity above about 2000 cP, above about 5000 cP, above about 7500 cP, or above about 10,000 cP at about 25 °C. In further preferred embodiments, the vinyl functionalized organopolysiloxane has a viscosity above about 15,000 cP at about 25 °C.

[0260] In certain embodiments, the vinyl functionalized organopolysiloxane has a viscosity between about 10,000 and about 2,000,000 cSt at about 25 °C. In preferred embodiments, the vinyl functionalized organopolysiloxane has a viscosity above about 20,000, above about 40,000, above about 60,000, above about 80,000, or above about 100,000 cSt at about 25 °C. In further preferred embodiments, the vinyl functionalized organopolysiloxane has a viscosity above about 125,000 or above about 150,000 cSt at about 25 °C. In preferred embodiments, the vinyl functionalized organopolysiloxane has a viscosity below about 1,000,000 cSt, below about 500,000 cSt, below about 450,000, below about 400,000, below about 350,000, below about 300,000, or below about 250,000 cSt at about 25 °C. In further preferred embodiments, the vinyl functionalized organopolysiloxane has a viscosity below about 200,000 or below about 180,000 cSt at about 25 °C. In further preferred embodiments, the vinyl functionalized

organopolysiloxane has a viscosity of about 165,000 cSt at about 25 °C.

[0261] In certain embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight between about 60,000 Da and about 500,000 Da. In preferred embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight above about 72,000 Da, about 84,000 Da, about 96,000 Da, or about 100,000 Da. In further preferred embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight above about 140,000 Da, or about 150,000 Da. In preferred embodiments, the vinyl

functionalized organopolysiloxane has an average molecular weight below about 200,000 Da, below about 190,000 Da, about 180,000 Da, or about 170,000 Da. In further preferred embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight below about 160,000 Da. In further preferred embodiments, the vinyl functionalized

organopolysiloxane has an average molecular weight of about 155,000 Da.

[0262] In certain embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight between about 400 and about 500,000 Da. In preferred embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight above about 500 Da, about 800 Da, about 1,200 Da, or about 1,800 Da. In further preferred embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight above about 2,000 Da. In preferred embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight below about 250,000 Da, below about 140,000 Da, below about 100,000 Da, below about 72,000 Da, below about 62,700 Da, below about 49,500 Da, below about 36,000 Da, or below about 28,000 Da. In further preferred embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight below about 17,200 Da. In further preferred embodiments, the vinyl functionalized organopolysiloxane has an average molecular weight between about 2,200 Da and 6,000 Da.

[0263] In certain embodiments, the molar ratio of Si-H functional group to alkenyl (e.g, vinyl) functional group is from about 60: 1 to about 1:5. In preferred embodiments, the molar ratio of Si-H functional group to alkenyl-functional group from is about 45: 1 to about 15:1. In certain embodiments, the molar ratio of Si-H functional group to alkenyl-functional group is from about 60: 1 to about 1:5. In preferred embodiments, the molar ratio of Si-H functional group to alkenyl-functional group from is about 45:1 to about 15:1. In certain embodiments, the Si-H to alkenyl molar ratio of the polymers in the composition is about 1 : 5 to about 60: 1 ; about 10:1 to about 30:1; or about 20:l to about 25:1. In certain embodiments, the molar ratio of Si-H functional group to alkenyl-functional group from is about 10:1 to about 100:1. In preferred embodiments, the molar ratio of Si-H functional group to alkenyl-functional group from is about 30: 1 to about 60: 1. In preferred embodiments, the molar ratio of Si-H functional group to alkenyl-functional group from is about 20: 1 to about 50: 1.

[0264] In one embodiment, the unsaturated organopolymer is an organopolymer with one or more unsaturated function groups, non-limiting examples of which include one or more of vinyl groups, alkynyl groups, alkenyl groups, unsaturated fatty alcohols, unsaturated fatty acids, unsaturated fatty esters, unsaturated fatty amide, unsaturated fatty urethane, unsaturated fatty urea, ceramide, cocetin, lecithin and sphingosine. In one embodiment, the unsaturated organopolymer is a vinyl functionalized organopolysiloxane. In one embodiment, the unsaturated organopolymer is an alkynyl functionalized organopolysiloxane, e.g., an ethynyl functionalized organopolysiloxane or a propynyl functionalized organopolysiloxane. In one embodiment, the unsaturated organopolymer is an alkenyl functionalized organopolysiloxane, e.g., an allyl functionalized organopolysiloxane or a crotyl functionalized organopolysiloxane. [0265] In one embodiment, the vinyl functionalized organopolysiloxane is vinyl terminated. In preferred embodiments, the vinyl functionalized organopolysiloxane is selected from vinyl terminated polydimethylsiloxane, vinyl terminated diphenylsiloxane-dimethylsiloxane copolymers, vinyl terminated polyphenylmethylsiloxane, vinylphenylmethyl terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl terminated

trifluoropropylmethylsiloxane-dimethylsiloxane copolymer, vinyl terminated diethylsiloxane- dimethylsiloxane copolymer, vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy terminated, vinylmethylsiloxane-dimethylsiloxane copolymers, silanol terminated,

vinylmethylsiloxane-dimethylsiloxane copolymers, vinyl terminated, vinyl gums,

vinylmethylsiloxane homopolymers, vinyl T-structure polymers, vinyl Q-structure polymers, monovinyl terminated polydimethylsiloxanes, vinylmethylsiloxane terpolymers,

vinylmethoxysilane homopolymers, vinyl terminated polyalkylsiloxane polymers, vinyl terminated polyalkoxysiloxane polymers and combinations thereof. In further preferred embodiments, the vinyl functionalized organopolysiloxane is vinyl dimethicone.

[0266] In a preferred embodiment, the Si-H units in the hydride functionalized polysiloxane are spaced on average by at least about 1 monomer units, about 2 monomer units, about 5 monomer units, about 10 monomer units, about 20 monomer units, about 40 monomer units, about 200 monomer units, about 400 monomer units, about 1,000 monomer units, or about 2,000 monomer units.

[0267] In certain embodiments, the hydride functionalized polysiloxane has a viscosity between about 2 to about 500,000 cSt at about 25 °C. In preferred embodiments, the hydride functionalized polysiloxane has a viscosity above about 3 cSt, above about 4 cSt, or above about 12 cSt at about 25 °C. In further preferred embodiments, the hydride functionalized polysiloxane has a viscosity above about 40 cSt at about 25 °C. In preferred embodiments, the hydride functionalized polysiloxane has a viscosity below about 200,000, below about 100,000, below about 50,000, below about 20,000, below about 10,000, below about 5,000, below about 2,000, or below about 1,000 cSt at about 25 °C. In further preferred embodiments, the hydride functionalized polysiloxane has a viscosity below about 500 cSt at about 25 °C. In further preferred embodiments, the hydride functionalized polysiloxane has a viscosity between about 45 to about 100 cSt at about 25 °C. [0268] In certain embodiments, the hydride functionalized polysiloxane having Si-H units includes such Si-H units at terminal units of the polymer, in non-terminal monomer units of the polymer, or a combination thereof. In preferred embodiments, the hydride functionalized polysiloxane having Si-H units includes such Si-H units in non-terminal monomer units of the polymer. In preferred embodiments, the Si-H-containing monomer units in the hydride functionalized polysiloxane are spaced on average by at least about 1 monomer units, about 2 monomer units, about 5 monomer units, about 10 monomer units, about 20 monomer units, about 40 monomer units, about 200 monomer units, about 400 monomer units, about 1,000 monomer units, or about 2,000 monomer units.

[0269] In certain embodiments, the hydride functionalized polysiloxane having Si-H units has a weight percent of Si-H-containing monomer units of between about 0.003 and about 50%, and preferably, between about 0.01 and about 25%. In certain embodiments, the hydride functionalized polysiloxane having Si-H units has an Si-H content of between about 0.1 mmol/g and about 20 mmol/g, about 0.5 mmol/g and about 10 mmol/g, and preferably, between about 1 mmol/g and about 5 mmol/g. An approximate molar amount of the Si-H units in the hydride functionalized polysiloxane can be calculated based on the average molecular weight of the organopolysiloxane. Average molecular weight, or molar mass, of the ingredients disclosed herein are commonly provided by the supplier of the ingredients, expressed in units of Dalton (Da) or its equivalent g/mol.

[0270] In preferred embodiments, the hydride functionalized polysiloxane is selected from hydride terminated polydimethylsiloxane, hydride terminated polyphenyl- (dimethylhydrosiloxy)siloxane, hydride terminated methylhydrosiloxane-phenylmethylsiloxane copolymer, trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymers, polymethylhydrosiloxanes, trimethylsiloxy terminated, polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer, methylhydrosiloxane- phenyloctylmethylsiloxane terpolymer, and combinations thereof. In further preferred embodiments, the hydride functionalized polysiloxane is hydrogen dimethicone.

[0271] Exemplary hydride functionalized polysiloxanes include without limitation alkyltrihydrosilanes, aryltrihydro-silanes, dialkyldihydrosilanes, diaryidihydrosilanes, trialky lhydrosilanes, triarylhydrosilanes, alkylhydrosiloxanes and arylhydrosiloxanes. Special mention may be made of polymethylhydrosiloxanes, t-butyldimethylhydrosilane, triethylhydrosilane, diethyldihydrosilane, triisopropylhydrosilane and mixtures thereof.

[0272] In some embodiments, the hydride functionalized polysiloxane is a hydrosilicon compound having at least 2 silicon-bonded hydrogen atoms per molecule, which preferably consists essentially of RHSiO- groups, R2ZS1O- groups and optionally R2S1O- groups and preferably has a viscosity at about 25° C of no more than 1,000 mm ² /s, wherein R denotes an alkyl or aryl group having no more than 8 carbon atoms, and Z denotes H or R

[0273] In certain embodiments, the organosiloxane polymers can be prepared according to the methods described in the disclosures of U.S. Patent Nos. 8,691,202, 9,114,096, 9,308,221,

9,333,223, 9,724,363, 9,937,200 and 10,022,396 and International Patent Publication No. WO 2017/083398, the disclosures of which are incorporated herein by reference in their entireties. The siloxane polymers can be also prepared according to other methods apparent to those of skill in the art

6.1.8 Single Formulation Organopolysiloxane Polymer For Use With The Compositions And Methods Provided Herein

[0274] Without being bound by theory, the ability of the ligand to reduce or prevent the activity of the catalyst to cross-link the unsaturated organopolymer and the hydride

functionalized polysiloxane makes it possible to formulate the various components into a single formulation without cross-linking and polymer-formation prior to the application of the formulation, e.g., by applying the formulation to the skin of a subject Without being bound by theory, the ability of the encapsulating agent to reduce or prevent the activity of the catalyst to cross-link the unsaturated organopolymer and the hydride functionalized polysiloxane, or to reduce or prevent the activity of hydride functionalized polysiloxane to react with the unsaturated organopolymer as facilitated by catalyst, makes it possible to formulate the various components into a single formulation without cross-linking and polymer-formation prior to the application of the formulation, e.g., by applying the formulation to the skin of a subject

[0275] Without being bound by theory, the ability of the ligand to reduce or prevent the activity of the catalyst to cross-link the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane makes it possible to formulate the various components into a single formulation without cross-linking and polymer-formation prior to the application of the formulation, e.g., by applying the formulation to the skin of a subject Without being bound by theory, the ability of the encapsulating agent to reduce or prevent the activity of the catalyst to cross-link the vinyl functionalized organopolysiloxane and the hydride functionalized

polysiloxane, or to reduce or prevent the activity of hydride functionalized polysiloxane to react with the vinyl functionalized organopolysiloxane as facilitated by catalyst, makes it possible to formulate the various components into a single formulation without cross-linking and polymer- formation prior to the application of the formulation, e.g., by applying the formulation to the skin of a subject.

[0276] Provided herein is a single formulation that enables one-step room temperature vulcanizing (RTV). In one embodiment, the formulation provided herein is capable of vulcanizing at room temperature in one-step. In one embodiment, the formulation provided herein is capable of vulcanizing at room temperature in one-step, without the need to a priori separate into formulations containing hydride functional groups and the catalyst individually.

6.1.9 Reinforcing Constituents For Use With The Methods Provided Herein

[0277] In preferred embodiments, a composition provided herein further comprises one or more reinforcing constituent(s). In certain embodiments, the reinforcing constituent is selected from surface treated carbon, silver, mica, zinc sulfide, zinc oxide, titanium dioxide, aluminum oxide, clay (e.g., AI2O3, S1O2), chalk, talc, calcite (e.g., CaCCb), barium sulfate, zirconium dioxide, polymer beads and silica (e.g., silica aluminates, calcium silicates, or surface treated silica (e.g., fumed silica, hydrated silica, or anhydrous silica)), or a combination thereof. Such reinforcing constituents reinforce the physical properties of the layer as discussed herein. In preferred embodiments, the reinforcing constituent is surface treated silica, for example, silica treated with hexamethyldisilazane, polydimethylsiloxane, hexadecylsilane or methacrylsilane. In further preferred embodiments, the reinforcing constituent is fumed silica, including fumed silica having been surface treated with hexamethyldisilazane. In further preferred embodiments, the reinforcing constituent comprises nanofibers.

[0278] In certain embodiments, the particles of the reinforcing constituent have an average surface area of between about 50 and about 1000 m ² /g. In certain embodiments, the particles of the reinforcing constituent have an average surface area of between about 50 and about 500 m ² /g. In preferred embodiments, the particles of the reinforcing constituent have an average surface area of between about 100 and about 3 SO m ² /g. In further preferred embodiments, the particles of the reinforcing constituent have an average surface area of between about 135 and about 250 m ² /g. In certain embodiments, the reinforcing constituent has an average particle diameter of between about 1 nm and about 20 mm. In preferred embodiments, the reinforcing constituent has an average particle diameter of between about 2 nm and about 1 mm, and further preferably between about 5 nm and about 50 nm.

6.1.10 Optional Additional agents

[0279] In some embodiments, the film is used in combination with one or more additional therapeutic agents. In some embodiments, the additional therapeutic agent is a moisturizer, mineral oil, petroleum jelly, coal tar, anthralin, corticosteroids, fluocinonide, vitamin D3 analogues, retinoids, phototherapy, methotrexate, cyclosporine, a monoclonal antibody, pimecrolimus, tacrolimus, azathioprine, fluoruracil, salicylic acid, benzoyl peroxide, antibiotics or alpha-hydroxy acids.

6.2 Additives For Use With The Compositions And Methods Provided Herein

[0280] In certain embodiments, the composition further comprises one or more additives. In certain embodiments, the composition provided herein further independently comprise(s) one or more additives. Suitable additives include, but are not limited to, feel modifiers, tack modifiers, spreadability enhancers, diluents, adhesion modifiers, volatile siloxanes, emulsifiers, emollients, surfactants, lubricants, thickeners, solvents, film formers, humectants, preservatives, pigments, skin permeation enhancers, optic modifiers, gas transport modifiers, liquid transport modifiers, pH modifiers, sensitizing modifiers, aesthetic modifiers, and a combination thereof. Additional suitable additives are disclosed in the International Nomenclature Cosmetic Ingredient (INCI) dictionary, which is incorporated herein by reference in its entirety. In preferred embodiments, the emulsifiers are alkoxydimethicone, alkyldimethicone, amodimethicone, sulfodimethicone, phosphodimethicone, borodimethicone, halodimethicone, fluorodimethicone, chlorodimethicone, bromodimethicone, charged dimethicone, and a combination thereof. In preferred embodiments, the emulsifiers are of linear-type, branch-type, elastomeric-type network, elastomeric-type organic/inorganic network, and a combination thereof.

[0281] In certain embodiments, the composition further comprises one or more additional agents. In certain embodiments, the composition provided herein further independently comprises) one or more additional agents, including cosmetic agents, therapeutic agents, stimuli-responsive agents, sensing agents, drag-delivery agents, optical agents, coloring agents, pigments, scattering agents, sorbing agents, temperature-active agents, heat-active agents, UV- active agents, light-active agents, sound-active agents, pressure-active agents, motion-active agents, radioactive agents, electrical agents, magnetic agents, and other beneficial agents.

6.2.1 Cosmetic Agents

[0282] Suitable cosmetic agents include, but are not limited to, moisturizers, sunscreens, UV protecting agents, skin-protectant agents, skin-soothing agents, skin-lightening agents, skin- brightening agents, skin-softening agents, skin- smoothening agents, skin-bleaching agents, skin- exfoliating agents, skin-tightening agents, cosmeceutical agents, vitamins, anti-oxidants, cell- signaling agents, cell-modulating agents, cell-interacting agents, skin tanning agents, anti-aging agents, anti-wrinkle agents, spot reducers, alpha-hydroxy acids, beta-hydroxy acids, ceramides, and a combination thereof.

6.2.2 Therapeutic Agents

[0283] Suitable therapeutic agents include, but are not limited to nerve modulating agents, pain-relievers, analgesics, anti-itching agents, anti-irritants, counterirritants, immunomodulating agents, immune system boosting agents, immune system suppressing agents, anthralin, fiuocinonide, methotrexate, cyclosporine, pimecrolimus, tacrolimus, azathioprine, fiuoruracil, ceramides, anti-acne agents (beta-hydroxy acids, salicylic acids, benzoyl peroxide), anti- flammatory agents, antihistamines, corticosteroids, NSAIDs (Non- Steroidal Anti-Inflammatory Drags), blood-coagulating agents, antineoplastics, microbiome modulating agents, anti-septic agents, antibiotics, anti-bacteria agents, anti-fungal agents, anti- viral agents, anti-allergenic agents, skin protection agents, coal tars, insect-repelling agents, phototherapy agents, magnetotherapy agents, sonotherapy agents, thermotherapy agents, skin thermal regulating (cooling or heating) agents, or a combination thereof.

6.2.3 Beneficial Agents

[0284] Suitable beneficial agents include, but are not limited to, anti-oxidants, vitamins, vitamin D3 analogues, retinoids, minerals, mineral oil, petroleum jelly, fatty acids, plant extracts, polypeptides, antibodies, proteins, sugars, lipids, fatty acids, alcohols, esters, ceramides, chemokines, cytokines, hormones, neurotransmitters, lubricants, humectants, emollients, a combination thereof, and other similar agents beneficial for topical application known in the art.

6.3 Methods OfUsine

[0285] Provided herein is a method of using a composition provided herein as a single formulation in a one-step method without the need to separate the hydride and the catalyst complex from each other before application to the skin of a subject.

[0286] Provided herein is a method of using a composition provided herein to form a thin film on the skin of a subject In certain embodiments, such a method comprises separating the ligand from the catalyst {e.g, transition metal) or from the hydride functionalized polysiloxane in a composition provided herein. Without being limited by theory, separating the ligand from the catalyst {e.g., transition metal) or from the hydride functionalized polysiloxane accelerates the cross-linking reaction. In certain embodiments, such a composition comprises (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride

functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, such a composition comprises (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the separating step involves evaporating the ligand, absorbing the ligand into another phase, absorbing the ligand into the skin of a subject, absorbing the ligand into another ingredients forming a complex, transforming the ligand into non-complex with the transition metal or with the hydride functionalized polysiloxane, heating the composition, cooling the composition, applying ultrasound on the composition, applying electromagnetic waves on the composition, applying visible light on the composition, applying ultraviolet light on the composition, or applying infrared radiation on the composition. Provided herein is a method of using a composition provided herein as a single formulation in a one-step method, comprising separating at least one divinyl disiloxane from platinum in a composition provided herein, such as a composition that comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the divinyl disiloxane at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride

functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. Provided herein is a method of using a composition provided herein as a single formulation in a one-step method, comprising separating at least one divinyl disiloxane from platinum in a composition provided herein, such as a composition that comprises (a) the platinum; (b) at least one vinyl functionalized

organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the divinyl disiloxane at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the method comprises separating the ligand from the transition metal or from the hydride functionalized polysiloxane by evaporating the ligand with or without using heat.

[0287] Provided herein is a method of using a composition provided herein to form a thin film on the skin of a subject In certain embodiments, such a method comprises separating the encapsulating agent from the catalyst (e.g, transition metal) or from the hydride functionalized polysiloxane in a composition provided herein. Without being limited by theory, separating the encapsulating agent from the catalyst (e.g., transition metal) accelerates the cross-linking reaction or separating the encapsulating agent from the hydride functionalized polysiloxane enables the cross-linking reaction. In certain embodiments, such a composition comprises (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down or prohibit cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, such a composition comprises (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down or prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In certain embodiments, the separating step involves evaporating the encapsulating agent, absorbing the encapsulating agent into another phase, absorbing the encapsulating agent into the skin of a subject, absorbing the encapsulating agent into another ingredients forming a complex, transforming the encapsulating agent into non- microcapsule with the transition metal or with the hydride functionalized polysiloxane, heating the composition, cooling the composition, applying ultrasound on the composition, applying electromagnetic waves on the composition, applying visible light on the composition, applying ultraviolet light on the composition, or applying infrared radiation on the composition. Provided herein is a method of using a composition provided herein as a single formulation in a one-step method, comprising separating at least one polyurethane- 1 from platinum or from the hydride functionalized polysiloxane in a composition provided herein, such as a composition that comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the polyurethane- 1 at a concentration sufficient to slow down or prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. Provided herein is a method of using a composition provided herein as a single formulation in a one-step method, comprising separating at least one polyurethane- 1 from platinum or from the hydride functionalized polysiloxane in a composition provided herein, such as a composition that comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized

polysiloxane; and (d) the polyurethane- 1 at a concentration sufficient to slow down or prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the method comprises separating the encapsulating agent from the transition metal or from the hydride functionalized polysiloxane by evaporating the encapsulating agent with or without using heat.

[0288] The present invention is based, at least in part, on the discovery that durable, natural looking, non-invasive compositions that are used in cosmetic applications for masking skin and body imperfections are useful in treating conditions of compromised skin barrier function such as dermatological disorders or conditions and post-laser or light-treatment recovery management or chemical peel treatment management Provided herein is a durable, convenient, long-lasting coating with skin occlusive benefits. The formulation, composition or film of the invention provides a transparent or a tinted coating for the treatment site. The formulations, compositions or films of the invention are more comfortable because each form an aesthetically pleasing, durable, skin conforming flexible layer over the skin, thereby increasing subject compliance as compared to current coatings or dressings or patches. Moreover, the chemical and physical properties of the formulation, composition or film of the invention are tunable to form a coating that is best suited for the location on the subject and the type of dermatological disorder or condition to be treated or the location on the subject of the laser or light or chemical treatment and the type of laser or light or chemical peel treatment used.

[0289] In one embodiment, provided herein is a method for treating a dermatological disorder in a subject in need thereof, comprising: applying to the subject’s skin a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated

organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating the dermatological disorder.

[0290] In one embodiment, provided herein is a method for treating a dermatological disorder in a subject in need thereof, comprising: applying to the subject’s skin a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating the dermatological disorder.

[0291] In one embodiment, provided herein is a method for treating a dermatological disorder in a subject in need thereof, comprising: applying to the subject’s skin a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating the dermatological disorder.

[0292] In one embodiment, provided herein is a method for treating a dermatological disorder in a subject in need thereof, comprising: applying to the subject’s skin a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating the dermatological disorder.

[0293] In one embodiment, provided herein is a method for treating symptoms of conditions of compromised skin barrier function with the formulations and films disclosed herein. In one aspect of this embodiment, the invention provides formulations, film and methods for treating itchy skin; for treating raw skin; for treating dry skin; for treating flaking or peeling skin; for treating blisters on skin; for treating redness or swelling or inflammation of the skin; or for treating oozing, scabbing and scaling skin.

[0294] In one embodiment, provided herein is a method for occluding skin on a subject in need thereof, comprising: applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby occluding the skin.

[0295] In one embodiment, provided herein is a method for occluding skin on a subject in need thereof, comprising: applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby occluding the skin.

[0296] In one embodiment, provided herein is a method for occluding skin on a subject in need thereof, comprising: applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby occluding the skin.

[0297] In one embodiment, provided herein is a method for occluding skin on a subject in need thereof, comprising: applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby occluding the skin.

[0298] In a specific embodiment, occlusion of skin is used to treat conditions of

compromised skin barrier such as dermatological disorders and skin after light or laser or chemical peel treatment

[0299] In one embodiment, provided herein is a method for hydrating skin in a subject in need thereof, comprising: applying to the subject’s skin a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby hydrating the skin.

[0300] In one embodiment, provided herein is a method for hydrating skin in a subject in need thereof, comprising: applying to the subject’s skin a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby hydrating the skin.

[0301] In one embodiment, provided herein is a method for hydrating skin in a subject in need thereof, comprising: applying to the subject’s skin a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane, such that a film is formed on skin, thereby hydrating the skin. [0302] In one embodiment, provided herein is a method for hydrating skin in a subject in need thereof, comprising: applying to the subject’s skin a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby hydrating the skin.

[0303] In at least one embodiment, the subject has one or more dermatological disorders. In at least one embodiment, the subject has one dermatological disorder. In at least one

embodiment, the subject has more than one dermatological disorder. In at least one embodiment, the subject has a condition that results in or is associated with a dermatological disorder.

[0304] In at least one embodiment, the dermatological disorder is lichen simplex chronicus, cutaneous lupus, psoriasis, eczema, chronic dry skin, xeroderma, rosacea, ichthyosis, or an ulcer, or any combination thereof. In a specific embodiment, the dermatological disorder is xeroderma, eczema, psoriasis, rosacea and ichthyosis or any combination thereof. In a specific embodiment, the eczema is atopic dermatitis. In a particular embodiment, the dermatological disorder is xeroderma, atopic dermatitis, psoriasis, rosacea and ichthyosis or any combination thereof. In a particular embodiment, the dermatological disorder is an ulcer.

[0305] In one embodiment, provided herein are non-invasive formulations that form a film upon application to the subject, thereby ameliorating dermatological disorders. In one embodiment, provided herein are methods of using such formulations. In one embodiment, provided herein are cleansers to remove the film.

[0306] In one embodiment, provided herein is a composition for treating a dermatological disorder in a subject in need thereof, in which a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In one embodiment, provided herein is a composition for treating a dermatological disorder in a subject in need thereof, in which a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; wherein the catalyst facilitates in situ cross- linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin.

[0307] In one embodiment, provided herein is a composition for treating a dermatological disorder in a subject in need thereof, in which a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In one embodiment, provided herein is a composition for treating a dermatological disorder in a subject in need thereof, in which a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin.

[0308] In one embodiment, provided herein are films to treat a dermatological disorder prepared by a process comprising the steps of: a) applying a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In one embodiment, provided herein are films to treat a dermatological disorder prepared by a process comprising the steps of: a) applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin.

[0309] In one embodiment, provided herein are films to treat a dermatological disorder prepared by a process comprising the steps of: a) applying a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In one embodiment, provided herein are films to treat a dermatological disorder prepared by a process comprising the steps of: a) applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane, such that a film is formed on skin.

[0310] In one embodiment, provided herein are methods for delivering an agent to a subject to treat a dermatological disorder, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross- linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject. In one embodiment, provided herein are methods for delivering an agent to a subject to treat a dermatological disorder, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject.

[0311] In one embodiment, provided herein are methods for delivering an agent to a subject to treat a dermatological disorder, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized

organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject In one embodiment, provided herein are methods for delivering an agent to a subject to treat a dermatological disorder, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject.

[0312] In some aspects, provided herein is a kit for use in treating a subject with a dermatological disorder a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; and instructions for use. In some aspects, provided herein is a kit for use in treating a subject with a dermatological disorder a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; and instructions for use.

[0313] In some aspects, provided herein is a kit for use in treating a subject with a dermatological disorder a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; and instructions for use. In some aspects, provided herein is a kit for use in treating a subject with a dermatological disorder a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; and instructions for use.

[0314] In one embodiment, provided herein are therapeutic formulations for application to treat a dermatological disorder in a subject in need thereof, comprising at least one preselected function modulating component, in which the composition forms a therapeutic film upon application to the subject

[0315] In one embodiment, provided herein are therapeutic formulations for application to a subject to treat a dermatological disorder that target a treatment area on the subject, comprising at least one preselected treatment specific component, wherein the composition forms a therapeutic film upon application to the target treatment area on the subject.

[0316] In one embodiment, provided herein is a film removing cleanser for use in removing a therapeutic film to treat a dermatological disorder, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane. In one embodiment, provided herein is a film removing cleanser for use in removing a therapeutic film to treat a dermatological disorder, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane.

[0317] In one embodiment, provided herein is a film removing cleanser for use in removing a therapeutic film to treat a dermatological disorder, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane. In one embodiment, provided herein is a film removing cleanser for use in removing a therapeutic film to treat a dermatological disorder, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane.

[0318] In another embodiment, provided herein is a film removing cleanser comprising a film wetting component, a penetration component, a film swelling component and a film release component.

[0319] In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to skin to treat a dermatological disorder, wherein said formulation comprises a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to skin to treat a dermatological disorder, wherein said formulation comprises a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross- linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0320] In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to skin to treat a dermatological disorder, wherein said formulation comprises a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to skin to treat a dermatological disorder, wherein said formulation comprises a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized

organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0321] In some embodiments, provided herein is a method for repairing a therapeutic film applied to skin to treat a dermatological disorder comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. In some embodiments, provided herein is a method for repairing a therapeutic film applied to skin to treat a dermatological disorder comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. [0322] In some embodiments, provided herein is a method for repairing a therapeutic film applied to skin to treat a dermatological disorder comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. In some embodiments, provided herein is a method for repairing a therapeutic film applied to skin to treat a dermatological disorder comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film.

[0323] In some embodiments, provided herein is a kit for repairing a therapeutic film to treat a dermatological disorder, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film to treat a dermatological disorder, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross- linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0324] In some embodiments, provided herein is a kit for repairing a therapeutic film to treat a dermatological disorder, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film to treat a dermatological disorder, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0325] In some embodiments, provided herein are methods for treating a subject post-laser treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject post-laser treatment In some embodiments, provided herein are methods for treating a subject post-laser treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject post-laser treatment.

[0326] In some embodiments, provided herein are methods for treating a subject post-laser treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject post-laser treatment.

In some embodiments, provided herein are methods for treating a subject post-laser treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject post-laser treatment

[0327] In some embodiments, provided herein are non-invasive formulations that form a film upon application to a subject post laser treatment, thereby facilitating healing of the subject post- laser treatment In some embodiments, provided herein are methods of using such formulations. In some embodiments, provided herein are cleansers to remove the film.

[0328] In some embodiments, provided herein is a composition for treating a subject post- laser treatment, wherein a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin. In some embodiments, provided herein is a composition for treating a subject post-laser treatment, wherein a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin.

[0329] In some embodiments, provided herein is a composition for treating a subject post- laser treatment, wherein a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin. In some embodiments, provided herein is a composition for treating a subject post-laser treatment, wherein a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin.

[0330] In some embodiments, provided herein are formulations for application to a subject post-laser treatment that comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin. In some embodiments, provided herein are formulations for application to a subject post-laser treatment that comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin.

[0331] In some embodiments, provided herein are formulations for application to a subject post-laser treatment that comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin.

In some embodiments, provided herein are formulations for application to a subject post-laser treatment that comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin.

[0332] In some embodiments, provided herein is a kit for use in treating a post-laser treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane; and instructions for use. In some embodiments, provided herein is a kit for use in treating a post-laser treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; and instructions for use.

[0333] In some embodiments, provided herein is a kit for use in treating a post-laser treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; and instructions for use. In some embodiments, provided herein is a kit for use in treating a post-laser treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; and instructions for use.

[0334] In some embodiments, provided herein are therapeutic formulations for application to a subject post-laser treatment, comprising at least one preselected function modulating component, in which the composition forms a therapeutic film upon application to the subject

[0335] In some embodiments, provided herein are therapeutic formulations for application to a subject post-laser treatment on the subject that target a treatment area on a subject, wherein the targeted area comprises an area that has been at least partially laser-treated, comprising at least one preselected treatment specific component, wherein the composition forms a therapeutic film upon application to the target treatment area on the subject.

[0336] In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used for post-laser treatment recovery management, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane. In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used for post-laser treatment recovery management, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane.

[0337] In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used for post-laser treatment recovery management, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane. In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used for post-laser treatment recovery management, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane.

[0338] In some embodiments, provided herein is a film removing cleanser comprising a film wetting component, a penetration component, a film swelling component and a film release component.

[0339] In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject post-laser treatment, wherein said formulation comprises a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated

organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject post-laser treatment, wherein said formulation comprises a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0340] In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject post-laser treatment, wherein said formulation comprises a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject post-laser treatment, wherein said formulation comprises a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0341] In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject post-laser treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject post-laser treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film.

[0342] In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject post-laser treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject post-laser treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film.

[0343] In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-laser treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In some

embodiments, provided herein is a kit for repairing a therapeutic film used for post-laser treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin.

[0344] In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-laser treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-laser treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin.

[0345] In some embodiments, provided herein are methods for treating a subject post-light treatment, comprising applying to the subject a formulation comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross- linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject post-light treatment.

In some embodiments, provided herein are methods for treating a subject post-light treatment, comprising applying to the subject a formulation comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject post- light treatment.

[0346] In some embodiments, provided herein are methods for treating a subject post-light treatment, comprising applying to the subject a formulation comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized

organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject post-light treatment In some embodiments, provided herein are methods for treating a subject post-light treatment, comprising applying to the subject a formulation comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject post-light treatment

[0347] In some embodiments, provided herein are non-invasive formulations that form a film upon application to a subject post light treatment, thereby facilitating healing of the subject post- light treatment The invention also provides methods of using such formulations. In another embodiment, the invention provides cleansers to remove the film.

[0348] In some embodiments, provided herein is a composition for treating a subject post- light treatment, wherein the composition provided herein comprises a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin. In some embodiments, provided herein is a composition for treating a subject post-light treatment, wherein the composition provided herein comprises a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin.

[0349] In some embodiments, provided herein is a composition for treating a subject post- light treatment, wherein the composition provided herein comprises a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane upon application to skin, such that a film is formed on skin. In some embodiments, provided herein is a composition for treating a subject post-light treatment, wherein the composition provided herein comprises a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin.

[0350] In some embodiments, provided herein are formulations for application to a subject post-light treatment that comprise a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin. In some embodiments, provided herein are formulations for application to a subject post-light treatment that comprise a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin.

[0351] In some embodiments, provided herein are formulations for application to a subject post-light treatment that comprise a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin. In some embodiments, provided herein are formulations for application to a subject post-light treatment that comprise a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin.

[0352] In some embodiments, provided herein are films for treating a subject post-light treatment prepared by a process comprising the steps of: a) applying a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross- linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In some embodiments, provided herein are films for treating a subject post-light treatment prepared by a process comprising the steps of: a) applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin.

[0353] In some embodiments, provided herein are films for treating a subject post-light treatment prepared by a process comprising the steps of: a) applying a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized

organopolysiloxane; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In some embodiments, provided herein are films for treating a subject post-light treatment prepared by a process comprising the steps of: a) applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. [0354] In some embodiments, provided herein are methods for delivering an agent to a subject post-light treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject In some embodiments, provided herein are methods for delivering an agent to a subject post-light treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject.

[0355] In some embodiments, provided herein are methods for delivering an agent to a subject post-light treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject. In some embodiments, provided herein are methods for delivering an agent to a subject post-light treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject

[0356] In some embodiments, provided herein is a kit for use in treating a post-light treatment on a subject in need thereof with a comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; and instructions for use. In some embodiments, provided herein is a kit for use in treating a post-light treatment on a subject in need thereof with a comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; and instructions for use.

[0357] In some embodiments, provided herein is a kit for use in treating a post-light treatment on a subject in need thereof with a comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; and instructions for use. In some embodiments, provided herein is a kit for use in treating a post-light treatment on a subject in need thereof with a comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; and instructions for use.

[0358] In some embodiments, provided herein are therapeutic formulations for application to a subject post-light treatment, comprising at least one preselected function modulating component, in which the composition forms a therapeutic film upon application to the subject

[0359] In some embodiments, provided herein are therapeutic formulations for application to a subject post-light treatment on the subject that target a treatment area on a subject, wherein the targeted area comprises an area that has been at least partially light-treated, comprising at least one preselected treatment specific component, wherein the composition forms a therapeutic film upon application to the target treatment area on the subject.

[0360] In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used for post-light treatment recovery management, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane. In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used for post-light treatment recovery management, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane. [0361] In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used for post-light treatment recovery management, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane. In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used for post-light treatment recovery management, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane.

[0362] In some embodiments, provided herein is a film removing cleanser comprising a film wetting component, a penetration component, a film swelling component and a film release component.

[0363] In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject post-light treatment, wherein said formulation comprises a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated

organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject post-light treatment, wherein said formulation comprises a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0364] In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject post-light treatment, wherein said formulation comprises a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject post-light treatment, wherein said formulation comprises a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0365] In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject post-light treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation provided herein comprises a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject post-light treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation provided herein comprises a catalyst; at least one encapsulating agent; at least one unsaturated

organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film.

[0366] In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject post-light treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation provided herein comprises a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject post-light treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation provided herein comprises a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film.

[0367] In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-light treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-light treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0368] In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-light treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross- linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-light treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0369] In some embodiments, provided herein are methods for treating a subject after a chemical peel treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject after a chemical peel treatment In some embodiments, provided herein are methods for treating a subject after a chemical peel treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject after a chemical peel treatment

[0370] In some embodiments, provided herein are methods for treating a subject after a chemical peel treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject after a chemical peel treatment. In some embodiments, provided herein are methods for treating a subject after a chemical peel treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin, thereby treating a subject after a chemical peel treatment.

[0371] In some embodiments, provided herein are non-invasive formulations that form a film upon application to a subject post laser treatment, thereby facilitating healing of the subject after a chemical peel treatment. The invention also provides methods of using such formulations. In another embodiment, the invention provides cleansers to remove the film. [0372] In some embodiments, provided herein is a composition for treating a subject after a chemical peel treatment, wherein the composition provided herein comprises a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin. In some embodiments, provided herein is a composition for treating a subject after a chemical peel treatment, wherein the composition provided herein comprises a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane upon application to skin, such that a film is formed on skin.

[0373] In some embodiments, provided herein is a composition for treating a subject after a chemical peel treatment, wherein the composition provided herein comprises a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane upon application to skin, such that a film is formed on skin. In some embodiments, provided herein is a composition for treating a subject after a chemical peel treatment, wherein the composition provided herein comprises a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane upon application to skin, such that a film is formed on skin.

[0374] In some embodiments, provided herein are formulations for application to a subject after a chemical peel treatment that comprise a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin. In some embodiments, provided herein are formulations for application to a subject after a chemical peel treatment that comprise a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin.

[0375] In some embodiments, provided herein are formulations for application to a subject after a chemical peel treatment that comprise a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin. In some embodiments, provided herein are formulations for application to a subject after a chemical peel treatment that comprise a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin and the film has an appearance of natural skin.

[0376] In some embodiments, provided herein are films for treating a subject after a chemical peel treatment prepared by a process comprising the steps of: applying a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated

organopolymer; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In some embodiments, provided herein are films for treating a subject after a chemical peel treatment prepared by a process comprising the steps of: applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, such that a film is formed on skin.

[0377] In some embodiments, provided herein are films for treating a subject after a chemical peel treatment prepared by a process comprising the steps of: applying a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin. In some embodiments, provided herein are films for treating a subject after a chemical peel treatment prepared by a process comprising the steps of: applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, such that a film is formed on skin.

[0378] In some embodiments, provided herein are methods for delivering an agent to a subject after a chemical peel treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated

organopolymer; and at least one hydride functionalized polysiloxane, optionally further comprising one or more agents; and b) a catalyst optionally comprising one or more agents; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject In some embodiments, provided herein are methods for delivering an agent to a subject after a chemical peel treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, optionally further comprising one or more agents; and b) a catalyst optionally comprising one or more agents; in which the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject

[0379] In some embodiments, provided herein are methods for delivering an agent to a subject after a chemical peel treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, optionally further comprising one or more agents; and b) a catalyst optionally comprising one or more agents; in which the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject. In some embodiments, provided herein are methods for delivering an agent to a subject after a chemical peel treatment, comprising applying to the subject a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, optionally further comprising one or more agents; and b) a catalyst optionally comprising one or more agents; in which the catalyst facilitates in situ cross- linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby delivering the agent to the subject.

[0380] In some embodiments, provided herein is a kit for use in treating a after a chemical peel treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; and instructions for use. In some embodiments, provided herein is a kit for use in treating a after a chemical peel treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane; and instructions for use.

[0381] In some embodiments, provided herein is a kit for use in treating a after a chemical peel treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; and instructions for use. In some embodiments, provided herein is a kit for use in treating a after a chemical peel treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane; and instructions for use.

[0382] In some embodiments, provided herein are therapeutic formulations for application to a subject after a chemical peel treatment, comprising at least one preselected function modulating component, in which the composition forms a therapeutic film upon application to the subject

[0383] In some embodiments, provided herein are therapeutic formulations for application to a subject after a chemical peel treatment on the subject that target a treatment area on a subject, wherein the targeted area comprises an area that has been at least partially laser-treated, comprising at least one preselected treatment specific component, wherein the composition forms a therapeutic film upon application to the target treatment area on the subject

[0384] In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used after a chemical peel treatment, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane. In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used after a chemical peel treatment, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane.

[0385] In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used after a chemical peel treatment, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane. In some embodiments, provided herein is a film removing cleanser for use in removing a therapeutic film used after a chemical peel treatment, wherein the film is prepared by a process comprising the steps of applying a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, and wherein said catalyst facilitates in situ cross- linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane.

[0386] In some embodiments, provided herein is a film removing cleanser comprising a film wetting component, a penetration component, a film swelling component and a film release component. [0387] In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject after a chemical peel treatment, wherein said formulation provided herein comprises a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject after a chemical peel treatment, wherein said formulation provided herein comprises a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated

organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0388] In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject after a chemical peel treatment, wherein said formulation provided herein comprises a catalyst; at least one ligand; at least one vinyl functionalized

organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a formulation for repairing a therapeutic film applied to a subject after a chemical peel treatment, wherein said formulation provided herein comprises a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross- linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0389] In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject after a chemical peel treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject after a chemical peel treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film.

[0390] In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject after a chemical peel treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized

polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film. In some embodiments, provided herein is a method for repairing a therapeutic film applied to a subject after a chemical peel treatment comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on skin, thereby repairing the therapeutic film.

6.4 Kits For Use With The Compositions And Methods Provided Herein

[0391] In some aspects, provided herein is a kit for use in treating a subject with a dermatological disorder comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and instructions for use. In some aspects, provided herein is a kit for use in treating a subject with a dermatological disorder comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and instructions for use.

[0392] In some embodiments, provided herein is a kit for repairing a therapeutic film to treat a dermatological disorder, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film to treat a dermatological disorder, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross- linking of the at least one unsaturated organopolymer and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0393] In some aspects, provided herein is a kit for use in treating a post-laser treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and c) instructions for use. In some aspects, provided herein is a kit for use in treating a post-laser treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and c) instructions for use.

[0394] In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-laser treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-laser treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0395] In some aspects, provided herein is a kit for use in treating a post-light treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and instructions for use. In some aspects, provided herein is a kit for use in treating a post-light treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and instructions for use.

[0396] In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-light treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-light treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0397] In some aspects, provided herein is a kit for use in treating a after a chemical peel treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride

functionalized polysiloxane and instructions for use. In some aspects, provided herein is a kit for use in treating a after a chemical peel treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and instructions for use.

[0398] In some embodiments, provided herein is a kit for repairing a therapeutic film used after a chemical peel treatment, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one unsaturated organopolymer and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used after a chemical peel treatment, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross- linking of the at least one unsaturated organopolymer and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0399] In some embodiments, provided herein is a kit comprising a therapeutic formulation comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane. In some embodiments, the kit further comprises instructions for use of the kit, one or more brushes, one or more swabs, a film removing cleanser or a mirror. In some embodiments, the kit further comprises one or more finishing formulations. In some embodiments, provided herein is a kit comprising a therapeutic formulation comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane. In some embodiments, the kit further comprises instructions for use of the kit, one or more brushes, one or more swabs, a film removing cleanser or a mirror. In some embodiments, the kit further comprises one or more finishing formulations.

[0400] In some embodiments, provided herein is a kit for use in treating a subject with a dermatological disorder or treating a subject post-laser or light or chemical peel treatment, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and instructions for use. In some embodiments, the kit further comprises one or more additional cosmetic agents. In some embodiments, the kit further comprises one or more additional therapeutic agents. In some embodiments, the kit further comprises one or more brushes, one or more swabs, a film removing cleanser and/or a mirror. In some embodiments, provided herein is a kit for use in treating a subject with a dermatological disorder or treating a subject post-laser or light or chemical peel treatment, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane and instructions for use. In some embodiments, the kit further comprises one or more additional cosmetic agents. In some embodiments, the kit further comprises one or more additional therapeutic agents. In some embodiments, the kit further comprises one or more brushes, one or more swabs, a film removing cleanser and/or a mirror.

[0401] In some embodiments, provided herein is a kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst catalyzes an in situ cross- linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on the skin. In some embodiments, provided herein is a kit for repairing a cosmetic film in which the kit comprises a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane wherein the catalyst catalyzes an in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on the skin. In some embodiments, provided herein is a kit for repairing a therapeutic film in which the kit comprises a composition provided herein comprising a catalyst; at least one ligand; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane wherein the catalyst catalyzes an in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on the skin.

[0402] In some embodiments, provided herein is a kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane, wherein the catalyst catalyzes an in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on the skin. In some

embodiments, provided herein is a kit for repairing a cosmetic film in which the kit comprises a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane wherein the catalyst catalyzes an in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on the skin. In some embodiments, provided herein is a kit for repairing a therapeutic film in which the kit comprises a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane wherein the catalyst catalyzes an in situ cross-linking of the at least one unsaturated organopolymer; and at least one hydride functionalized polysiloxane such that a film is formed on the skin.

[0403] In some aspects, provided herein is a kit for use in treating a subject with a dermatological disorder comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane and instructions for use. In some aspects, provided herein is a kit for use in treating a subject with a dermatological disorder comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane and instructions for use.

[0404] In some embodiments, provided herein is a kit for repairing a therapeutic film to treat a dermatological disorder, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film to treat a dermatological disorder, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0405] In some aspects, provided herein is a kit for use in treating a post-laser treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane and c) instructions for use. In some aspects, provided herein is a kit for use in treating a post-laser treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane and c) instructions for use. [0406] In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-laser treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross- linking of the at least one vinyl functionalized organopolysiloxane and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-laser treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0407] In some aspects, provided herein is a kit for use in treating a post-light treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane and instructions for use. In some aspects, provided herein is a kit for use in treating a post-light treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane and instructions for use.

[0408] In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-light treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross- linking of the at least one vinyl functionalized organopolysiloxane and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used for post-light treatment management, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride

functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0409] In some aspects, provided herein is a kit for use in treating a after a chemical peel treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane and instructions for use. In some aspects, provided herein is a kit for use in treating a after a chemical peel treatment on a subject in need thereof with a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane and instructions for use.

[0410] In some embodiments, provided herein is a kit for repairing a therapeutic film used after a chemical peel treatment, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane and at least one hydride functionalized polysiloxane such that a film is formed on skin. In some embodiments, provided herein is a kit for repairing a therapeutic film used after a chemical peel treatment, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst facilitates in situ cross-linking of the at least one vinyl functionalized organopolysiloxane and at least one hydride functionalized polysiloxane such that a film is formed on skin.

[0411] In some embodiments, provided herein is a kit comprising a therapeutic formulation comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane.

In some embodiments, the kit further comprises instructions for use of the kit, one or more brushes, one or more swabs, a film removing cleanser or a mirror. In some embodiments, the kit further comprises one or more finishing formulations. In some embodiments, provided herein is a kit comprising a therapeutic formulation comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane. In some embodiments, the kit further comprises instructions for use of the kit, one or more brushes, one or more swabs, a film removing cleanser or a mirror. In some embodiments, the kit further comprises one or more finishing formulations.

[0412] In some embodiments, provided herein is a kit for use in treating a subject with a dermatological disorder or treating a subject post-laser or light or chemical peel treatment, the kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane and instructions for use. In some embodiments, the kit further comprises one or more additional cosmetic agents. In some embodiments, the kit further comprises one or more additional therapeutic agents. In some embodiments, the kit further comprises one or more brushes, one or more swabs, a film removing cleanser and/or a mirror. In some embodiments, provided herein is a kit for use in treating a subject with a dermatological disorder or treating a subject post-laser or light or chemical peel treatment, the kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane and instructions for use. In some embodiments, the kit further comprises one or more additional cosmetic agents. In some embodiments, the kit further comprises one or more additional therapeutic agents. In some embodiments, the kit further comprises one or more brushes, one or more swabs, a film removing cleanser and/or a mirror.

[0413] In some embodiments, provided herein is a kit comprising a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized

organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst catalyzes an in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on the skin. In some embodiments, provided herein is a kit for repairing a cosmetic film in which the kit comprises a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane wherein the catalyst catalyzes an in situ cross-linking of the at least one vinyl functionalized

organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on the skin. In some embodiments, provided herein is a kit for repairing a therapeutic film in which the kit comprises a composition provided herein comprising a catalyst; at least one ligand; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane wherein the catalyst catalyzes an in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on the skin.

[0414] In some embodiments, provided herein is a kit comprising a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane, wherein the catalyst catalyzes an in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on the skin. In some embodiments, provided herein is a kit for repairing a cosmetic film in which the kit comprises a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane wherein the catalyst catalyzes an in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on the skin. In some embodiments, provided herein is a kit for repairing a therapeutic film in which the kit comprises a composition provided herein comprising a catalyst; at least one encapsulating agent; at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane wherein the catalyst catalyzes an in situ cross-linking of the at least one vinyl functionalized organopolysiloxane; and at least one hydride functionalized polysiloxane such that a film is formed on the skin.

[0415] Unless otherwise specified, all properties of compositions, layers and/or devices disclosed herein are measured at room temperature (about 22-25 °C) and about 1 atmosphere air pressure.

6.5 Properties Of A Film Created Bv The Compositions And Methods Provided Herein

[0416] In one embodiment, the film formed by the composition provided herein remains substantially intact on said skin for about 24 hours or more.

[0417] In one embodiment, the film formed by the composition provided herein remains substantially intact on said skin for about 24 hours or more with routine daily activities and/or with demanding activities. [0418] In one embodiment, the film formed by the composition provided herein remains at least about 50 % intact, at least about 60% intact, at least about 70% intact, at least about 80% intact, at least about 90% intact, or at least about 95% intact by either area or by weight on said skin for about 24 hours or more with routine daily activities and/or with demanding activities.

[0419] In one embodiment, the film formed by the composition provided herein remains substantially intact on said skin for more than about 24 hours, more than about 30 hours, more than about 36 hours, more than about 48 hours, more than about 60 hours, more than about 72 hours, more than about 84 hours, more than about 96 hours, more than about 120 hours, more than about 144 hours, or more than about 168 hours with routine daily activities and/or with demanding activities.

[0420] In one embodiment, the film formed by the composition provided herein remains at least about 50 % intact, at least about 60% intact, at least about 70% intact, at least about 80% intact, at least about 90% intact, or at least about 95% intact by either area or by weight on said skin for more than about 24 hours, more than about 30 hours, more than about 36 hours, more than about 48 hours, more than about 60 hours, more than about 72 hours, more than about 84 hours, more than about 96 hours, more than about 120 hours, more than about 144 hours, or more than about 168 hours with routine daily activities and/or with demanding activities.

[0421] In one embodiment, the film formed by the composition provided herein remains substantially intact on said skin for more than about 24 hours, more than about 30 hours, more than about 36 hours, more than about 48 hours, more than about 60 hours, more than about 72 hours, more than about 84 hours, more than about 96 hours, more than about 120 hours, more than about 144 hours, or more than about 168 hours with routine daily activities and/or with demanding activities as determined by the Film Durability on Skin Test

[0422] In one embodiment, the film formed by the composition provided herein remains at least about 50 % intact, at least about 60% intact, at least about 70% intact, at least about 80% intact, at least about 90% intact, or at least about 95% intact by either area or by weight on said skin for more than about 24 hours, more than about 30 hours, more than about 36 hours, more than about 48 hours, more than about 60 hours, more than about 72 hours, more than about 84 hours, more than about 96 hours, more than about 120 hours, more than about 144 hours, or more than about 168 hours with routine daily activities and/or with demanding activities as determined by the Film Durability on Skin Test [0423] In one embodiment, the film formed by the composition provided herein has a set-to- touch time of greater than about 30 seconds and less than about 7 minutes, greater than about 30 seconds and less than about 4 minutes, greater than about 30 seconds and less than about 2 minutes, or of about 2 minutes.

[0424] In one embodiment, the film formed by the composition provided herein has a set-to- touch time of greater than about 30 seconds and less than about 7 minutes, greater than about 30 seconds and less than about 4 minutes, greater than about 30 seconds and less than about 2 minutes, or of about 2 minutes, as determined by the Set-to-Touch Time of Film Test

[0425] In one embodiment, the film formed by the composition provided herein has an average thickness of less than about 1000 microns, less than about 100 microns, of about 0.5 to about 100 microns, about 1 to about 90 microns, about 10 to about 80 microns, about 30 to about 70 microns, about 40 to about 60 microns, or about 50 microns.

[0426] In one embodiment, the film formed by the composition provided herein has an average thickness of less than about 1000 microns, less than about 100 microns, of about 0.5 to about 100 microns, about 1 to about 90 microns, about 10 to about 80 microns, about 30 to about 70 microns, about 40 to about 60 microns, or about 50 microns, as determined by the ASTM D3767 test using Cowhide Tooling leather.

[0427] In one embodiment, the film formed in vitro by said composition has a leather adhesive force of greater than about 30 N/mm, greater than about 60 N/mm, greater than about 80 N/mm, greater than about 100 N/mm, or greater than 200 N/mm, as determined by the Leather Peel Adhesion Test

[0428] In one embodiment, the film formed in vitro by said composition, upon exposure of said test film to environmental factors selected from: heat, cold, wind, water, humidity, bodily fluids, blood, pus/liquor puris, urine, saliva, sputum, tears, semen, milk, vaginal secretion, sebum, saline, seawater, soapy water, detergent water, or chlorinated water, or a combination thereof, has a weight increase, at a time point between about 1-hour and about 168 hours after formation, of less than about 10%, less than about 5, or less than about 1%, as determined by the ASTM D2765-95 test.

[0429] In one embodiment, the film formed in vitro by said composition has a tensile strength greater than about 0.25 MPa, greater than about 0.5 MPa, greater than about 1.0 MPa, or greater than about 2.0 MPa, and In one embodiment, said film has a tensile strength less than about 5 MPa, or In one embodiment, said film has a tensile strength at about 3.0 MPa, as determined by the Cyclic and Extension Pull Test

[0430] In one embodiment, the film formed in vitro by said composition has a fracture strain of greater than about 100%, greater than about 200%, greater than about 400%, greater than about 600%, greater than about 800%, greater than about 1000%, greater than about 1200%, or greater than about 1500%, as determined by the Cyclic and Extension Pull Test

[0431] In one embodiment, the film formed in vitro by said composition has a tensile modulus of about 0.01 to about 40 MPa, about 0.05 to about 20 MPa, about 0.1 to about 10 MPa, about 0.1 to about 5 MPa, about 0.1 to about 1 MPa, about 0.25 to about 0.75 MPa, or at about 0.5 MPa, as determined by the Cyclic and Extension Pull Test

[0432] In one embodiment, the film formed in vitro by said composition has a shear modulus of about 0.05 to about 10 MPa, about 0.1 to about 5 MPa, about 0.1 to about 1 MPa, about 0.25 to about 0.75 MPa, or at about 0.5 MPa, as determined by the Cyclic and Extension Pull Test.

[0433] In one embodiment, the film formed in vitro by said composition has a cyclic tensile residual strain of less than about 10%, less than about 5%, less than about 2.5%, less than about

1%, less than about 0.5%, less than about 0.25%, or less than about 0.1%, as determined by the Cyclic and Extension Pull Test.

[0434] In one embodiment, the film formed in vitro by said composition has a cyclic tensile hysteresis loss energy of less than about 1 kJ/m ³ , less than about 0.5, kJ/m ³ , or less than about 0.2 kJ/m ³ , as determined by the Cyclic and Extension Pull Test.

[0435] In one embodiment, the film formed in vitro by said composition has a fracture toughness of greater than about 500 kJ/m ³ , greater than about 5,000 kJ/m ³ , greater than about 10,000 kJ/m ³ , or greater than about 50,000 kJ/m ³ , as determined by the Cyclic and Extension Pull Test.

[0436] In one embodiment, the film formed in vitro by said composition has an oxygen transmission rate of greater than about 5x10 ^-9 cm ³ /(cm ² s), greater than about 5x10 ^-7 cm ³ /(cm ² s), greater than about 5x10 ^-5 cm ³ /(cm ² s), greater than about 5x10 ^-4 cm ³ /(cm ² s), greater than about 5x10 ^-3 cm ³ /(cm ² s), greater than about 5x10 ^-2 cm ³ /(cm ² s), or greater than about 0.5 cm ³ /(cm ² s), and In one embodiment, said film has an oxygen transmission rate of less than about 5 cm ³ /(cm ² s), as determined by the ASTM F2622 test.

[0437] In one embodiment, the film formed in vitro by said composition has an oxygen permeance of greater than about 5x10 ^-11 cm ³ /(cm ² s cm Hg), greater than about 5x10 ^-9 cm ³ /(cm ² s cm Hg), greater than about 5x10 ^-7 cm ³ /(cm ² s cm Hg), greater than about 5x10 ^-6 , 5x10 ^-5 cm ³ /(cm ² s cm Hg), greater than about 5x10 ^-4 cm ³ /(cm ² s cm Hg), greater than about 5x10 ^-3 cm ³ /(cm ² s cm Hg), greater than about or 5x10 ^-2 cm ³ /(cm ² s cm Hg), and In one embodiment, said film has an oxygen permeance of less than about 0.5 cm ³ /(cm ² s cm Hg), as determined by the ASTM F2622 test.

[0438] In one embodiment, the film formed in vitro by said composition has an oxygen permeability coefficient of greater than about 5x10 ^-4 Barrer, greater than about 5x10 ^-2 Barrer, greater than about 5 Barrer, greater than about 50 Barrer, greater than about 500 Barrer, or greater than about 5,000 Barrer, and In one embodiment, said film has an oxygen permeability coefficient of less than about 20,000 Barrer, as determined by the ASTM F2622 test.

[0439] In one embodiment, the film formed in vitro by said composition has a water vapor transmission rate of greater than about 1x10 ^-9 cm ³ /(cm ² s), greater than about 1x10 ^-8 cm ³ /(cm ² s), greater than about 1x10 ^-4 , 1x10 ^-6 cm ³ /(cm ² s), greater than about 1x10 ^-5 cm ³ /(cm ² s), or greater than about 1x10 ^-4 cm ³ /(cm ² s), and In one embodiment, said film has a water vapor transmission rate of less than about x10 ^-1 cm ³ /(cm ² s) or less than about x10 ^-2 cm ³ /(cm ² s), as determined by the ASTM F1249 test.

[0440] In one embodiment, the film formed in vitro by said composition has a water vapor permeance of greater than about 1x10 ^-11 cm ³ /(cm ² s cm Hg), greater than about 1x10 ^{- 10} cm ³ /(cm ² s cm Hg), greater than about 1x10 ^-9 cm ³ /(cm ² s cm Hg), greater than about 1x10 ^-8 cm ³ /(cm ² s cm Hg), greater than about 1x10 ^-7 cm ³ /(cm ² s cm Hg), and In one embodiment, said film has a water vapor permeance of less than about 2x10 ^-3 cm ³ /(cm ² s cm Hg) or less than about 2x10 ^-2 cm ³ /(cm ² s cm Hg), as determined by the ASTM F1249 test

[0441] In one embodiment, the film formed in vitro by said composition has a water vapor permeability coefficient of greater than about 1x10 ^-3 Barrer, greater than about 0.01 Barrer, greater than about 0.1 Barrer, greater than about 1 Barrer, greater than about 10 Barrer, greater than about 100 Barrer, greater than about 1x10 ³ Barrer, or greater than about 1x10 ⁴ Barrer, and In one embodiment, said film has a water vapor permeability coefficient of less than about lxl 0 ⁶ Barrer or less than about lxl 0 ⁵ Barrer, as determined by the ASTM F1249 test

[0442] In one embodiment, said film has a transepidermal water loss of less than about 40 g/(m ² hr), less than about 20 g/(m ² hr), less than about 10 g/(m ² hr), less than about 5 g/(m ² hr), or less than about 1 g/(m ² hr), as determined by Transepidermal Water Loss (TEWL)

Measurement Test using an evaporimeter at a time point between about 1-hour and about 168 hours after application of the composition.

[0443] In one embodiment, said film has a skin hydration of greater than about 20 arbitrary units, greater than about 40 arbitrary units, greater than about 60 arbitrary units, or greater than about 80 arbitrary units of Comeometer, as determined by the Dobrev method using a

Corneometer at a time point between about 1-hour and about 168 hours after application of the composition.

[0444] In one embodiment, said film has a skin hydration of greater than about 20 microSiemens, greater than about 50 microSiemens, greater than about 100 microSiemens, greater than about 200 microSiemens, or greater than about 400 microSiemens, as determined by the Clarys method using a Conductance or Impedance Meter at a time point between about 1 - hour and about 168 hours after application of the composition.

[0445] In one embodiment, said film has a skin retraction time decreased by about 5%, decreased by about 10%, decreased by about 25%, decreased by about 50%, or decreased by about 75%, as determined by the Dobrev method using a Cutometer or Suction Cup at a time point between about 1-hour and about 168 hours after application of the composition.

[0446] In one embodiment, the film formed in vitro by said composition has a shine and/or gloss change of the area treated with said composition of less than about 20%, less than about 10%, or less than about 5%, as determined by the ASTM D523 test using Cowhide Tooling leather in natural color as substrate.

[0447] In one embodiment, the film formed in vitro by said composition has a color L* scale change of the area treated with said composition of less than about 2, less than about 1.5, less than about 1, or less than about 0.5, as determined by the ASTM E313 test using Cowhide Tooling leather in natural color as substrate. [0448] In one embodiment, the film formed in vitro by said composition has a color a* scale change of the area treated with said composition of less than about 2, less than about 1.5, less than about 1, or less than about 0.5, as determined by the ASTM E313 test using Cowhide Tooling leather in natural color as substrate.

[0449] In one embodiment, the film formed in vitro by said composition has a color b* scale change of the area treated with said composition of less than about 2, less than about 1.5, less than about 1, or less than about 0.5, as determined by the ASTM E313 test using Cowhide Tooling leather in natural color as substrate.

[0450] In one embodiment, the film formed in vitro by said composition has a tensile strength between about 0.01 MPa and about 10 MPa, as determined by the Cyclic and Extension Pull Test.

[0451] In one embodiment, the film formed in vitro by said composition has a tensile strength between about 0.1 MPa and about 2.5 MPa, as determined by the Cyclic and Extension

Pull Test.

[0452] In one embodiment, the film formed in vitro by said composition has a fracture strain between about 10% and about 1500%, as determined by the Cyclic and Extension Pull Test.

[0453] In one embodiment, the film formed in vitro by said composition has a fracture strain between about 10% and about 600%, as determined by the Cyclic and Extension Pull Test.

[0454] In one embodiment, the film formed in vitro by said composition has a tensile modulus between about 0.01 and about 10 MPa, as determined by the Cyclic and Extension Pull Test

[0455] In one embodiment, the film formed in vitro by said composition has a tensile modulus between about 0.01 and about 2.5 MPa, as determined by the Cyclic and Extension Pull Test In one embodiment, the film formed in vitro by said composition has a cyclic tensile residual strain between about 0.1% and about 10%, as determined by the Cyclic and Extension Pull Test.

[0456] In one embodiment, the film formed in vitro by said composition has a cyclic tensile residual strain between about 0.1% and about 5%, as determined by the Cyclic and Extension Pull Test. [0457] In one embodiment, the film formed in vitro by said composition has a cyclic tensile hysteresis loss energy between about 0.01 kJ/m ³ and about 1 kJ/m ³ , as determined by the Cyclic and Extension Pull Test

[0458] In one embodiment, the film formed in vitro by said composition has a cyclic tensile hysteresis loss energy between about 0.05 kJ/m ³ and about 0.5 kJ/m ³ , as determined by the Cyclic and Extension Pull Test.

[0459] In one embodiment, the film formed in vitro by said composition has a fracture toughness between about 500 kJ/m ³ and about 50,000 kJ/m ³ , as determined by the Cyclic and Extension Pull Test

[0460] In one embodiment, the film formed in vitro by said composition has a fracture toughness between about 1,000 kJ/m ³ and about 12,000 kJ/m ³ , as determined by the Cyclic and Extension Pull Test

[0461] In one embodiment, the film formed in vitro by said composition has an oxygen transmission rate of about 0.5 cm ³ /(cm ² s), as determined by the ASTM F2622 test

[0462] In one embodiment, the film formed in vitro by said composition has an oxygen transmission rate of greater than about 0.18 cm ³ /(cm ² s), as determined by the ASTM F2622 test.

[0463] In one embodiment, the film formed in vitro by said composition has an oxygen permeance of about 0.005 cm ³ /(cm ² s cm Hg), as determined by the ASTM F2622 test.

[0464] In one embodiment, the film formed in vitro by said composition has an oxygen permeance of greater than about 0.002 cm ³ /(cm ² s cm Hg), as determined by the ASTM F2622 test

[0465] In one embodiment, the film formed in vitro by said composition has an oxygen permeability coefficient of about 3.5x10 ⁵ Barrer, as determined by the ASTM F2622 test

[0466] In one embodiment, the film formed in vitro by said composition has an oxygen permeability coefficient of greater than about 1 4x10 ⁵ Barrer, as determined by the ASTM F2622 test

[046h In one embodiment, the film formed in vitro by said composition has a water vapor transmission rate of about 5x10 ^-4 cm ³ /(cm ² s), as determined by the ASTM F1249 test [0468] In one embodiment, the film formed in vitro by said composition has a water vapor transmission rate of greater than about 5x10 ^-5 cm ³ /(cm ² s), as determined by the ASTM F1249 test

[0469] In one embodiment, the film formed in vitro by said composition has a water vapor permeance of about 5x10 ^-6 cm ³ /(cm ² s cm Hg), as determined by the ASTM F1249 test.

[0470] In one embodiment, the film formed in vitro by said composition has a water vapor permeance of greater than about 5x10 ^-7 cm ³ /(cm ² s cm Hg), as determined by the ASTM F1249 test

[0471] In one embodiment, the film formed in vitro by said composition has a water vapor permeability coefficient of about 350 Barrer, as determined by the ASTM F1249 test.

[0472] In one embodiment, the film formed in vitro by said composition has a water vapor permeability coefficient of greater than about 35 Barrer, as determined by the ASTM F1249 test

6.6 Assays For Use With The Compositions And Methods Provided Herein

[0473] In certain embodiments, a film resulting from a composition described herein, e.g., by applying the composition to the skin of a subject has specified properties. The following assays can be used to demonstrate the properties of the film generated with the composition and methods provided herein.

6.6.1 Rheometer Viscosity Measurement Test

[0474] The following test method may be used to determine the dynamic viscosity (Pa-s) of fluid materials at 0.5 s ^-1 , using a Bohlin CVOIOO Rheometer (Malvern Instruments) mounted with 20mm Parallel plate geometry. Similar Rheometers can be used for viscosity

measurements. For each material tested, at least 3 samples are measured, and average viscosity and standard deviation of the measurements are recorded.

[0475] About 1 g of each test sample is required. Visually inspect the sample to ensure the sample appears uniform. Turn on the Bohlin Rheometer and the temperature controller; start the Bohlin software and load the viscosity stability test template; install the geometry and zero the instrument. Make sure that both the geometry and plate are clean, which is critical for accurate test results. Place about 1 g of the test sample onto the bottom plate of the Rheometer in a mound centered below the geometry. Lower the geometry to the correct gap (about 250mm). Clean any excess sample from the sides of the geometry using the flat end of a spatula. Start the test and allow the test to run to completion, then record the viscosity (Pa· s) data.

[0476] In certain embodiments, a film generated with the compositions and methods provided herein has particular dynamic viscosity. In certain embodiments, the dynamic viscosity can be determined using the assay of the Rheometer Viscosity Measurement Test provided herein.

6.6.2 Film Durability on Skin Test

[0477] Application of Test Composition. Healthy subjects (at least 3) are selected irrespective of age, race or gender. Tests are conducted at room temperature and about 50% relative humidity. Drawn 4x4 cm ² square outlines on selected volar forearm areas using a standard template as guide. Using a balance, weigh out appropriate amounts (e.g, about 0.1 g to about 0.3 g) of the test composition onto weigh boats. Apply the test composition evenly over the 4x4 cm ² squares on the forearm using a fingertip, preferably wearing finger cot. Make sure that all areas of the squares are covered by the composition.

[0478] Measurement The composition is allowed to sit untouched over the area for about 15 minutes. The subject is then allowed to resume daily activities. The subjects are permitted to conduct either only routine daily activities, or routine daily activities with demanding activities, for example, exercising, swimming, steam room, sauna, and the like. The type and length of each demanding activity are recorded. The layers formed by the test composition are left on skin for about 24 hours or more. At certain time points after application of the composition, durability of layers are assessed by measuring the percentage of the area intact on the skin using an 8x8 square grid of 0.5x0.5 cm ² each (total 64 squares). Any excess layer outside of the 4x4 cm ² square area is not considered in the evaluation. Each square is only considered to be durable if there is no visible imperfection, e.g., seams, flaking, cracking, and/or peeling, of the layer. Record the observations.

[0479] In certain embodiments, a film generated with the compositions and methods provided herein has particular film durability. In certain embodiments, the film durability can be determined using the assay of the Film Durability on Skin Test provided herein. 6.6.3 Set-to-Touch Time and Tack-Free Time of Film Test

[0480] This method was modified from ASTM D5895-03 Evaluating Drying or Curing During Film Formation of Organic Coatings Using Mechanical Recorders. The materials and application of test composition to the selected subjects are the same as described in the Film Durability on Skin Test The test can also be conducted on other substrates instead of human skin, for example, on Cowhide Tooling leather in natural color, polyurethane, or polypropylene substrates with comparable results. For each composition tested, at least 3 samples are tested, and average set-to-touch time, average tack-free time and standard deviation of the

measurements are recorded.

[04$ 1 ] Measurement. Start a timer when the test composition is applied to the entire test area on the forearm. Allow the composition to sit untouched over the area for a certain period of time, e.g., 30 seconds or one minute. At certain time points, touch one comer of the test area lightly using a fingertip, and visually evaluate: first the presence or absence of any test composition on the fingertip (Set-to-Touch Time); then the presence or absence of any film surface being pulled up by the fingertip (Tack-Free Time of Film Test). Repeat the fingertip evaluation on untouched portions of the test area at a certain time interval, e.g., every 15 seconds or 30 seconds or one minute. The time at which no more test composition is observed on the fingertip is reported as the“set-to-touch time” of the test composition. The time at which no more film surface is pulled up by the fingertip is reported as the“tack-free time” of the test composition.

[0482] In certain embodiments, a film generated with the compositions and methods provided herein has particular set-to-touch time and tack-free time. In certain embodiments, the set-to-touch time and tack-free time can be determined using the assay of the Set-to-Touch Time and Tack-Free Time of Film Test provided herein.

6.6.4 Set-to-Touch Time and Tack-Free Time of Film Test in-vitro

[0483] This method was modified from ASTM D5895-03 Evaluating Drying or Curing

During Film Formation of Organic Coatings Using Mechanical Recorders. The materials and application of test composition to the selected substrates are described as follows: Place a 50- micron spacer (for example, one layer of 3M Magic Scotch Tape) onto the substrate sheet size 4.5”xl.5”, forming an opening rectangular of 3.75”x 0.75”, exposing the substrate surface. Apply test composition onto the substrate, then gliding the glass slide back and forth along the spacer edges to deposit a smooth and uniform layer of test composition. The test can also be conducted on many substrates such as on Cowhide Tooling leather in natural color,

polyurethane, or polypropylene substrates with comparable results. For each composition tested, at least 3 samples are tested, and average set-to-touch time, average tack-free time and standard deviation of the measurements are recorded.

[0484] Measurement. Start a timer when the test composition is applied to the entire test area on the substrate. Allow the test composition to sit untouched over the area at room temperature and ambient humidity for a certain period of time, e.g., 30 seconds or one minute. At certain time points, place a 1.5cmx4cm polypropylene sheet on the surface of the test composition, then place a 1 Sg weight on top of polypropylene sheet. Wait for 2 seconds, before removing the weight and the polypropylene sheet from the surface of the test composition. Visually evaluate: first the presence or absence of any test composition on the polypropylene sheet. Repeat the polypropylene sheet evaluation on untouched portions of the test area at a certain time interval, e.g., every 15 seconds or 30 seconds or one minute. The time at which no more test composition on the polypropylene sheet is observed is reported as the“set-to-touch time” of the test composition. After“set-to-touch time” is reported, transfer the specimen to the 30-degree slope surface to evaluate the“tack-free time”. Place the specimen 6 inches up along the slope surface away from the lowest point and secure the specimen on the slope surface. Drop a 1/32” diameter stainless steel ball onto the top part of the film surface from a distance an inch above the film surface. Observe the movement of the stainless steel ball on the film surface as the ball trying to roll down on its own gravity. Report“tack-free time” when the ball is able to roll from the top to the bottom part of the film surface continuously, without any interruption from the frictional film surface as the film becomes tack-free.

[0485] In certain embodiments, a film generated with the compositions and methods provided herein has particular set-to-touch time and tack-free time. In certain embodiments, the set-to-touch time and tack-free time can be determined using the assay of the Set-to-Touch Time and Tack-Free Time of Film Test in-vitro provided herein. 6.6.5 Peel Adhesion Test

[0486] This test method for adhesive force was developed in accordance with ASTM C794 Adhesion-in-Peel of Elastomeric Joint Sealants. Instron 3342 single column

tension/compression testing system (Instron, Norwood, MA) with 100N load cell (Instron #2519- 103) mounted with extension grip geometry may be used, with polypropylene sheet of 1/32” thickness as test substrate. Other similar equipment and other soft, flexible test substrates can also be used to measure the peeling force. The materials and application of test composition to the selected substrates are described as follows: Place a 50-micron spacer (for example, one layer of 3M Magic Scotch Tape) onto the substrate sheet size 4.5”xl.5”, forming an opening rectangular of 3.75”x 0.75”, exposing the substrate surface. Apply test composition onto the substrate, then gliding the glass slide back and forth along the spacer edges to deposit a smooth and uniform layer of test composition. Allow the test composition to sit untouched over the area at room temperature and ambient humidity for 24 hours. Then, place a silicone adhesive tape (Mepitac) of 0.75” width on top of the film to fully cover the film surface on the polypropylene substrate, wait at room temperature and ambient humidity for 24 hours before the specimen is ready for measurement. For each material tested, at least 3 samples are measured, and average peeling force and standard deviation of the measurements are recorded.

[0487] Measurement. Partially peel the silicone tape-covered test specimen at one end by hand to separate enough of the silicone tape-covered film from the polypropylene substrate for effective grip by extension grip geometry mounts of the instrument. Secure each peeling side in its own instrument grip. Make sure the strips are clamped substantially parallel to the geometry. Perform the extension test at a rate of 1 mm/s until the two peeling strips separate completely from each other. Record the peeling force vs. time data. The sample’s average peeling force (N/m) is calculated by averaging the instantaneous force (N) measured by the instrument during the experiment normalized by the sample width (0.75” or 0.019 m).

[0488] In certain embodiments, a film generated with the compositions and methods provided herein has particular adhesive force. In certain embodiments, the adhesive force can be determined using the assay of the Peel Adhesion Test provided herein. 6.6.6 Curl Test for Tension of Curved Specimen

[0489] The deposition of the test article on substrate such as skin or elastic band or parafilm results in residual compressive stress within the film due to volume loss (strain), which in turn translate to the tensile stress on the underneath substrate. The combined result of the film deposited on substrate could be observed and quantified based on the level of surface curvature of the substrate after the deposition of the film.

[0490] To prepare the test article for curl test, first the test article was deposited onto either an elastic synthetic rubber sheet or a parafilm substrate as described earlier in the application of test composition to the selected substrates. The materials and application of test composition to the selected substrates are described as follows: Place a 50-micron spacer (for example, one layer of 3M Magic Scotch Tape) onto the substrate sheet size 4.5”xl.5”, forming an opening rectangular of 3.75”x 0.75”, exposing the substrate surface. Apply test composition onto the substrate, then gliding the glass slide back and forth along the spacer edges to deposit a smooth and uniform layer of test composition. Allow the test composition to sit untouched over the area at room temperature and ambient humidity for 24 hours.

[0491] Measurement. Use a Vernier Caliper or optical microscope to measure the end-to-end distance of the width side of the test specimen that is curved upward. The end-to-end distance refers to the chord length, forming an incomplete upward circle where subsequent calculation of corresponding radius of the circle is computed. Report the radius value and its reciprocal as the “curvature” value. Use the curvature value to calculate the tension incurred on the substrate. In the case of originally curved surface with inherent tension such as skin, the change in tension incurred by the deposited top layer, will modify the inherent tension accordingly.

[0492] In certain embodiments, a film generated with the compositions and methods provided herein has particular tension. In certain embodiments, the tension can be determined using the assay of the Curl Test for Tension of Curved Specimen provided herein.

6.6.7 Cyclic and Extension Pull Test

[0493] These test methods for Cyclic Tensile Residual Strain (Instant Residual Strain),

Cyclic Tensile Hysteresis Loss Energy, Tensile (Young’s) Modulus, Shear Modulus, Tensile Strength/Maximum Stress, Fracture Strain, and Fracture Toughness was developed to be better suited for the specimens disclosed herein in compliance with ASTM D638, ASTM D412, ASTM D1876 test guidelines. Instron 3342 single column tension/compression testing system (Instron, Norwood, MA) with 100N load cell (Instron #2519-103) mounted with extension grip geometry may be used. Other similar equipment can also be used to measure the properties tested herein. For each material tested, at least 3 samples are measured, and average results and standard deviation of the measurements are recorded.

[0494] About 10 g of the composition tested is needed for each sample. The samples are cast inside dumbbell shaped molds mounted on Teflon, consistent with the ASTM D638 guidelines. The dimensions of the“neck” of the mold are about 20 mm in length, about 5 mm in width and about 1.5 mm in depth. The dimensions of the“handles/bell” of the mold are about 20 mm in length, about 15 mm in width and about 1.5 mm in depth, which provides adequate area to insure secure slip-free grip during testing. Level the top surface of the filled mold with a smooth microscope slide. Ensure that the molds are filled without voids and the top surface is smooth. The casted samples are allowed to fully cure and dry for about 20 to about 30 hours. The specimens formed are extracted from their individual molds by means of a spatula. Width and thickness of the“neck” of the finished specimens are measured with a caliper, recorded and input into the instrument. The Area of the“neck” portion of the specimen is calculated by its width and thickness.

[0495] Layers formed by compositions disclosed herein can also be tested once separated from the substrates. Such a layer can be formed or trimmed into a rectangular shape, and the Area of a cross-section of a layer can be calculated by its width and thickness. In such as case, the ends of the rectangular specimen would be considered the“handle/bell” portions whereas the middle of the rectangular specimen would be considered the“neck” portion.

[0496] An alternative specimen preparation is to place a 50-micron spacer (for example, one layer of 3M Magic Scotch Tape) onto the polypropylene substrate sheet size 4.5”xl.5”, forming an opening rectangular of 3.75”x 0.75”, exposing the substrate surface. Apply test composition onto the substrate, then gliding the glass slide back and forth along the spacer edges to deposit a smooth and uniform layer of test composition. Allow the test composition to sit untouched over the area at room temperature and ambient humidity for 24 hours.

[0497] Mechanical characterization of specimens is carried out on the Instron 3342 (Instron,

Norwood MA) equipped with 100N load-cell. Dumbbell or rectangular shaped specimens are mounted onto the instrument via Instron 2710-101 grips on each end, which are modified to insure the specimens do not slip or fail inside the grips during testing. The specimen is mounted onto the instrument such that all the rectangular“handle/bell” portions of the specimen and none of the“neck” of the specimen are fixed within the instrument grips. Make sure that the specimen is mounted substantially vertical in both vertical planes. The instrument grip distance is adjusted such that the sample is at neutral extension as indicated by the instrument force being close to zero (±0.01 N).

[0498] Two types of tests are performed sequentially on each specimen, first the Cyclic Test followed by the Extension Pull Test. It is noted that the Cyclic Test has negligible effects on the result of the Extension Pull Test on the same specimen. Each test is preprogrammed into the instrument.

[0499] Cyclic Test: The Cyclic Test is designed to determine the elasticity of the tested materials by measuring Cyclic Tensile Residual Strain (Instant Residual Strain). Generally, the more elastic the material, the faster it returns to its original shape after deformation. Lower Cyclic Tensile Residual Strain scores indicate better elasticity. For perfectly elastic materials, the Cyclic Tensile Residual Strain and cycle test area should approach zero.

[0500] The specimen is mounted onto the instrument as described above. Stretch the specimen slightly at about 1 mm/s by raising the geometry until a force of 0.06-0.08 N is registered by the instrument, record the stretched length of the“neck” portion of the specimen as the initial specimen length. Cyclic extension is performed at about 1 mm/s to a maximum extension of 15% of initial specimen length. A total of 15 (and up to 100) cycles are executed and the stress strain data is recorded.

[0501] The Cyclic Tensile Modulus is calculated as the straight line slope of the stress-strain curve of first cycle between 1% and 4% strain. The R squared value of the linear fit should be above 0.99 or the test data should be recorded as outlier and discarded. The Cyclic Tensile Residual Strain is calculated for each cycle as the strain difference between the loading and unloading curves at half the maximum stress achieved during the first cycle. The Cyclic Tensile Residual Strain for the first cycle as well as the average Cyclic Tensile Residual Strain for the 2nd through 12th cycles are recorded. The area bound by the loading and unloading curves of each cycle is also calculated as Cyclic Tensile Hysteresis Loss Energy. Good agreement is observed between the Cyclic Tensile Residual Strain and the calculated cycle area. [0502] The majority of the specimens formed by the compositions disclosed herein are sufficiently flexible and elastic such that the Cyclic Test could be repeated on the same sample without a significant change in calculated properties, which suggests that this test did not result in long lasting changes to the tested specimens.

[0503] Extension Pull Test: The Extension Pull Test was used to determine the stiffness and stretchiness/flexibility of a material by measuring the Tensile/Young’s Modulus and fracture strain, respectively.

[0504] The specimen is mounted onto the instrument as described above. Stretch the specimen slightly at about 10 mm/s by raising the geometry until a force of 0.01-0.02 N is registered by the instrument, record the stretched length of the“neck” portion of the specimen as “Original Length.” The extension Tensile/Y oung’s Modulus is calculated as the straight line slope of the stress-strain curve between 6% and 11% strain. The R squared value of the linear fit should be above 0.99 or the Tensile/Young’s Modulus is calculated from a more linear 5% strain range on the stress strain curve.

[0505] The Shear Modulus is determined from the same strain range as the Tensile/Y oung’s

Modulus. Shear Modulus is calculated as the slope of the best line fit between recorded stress and a - 1/a ² , where a is 1 plus the instantaneous strain.

[0506] Stretch the specimen at about 10 mm/s until it is broken at one side or completely.

Record the force applied at the time when the specimen is broken as the“Maximum Tensile Force.” Record the length of the“neck” portion of the specimen when it is broken extended beyond the Original Length of the specimen as the“Maximum Elongation Length.” Tensile Strength/Maximum Stress is calculated as the Maximum Tensile Force over the Area of the “neck” portion of the specimen. Fracture Strain is calculated as the Maximum Elongation Length as percentage of the Original Length.

[0507] Fracture Toughness (kJ/m ³ ) is calculated as the area under the stress-strain curve in the Extension Pull Test. The Yield Strain is determined as the strain at which the measured stress differed by more than 10% from the Neo-Hookean stress; the multiple of Shear Modulus and (a - 1/a ² ).

[0508] In certain embodiments, a film generated with the compositions and methods provided herein has particular Cyclic Tensile Residual Strain (Instant Residual Strain), Cyclic Tensile Hysteresis Loss Energy, Tensile (Y oung’s) Modulus, Shear Modulus, Tensile

Strength/Maximum Stress, Fracture Strain, and Fracture Toughness. In certain embodiments, the Cyclic Tensile Residual Strain (Instant Residual Strain), Cyclic Tensile Hysteresis Loss Energy, Tensile (Young’s) Modulus, Shear Modulus, Tensile Strength/Maximum Stress, Fracture Strain, and Fracture Toughness can be determined using the assay of the Cyclic and Extension Pull Test provided herein.

6.6.8 Transepidermal Water Loss (TEWL) Measurement Test

[0509] Evaporative water loss measurements provide an instrumental assessment of skin barrier function. Evaporimetry with TEWL Probe is fully described in Grove et al, Comparative metrology of the evaporimeter and the DermaLab® TEWL probe, Skin Res. & Tech. 1999, 5:1-8 and Grove et al, Computerized evaporimetry using the DermaLab® TEWL probe, Skin Res. & Tech. 1999, 5:9-13. The guidelines established for using the Servo Med Evaporimeter described by Pinnagoda (Pinnagoda et al, Guidelines for transepidermal water loss (TEWL) measurement, Contact Dermatitis 1990, 22: 164-178) are appropriate for the DermaLab® TEWL Probe as well.

[0510] Evaporative water loss measurements can be made using a recently calibrated Servo

Med Evaporimeter. Alternatively, these measurements can be made using a recently calibrated cyberDERM RG1 Evaporimeter System (Broomall, PA) with TEWL Probes (manufactured by Cortex Technology of Hadsund, Denmark and available in the US through cyberDERM, Inc. Broomall, PA), or other similar equipment

[0511] Both Evaporimeters are based on the vapor pressure gradient estimation method pioneered by Gert E. Nilsson (e.g., Nilsson, G.E., Measurement of water exchange through skin, Med Biol Eng Comput 1977, 15:209-218). There are slight dimensional differences and the sensor technology is greatly improved in the DermaLab® TEWL Probe but the underlying principles of the measurement remain the same. Both probes contain two sensors that measure the temperature and relative humidity at two fixed points along the axis normal to the skin surface. This arrangement is such that the device can electronically derive a value that corresponds to evaporative water loss expressed in gm/(m ² hr). The Evaporimeter System extracts value of average evaporative water loss rate collected over a twenty-second interval once steady state conditions had been achieved. [0512] Subjects are treated with test compositions on selected volar forearm test areas as described in the Film Durability on Skin Test Measurements are taken from each of the volar forearm sites prior to treatment and at various time points (for example, at about 1-hour, about 4- hour, about 6-hour, about 12-hour, about 24-hour, about 30-hour, about 36-hour, about 48-hour, or between 48 hours and one week time point) after application of the composition.

Measurements are taken following a minimum of 25 minutes acclimation period in a controlled environment with the relative humidity maintained at less than about 50% and temperature maintained at about 19-22 °C. Duplicate water loss readings are taken from each site. TEWL properties (g/(m ² hr)) are calculated based on the data recorded by the instrument.

Optical measurement based on Color L*a*b* test

[0513] This test uses a Minolta CR-400 Chroma meter in accordance with the instructions by the manufacturer, which are generally known in the art Triplicate measurements of L*(D65), a*(D65), and b*(D65) are then collected at >6 different locations of the test articles.

Barrier protection test based on viral penetration

[0514] Barrier protection test based on viral penetration is performed to evaluate the barrier performance of protective materials, which are intended to protect against blood borne pathogen hazards. Test articles were conditioned for a minimum of 24 hours at 21 ± 5°C and 60 ± 10% relative humidity (%RH) and then tested for viral penetraton using a FC174 bacteriophage suspension. At the end of the test, the observed side of the test article was rinsed with a sterile medium and assayed for the presence of FC174 bacteriophage. The viral penetration method complies with ISO 16604. Triplicate readings are taken from each test article.

[0515] In certain embodiments, a film generated with the compositions and methods provided herein has particular evaporative water loss. In certain embodiments, the evaporative water loss can be determined using the assay of the Transepidermal Water Loss (TEWL) Measurement Test provided herein.

6.6.9 Barrier protection test based on chemical protection against nickel contact

[0516] Nickel can be detected at the ppm level with a simple spot test containing 1% dimethylgly oxime and 10% ammonium hydroxide solution, which turns pink upon contact with nickel. A 0.2 M solution of nickel (II) sulfate hexahydrate solution is added to a substrate, and both are covered by the test article. The spot test solution is subsequently applied on the test A change of color to pink indicates that the nickel has penetrated the test article and come in contact with the color solution, or vice versa. In contrast, absence of color change indicates that the test article is not penetrated and that its barrier function is intact.

[0517] In certain embodiments, a film generated with the compositions and methods provided herein provides particular barrier protection against nickel contact In certain embodiments, the barrier protection against nickel contact can be determined using the assay of the barrier protection test based on chemical protection against nickel contact provided herein.

6.6.10 Barrier protection test based on protection from ultraviolet radiation

[0518] The presence of the test article could help reduce the skin absorption of ultraviolet light, particularly when the test article contains SPF active ingredients such as titanium dioxide, zinc oxide, avobenzone, octinoxate, octocrylene, homosalate, or oxybenzone.

[0519] To prepare the test article for barrier protection against UV radiation, first the test article was deposited onto a blank Cellophane sheet substrate as described earlier in the application of test composition to the selected substrates. Cellophane sheet size 12.78cm(L) x 8.55cm(W) is employed to match plateholder of UV-Vis Spectrophotometer. Measure UV absorbance with UV-Vis Spectrophotometer from the wavelength 260 nm to 400 nm with 1 nm scan interval. Report absorption data based on averaged value of at least 4 different spot locations.

[0520] In certain embodiments, a film generated with the compositions and methods provided herein provides particular barrier protection against UV radiation. In certain embodiments, the barrier protection against UV radiation can be determined using the assay of the barrier protection test based on protection from ultraviolet radiation provided herein.

[0521] In one embodiment, provided herein is a composition, comprising (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride

functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the transition metal is capable of cross- linking the unsaturated organopolymer and the hydride functionalized polysiloxane thereby forming a film over the skin of a subject. In one embodiment, provided herein is a composition, comprising (a) at least one transition metal; (b) at least one vinyl functionalized

organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the transition metal is capable of cross-linking the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane thereby forming a film over the skin of a subject. In one embodiment, the ligand slows down the cross-linking reaction. In one embodiment, the ligand slows down the cross-linking reaction via complexation, or coordination. In one embodiment, In one embodiment, the ligand is divinyltetramethyldisilane, linear vinyl siloxane, cyclic vinyl siloxane, tris (vinylsiloxy) siloxane, tetrakis (vinylsiloxy) silane, vinyl ketone, vinyl ester, acetylenic alcohol, sulfide, mercaptan, divinyl disiloxane, divinyl trisiloxane, divinyl tetrasiloxane, divinyl dimethicone, 1 ,5-divinyl-3-phenylpentamethyltrisilxoane, 1,1, 5,5- tetramethyl-3,3-diphenyl-l,5-divinyltrisiloxane, trivinyl trimethylcyclotrisiloxane, tetravinyl tetramethylcyclotetrasiloxane, pentavinyl pentamethylcyclopentasiloxane, hexavinyl

hexamethylcyclohexasiloxane, tris (vinyldimethylsiloxy) silane, tetrakis (vinyldimethylsiloxy) silane, methacryloxypropyl tris(vinyldimethylsiloxy) silane, dimethyl fumarate, dimethyl maleate, methyl vinyl ketone, methoxy butanone, methyl isobutynol, ethyl mercaptan, diethyl sulfide, hydrogen sulfide, or dimethyl disulfide. In one embodiment, the ligand is

divinyltetramethyldisilane, linear vinyl siloxane, cyclic vinyl siloxane, tris (vinylsiloxy) siloxane, or tetrakis (vinylsiloxy) silane. In one embodiment, the ligand is vinyl ketone, vinyl ester, acetylenic alcohol, sulfide, or mercaptan. In one embodiment, the ligand is divinyl disiloxane, divinyl trisiloxane, divinyl tetrasiloxane, or divinyl dimethicone. In one embodiment, the ligand is 1 ,5-divinyl-3-phenylpentamethyltrisilxoane or 1,1, 5,5-tetramethyl-3,3-diphenyl-l,5- divinyltrisiloxane. In one embodiment, the ligand is trivinyl trimethylcyclotrisiloxane, tetravinyl tetramethylcyclotetrasiloxane, pentavinyl pentamethylcyclopentasiloxane, or hexavinyl hexamethylcyclohexasiloxane. In one embodiment, the ligand is tris (vinyldimethylsiloxy) silane, tetrakis (vinyldimethylsiloxy) silane, or methacryloxypropyl tris(vinyldimethylsiloxy) silane. In one embodiment, the ligand is dimethyl fumarate, dimethyl maleate, methyl vinyl ketone or methoxy butanone. In one embodiment, the ligand is methyl isobutynol. In one embodiment, the ligand is ethyl mercaptan, diethyl sulfide, hydrogen sulfide or dimethyl disulfide. In one embodiment, the activity of the ligand to slow down the cross-linking reaction can be reduced or eliminated by evaporation of the ligand, degradation of the ligand, phase transformation of the ligand, chemical degradation of ligand, deactivation of ligand, use of vibrational energy, or use of electromagnetic waves. In one embodiment, the deactivation of the ligand can be triggered by exposure to a chemical, heat or light. In one embodiment, the chemical is an oxidative agent. In one embodiment, the chemical is a reducing agent. In one embodiment, the oxidative agent is oxygen. In one embodiment, the ligand is a volatile ligand.

In one embodiment, the volatile ligand is divinyltetramethyldisilane, divinyldisiloxane , divinyltrisiloxane, trivinyl trimethylcyclotrisiloxane, tetravinyl tetramethylcyclotetrasiloxane, tris (vinyldimethylsiloxy) silane, tetrakis (vinyldimethylsiloxy) silane, dimethyl maleate, methyl vinyl ketone, methyl isobutynol, ethyl mercaptan, diethyl sulfide, hydrogen sulfide, or dimethyl disulfide. In one embodiment, the ligand is an electromagnetic-driven ligand. In one embodiment, the electromagnetic-driven ligand is a platinum complex of triazine. In one embodiment, the platinum complex of triazine is tetrakis (1 -phenyl-3 -hexyl-triazenido) Pt (IV), Pt(II)-phosphine complex, platinum/oxalate complexs, Pt(II)-bis-(diketonates), dicarbonyl- Pt(IV)R3 complex, or sulfoxide-Pt(II) complex. In one embodiment, the ligand is a heat- sensitive ligand. In one embodiment, the heat-sensitive ligand is a platinum complex of triazine. In one embodiment, the platinum complex of triazine is tetrakis ( 1 -phenyl- 3 -hexyl-triazenido) Pt (IV), or Pt(n) -phosphine complex. In one embodiment, the ligand is a cold-sensitive ligand. In one embodiment, the ligand is an acoustic-driven ligand. In one embodiment, the ligand is 1,3- divinyltetramethyldisiloxane. In one embodiment, the ligand is 1,1,3,3,5,5-hexamethyl-l,5- divinyltrisiloxane. In one embodiment, the ligand is l,5-divinyl-3-phenylpentamethyltrisiloxane. In one embodiment, the ligand is 1,1,5,5-tetramethyl-3,3-diphenyl-l,5-divinyltrisiloxane. In one embodiment, the ligand is l,3,5-trivinyl-l,3,5-trimethylcyclotrisiloxane. In one embodiment, the ligand is 2,4,6,8-tetramethyltetravinylcyclotetrasiloxane. In one embodiment, the ligand is 1 3,5,7,9-pentamethyl-l,3,5,7,9-pentavinylcyclopentasiloxane. In one embodiment, the ligand is tris(vinyldimethylsiloxy)methylsilane. In one embodiment, the ligand is

tetrakis(vinyldimethylsiloxy)silane. In one embodiment, the ligand is

methacryloxypropyltris(vinyldimethylsiloxy)silane. In one embodiment, the ligand is 1,2- divinyltetramethyldisilane. In one embodiment, the ligand is methyl vinyl ketone. In one embodiment, the ligand is dimethyl maleate. In one embodiment, the ligand is dimethyl fumarate. In one embodiment, the ligand is (3E)-4-methoxy-3-buten-2-one. In one embodiment, the ligand is (E)-2-ethylhex-2-enal. In one embodiment, the ligand is pent-l-en-3-one. In one embodiment, in the ligand is maleic acid. In one embodiment, in the ligand is a polymer having at least one unsaturated group, a function group with one lone-pair electrons or a function group with ability to function as an electron donor. In one embodiment, in the ligand is a platinum poison. In one embodiment, the ligand is a siloxane polymer having at least one unsaturated group. In one embodiment, in the ligand is a vinyl-containing siloxane polymer. In one embodiment, the ligand is a divinyl-containing siloxane polymer. In one embodiment, the ligand is a divinyl-containing disiloxane. In one embodiment, the ligand is divinyl trisiloxane or divinyl tetrasilxoane. In one embodiment, the transition metal is platinum. In one embodiment, the molar ratio of transition metal to ligand is between about 10:1 to about 1:10000. In one embodiment, the molar ratio of transition metal to ligand is between about 1 :250 to about 1 :750. In one embodiment, the molar ratio of transition metal to ligand is between about 1 :500. In one embodiment, the molar ratio of hydride functionalized polysiloxane to ligand is between about 10: 1 to about 1 : 10000. In one embodiment, the molar ratio of hydride functionalized

polysiloxane to ligand is between about 1 :250 to about 1 :750. In one embodiment, the molar ratio of hydride functionalized polysiloxane to ligand is between about 1 :500. In one

embodiment, the vinyl to functional hydride molar ratio is between about 1:10 and about 1 : 100. In one embodiment, the vinyl to functional hydride molar ratio is between about 1:15 and about 1 :90. In one embodiment, the vinyl to functional hydride molar ratio is between about 1 :25 and about 1 :70. In one embodiment, the vinyl to functional hydride molar ratio is between about 1:30 and about 1:60. In one embodiment, the composition has a viscosity of between about 5,000 and 700,000 cSt or cP at about 25°C. In one embodiment, the vinyl functionalized

organopolysiloxane is selected from the group consisting of vinyl terminated

polydimethylsiloxane; vinyl terminated diphenylsiloxane-dimethylsiloxane copolymers; vinyl terminated polyphenylmethylsiloxane, vinylphenylmethyl terminated vinylphenylsiloxane- phenylmethylsiloxane copolymer; vinyl terminated trifluoropropylmethylsiloxane- dimethylsiloxane copolymer; vinyl terminated diethylsiloxane-dimethylsiloxane copolymer; vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy terminated;

vinylmethylsiloxane-dimethylsiloxane copolymers, silanol terminated; vinylmethylsiloxane- dimethylsiloxane copolymers, vinyl gums; vinylmethylsiloxane homopolymers; vinyl T-structure polymers; vinyl Q-structure polymers; monovinyl terminated polydimethylsiloxanes;

vinylmethylsiloxane terpolymers; vinylmethoxysilane homopolymers and combinations thereof. In one embodiment, the hydride functionalized polysiloxane is alkyl terminated. In one embodiment, the hydride functionalized polysiloxane is selected from the group consisting of hydride terminated polydimethylsiloxane; polyphenyl-(dimethylhydrosiloxy)siloxane, hydride terminated; methylhydrosiloxane-phenylmethylsiloxane copolymer, hydride terminated; methylhydrosiloxane-dimethylsiloxane copolymers, trimethylsiloxy terminated;

polymethylhydrosiloxanes, trimethylsiloxy terminated; polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer; methylhydrosiloxane- phenyloctylmethylsiloxane terpolymer and combinations thereof. In one embodiment, the hydride functionalized polysiloxane comprises trimethylsiloxy terminated methylhydrosiloxane- dimethylsiloxane copolymers. In one embodiment, the hydride functionalized polysiloxane has a percent SiH content of between about 3 and about 45%; or a SiH content of between about 0.5 and about 10 mmol/g; or a combination of both. In one embodiment, the hydride functionalized polysiloxane has a viscosity of about 5 to about 11,000 cSt or cP at about 25°C. In one embodiment, the hydride functionalized polysiloxane has at least 2 Si-H units on average. In one embodiment, the vinyl functionalized organopolysiloxane is a polymer of formula Ila and the

are each independently C1-20 alkyl, C2-20 alkenyl, Cs-10 aryl, hydroxyl or C1-20 alkoxyl; p and q are each independently an integer from between 10 and 6000; R ^1b , R ^2b , R ^3b , R ^6b , R ^7b and R ^8b are C1- 20 alkyl; R ^4b , R ^5b , R ^9b , R ^10b , R ^7b are each independently selected from the group consisting of hydrogen, C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl and C1-20 alkoxyl, wherein at least two of R ^4b , R ⁵⁶ , R ^9b , R ^10b are hydrogen; and m and n are each independently an integer from between 10 and 6000. In one embodiment, the composition further comprises an agent selected from the group consisting of sunscreens, anti-aging agents, anti-acne agents, anti-wrinkle agents, spot reducers, anti-oxidants, and vitamins. In one embodiment, the composition further comprises one or more feel modifiers, tack modifiers, spreadability enhancers, diluents, adhesion modifiers, optics modifiers, particles, volatile siloxanes, emulsifiers, emollients, surfactants, thickeners, solvents, film formers, humectants, preservatives, or pigments. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity between about 150,000 and about 185,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of between about 30 and about 100 cSt or cP at about 25°C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of about 45 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of about 50 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 10,000 cSt or cP at about 25 °C. In one embodiment, the composition further comprises a reinforcing constituent In one embodiment, the reinforcing constituent is selected from the group consisting of mica, zinc oxide, titanium dioxide, aluminum oxide, clay, silica, surface treated mica, surface treated zinc oxide, surface treated titanium dioxide, surface treated aluminum oxide, surface treated clay and surface treated silica.

[0522] In one embodiment, provided herein is a method of forming a thin film on the skin of a subject, wherein the method comprises: (i) applying a composition to the skin of the subject, wherein the composition comprises (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking; and (ii) separating the ligand from the transition metal. In one embodiment, provided herein is a method of forming a thin film on the skin of a subject, wherein the method comprises: (i) applying a composition to the skin of the subject, wherein the composition comprises (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking; and (ii) separating the ligand from the transition metal. In one embodiment, the method further comprises separating the ligand from the transition metal by evaporating the ligand. In one embodiment, the method further comprises separating the ligand from the transition metal by absorbing the ligand into another phase. In one embodiment, the method further comprises separating the ligand from the transition metal by absorbing the ligand into the skin of a subject In one embodiment, the method further comprises separating the ligand from the transition metal by absorbing the ligand into another ingredients forming a complex. In one embodiment, the method further comprises separating the ligand from the transition metal by transforming the ligand into non-complex with the transition metal. In one embodiment, the method further comprises separating the ligand from the transition metal by using heat In one embodiment, the method further comprises separating the ligand from the transition metal by cooling the composition. In one embodiment, the method further comprises separating the ligand from the transition metal by using heat generated with a blow-dry. In one embodiment, the method further comprises separating the ligand from the transition metal by using ultrasound. In one embodiment, the method further comprises separating the ligand from the transition metal by using electromagnetic waves. In one embodiment, the method further comprises separating the ligand from the transition metal by using visible light. In one embodiment, the method further comprises separating the ligand from the transition metal by using ultraviolet light. In one embodiment, the method further comprises separating the ligand from the transition metal by using infrared radiation.

[0523] In one embodiment, provided herein is a method of forming a thin film on the skin of a subject, wherein the method comprises: (i) applying a composition to the skin of the subject, wherein the composition comprises (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking; and (ii) separating the ligand from the hydride functionalized polysiloxane. In one embodiment, provided herein is a method of forming a thin film on the skin of a subject, wherein the method comprises: (i) applying a composition to the skin of the subject, wherein the composition comprises (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one ligand at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking; and (ii) separating the ligand from the hydride functionalized polysiloxane. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by evaporating the ligand. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by absorbing the ligand into another phase. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by absorbing the ligand into the skin of a subject In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by absorbing the ligand into another ingredients forming a complex. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by transforming the ligand into non-complex with the hydride functionalized polysiloxane. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by using heat. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by cooling the composition. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by using heat generated with a blow-dry. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by using ultrasound. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by using electromagnetic waves. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by using visible light. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by using ultraviolet light. In one embodiment, the method further comprises separating the ligand from the hydride functionalized polysiloxane by using infrared radiation.

In one embodiment, the composition forms a film over the skin of a subject. In one embodiment, the composition forms a film over the kerationous substrates of a subject. In one embodiment, the composition forms a film over the hair of a subject In one embodiment, the composition forms a film over the mucous membrane surfaces of a subject. In one embodiment, the composition forms a film over a medical device on the skin of a subject. In one embodiment, the composition forms a film over a wearable device on the skin of a subject In one embodiment, the composition forms a film over the epithelial layers of a subject. In one embodiment, the method further comprises decomposing the ligand using visible light and freeing the transition metal. In one embodiment, the method further comprises decomposing the ligand using visible light and freeing the hydride functionalized polysiloxane. In one embodiment, the composition is a one-step single formulation.

[0524] In one embodiment, provided herein is a composition, comprising (a) platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one divinyl disiloxane at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one divinyl disiloxane from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the divinyl disiloxane at a concentration sufficient to slow down cross- linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30, 90 or 180 days or for about 1, 2 or 3 years. In one embodiment, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane at about 25 °C to about 10 %, 1 %, 0.1 %, 0.01 %, 0.001 %,

0.0001 %, 0.00001 %, 0.000001 %, or 0.0000001 % of the reaction rate of the cross-linking reaction without the ligand.

[0525] In one embodiment, provided herein is a composition, comprising (a) platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one divinyl disiloxane at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one divinyl disiloxane from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the divinyl disiloxane at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the ligand is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized

polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30, 90 or 180 days or for about 1, 2 or 3 years. In one embodiment, the ligand is at a concentration sufficient to slow down the cross- linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane at about 25 °C to about 10 %, 1 %, 0.1 %, 0.01 %, 0.001 %,

0.0001 %, 0.00001 %, 0.000001 %, or 0.0000001 % of the reaction rate of the cross-linking reaction without the ligand. In one embodiment, the ligand is at a concentration of about 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 99.9 % by weight of the composition. In one

embodiment, the molar ratio between the ligand and the transition metal catalyst is about 10 ⁷ : 1, 10 ⁶ :1, 10 ⁵ :1, 10 ⁴ :1, 10 ³ :1, 10 ² :1, 10:1, 1:1, 1:2, 1:5, or 1:10. In one embodiment, the molar ratio between the ligand and the hydride functionalized polysiloxane is about 10 ⁷ :1, 10 ⁶ :1, 10 ⁵ :1,

10 ⁴ :1, 10 ³ :1, 10 ² :1, 10:1, 1:1, 1:2, 1:5, or 1:10.

[0526] In one embodiment, provided herein is a composition, comprising (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride

functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, wherein the encapsulating agent forms microcapsules with the transition metal or with hydride functionalized polysiloxane. In one embodiment, provided herein is a composition, comprising (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, wherein the encapsulating agent forms microcapsules with the transition metal or with hydride functionalized polysiloxane. In one embodiment, the components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the composition is a one-step single formulation. In one embodiment, the transition metal is capable of cross-linking the unsaturated organopolymer and the hydride functionalized polysiloxane thereby forming a film over the skin of a subject

[0527] In one embodiment, provided herein is a composition, comprising (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, wherein the encapsulating agent forms microcapsules with the transition metal or with hydride functionalized polysiloxane. In one embodiment, provided herein is a composition, comprising (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized

polysiloxane, wherein the encapsulating agent forms microcapsules with the transition metal or with hydride functionalized polysiloxane. In one embodiment, the components can be formulated and stored together as a mixture without significant cross-linking. In one

embodiment, the composition is a one-step single formulation. In one embodiment, the transition metal is capable of cross-linking the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane thereby forming a film over the skin of a subject In one embodiment, the encapsulating agent slows down the cross-linking reaction via encapsulating the transition metal. In one embodiment, the encapsulating agent prohibits the cross-linking reaction via encapsulating the transition metal. In one embodiment, the encapsulating agent slows down the cross-linking reaction via encapsulating the hydride functionalized polysiloxane. In one embodiment, the encapsulating agent prohibits the cross-linking reaction via encapsulating the hydride functionalized polysiloxane. In one embodiment, the encapsulating agent is

polyurethane- 1, polyurethane-11, polyurethane- 14, polyurethane-6, polyurethane-2,

polyurethane- 18 or their mixtures thereof. In one embodiment, the encapsulating agent is polyurethane- 1. In one embodiment, the activity of the encapsulating agent to slow down the cross-linking reaction can be reduced or eliminated by evaporation of the encapsulating agent, degradation of the encapsulating agent, phase transformation of the encapsulating agent, chemical degradation of encapsulating agent, deactivation of encapsulating agent, use of vibrational energy, or use of electromagnetic waves. In one embodiment, the activity of the encapsulating agent to prohibit the cross-linking reaction can be reduced or eliminated by evaporation of the encapsulating agent, degradation of the encapsulating agent, phase transformation of the encapsulating agent, chemical degradation of encapsulating agent, deactivation of encapsulating agent, use of vibrational energy, or use of electromagnetic waves. In one embodiment, the deactivation of the encapsulating agent can be triggered by exposure to a chemical, heat or light. In one embodiment, the chemical is an oxidative agent In one embodiment, the chemical is a reducing agent. In one embodiment, the oxidative agent is oxygen. In one embodiment, the encapsulating agent is a volatile encapsulating agent In one embodiment, the encapsulating agent is an electromagnetic-driven encapsulating agent. In one embodiment, the encapsulating agent is a heat-sensitive encapsulating agent. In one

embodiment, the encapsulating agent is a cold-sensitive encapsulating agent. In one

embodiment, the encapsulating agent is an acoustic-driven encapsulating agent. In one embodiment, the transition metal is platinum. In one embodiment, the vinyl to functional hydride molar ratio is between about 1:10 and about 1:100. In one embodiment, the vinyl to functional hydride molar ratio is between about 1:15 and about 1:90. In one embodiment, the vinyl to functional hydride molar ratio is between about 1 :25 and about 1 :70. In one

embodiment, the vinyl to functional hydride molar ratio is between about 1 :30 and about 1 :60.

In one embodiment, the composition has a viscosity of between about 5,000 and 700,000 cSt or cP at about 25°C. In one embodiment, the vinyl functionalized organopolysiloxane is selected from the group consisting of vinyl terminated polydimethylsiloxane; vinyl terminated diphenylsiloxane-dimethylsiloxane copolymers; vinyl terminated polypheny lmethylsiloxane, vinylphenylmethyl terminated vinylphenylsiloxane-pheny lmethylsiloxane copolymer; vinyl terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer; vinyl terminated diethylsiloxane-dimethylsiloxane copolymer; vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy terminated; vinylmethylsiloxane-dimethylsiloxane copolymers, silanol terminated; vinylmethylsiloxane-dimethylsiloxane copolymers, vinyl gums; viny lmethylsiloxane homopolymers; vinyl T-structure polymers; vinyl Q-structure polymers; monovinyl terminated polydimethylsiloxanes; vinylmethylsiloxane terpolymers; vinylmethoxysilane homopolymers and combinations thereof. In one embodiment, the hydride functionalized polysiloxane is alkyl terminated. In one embodiment, the hydride functionalized polysiloxane is selected from the group consisting of hydride terminated polydimethylsiloxane; polyphenyl- (dimethylhydrosiloxy)siloxane, hydride terminated; methylhydrosiloxane-phenylmethylsiloxane copolymer, hydride terminated; methylhydrosiloxane-dimethylsiloxane copolymers,

trimethylsiloxy terminated; polymethylhydrosiloxanes, trimethylsiloxy terminated;

polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer; methylhydrosiloxane-phenyloctylmethylsiloxane terpolymer and combinations thereof. In one embodiment, the hydride functionalized polysiloxane comprises trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymers. In one embodiment, the hydride functionalized polysiloxane has a percent SiH content of between about 3 and about 45%; or a SiH content of between about 0.5 and about 10 mmol/g; or a combination of both. In one embodiment, the hydride functionalized polysiloxane has a viscosity of about 5 to about 11,000 cSt or cP at about 25°C. In one embodiment, the hydride functionalized polysiloxane has at least 2 Si-H units on average. In one embodiment, the vinyl functionalized organopolysiloxane is a polymer of formula Ila and the hydride functionalized polysiloxane is a polymer of formula III:

^' are each independently C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or C1-20 alkoxyl; p and q are each independently an integer from between 10 and 6000; R ^1b , R ^2b , R ^3b , R ^6b , R ^7b and R ^8b are C1.20 alkyl; R ^4b , R ^5b , R ^9b , R ^10b , R ^7b are each independently selected from the group consisting of hydrogen, Ci-20 alkyl, C2-20 alkenyl, Cs-10 aryl, hydroxyl and Ci-20 alkoxyl, wherein at least two of R ^4b , R ⁵⁶ , R ^9b , R ^10b are hydrogen; and m and n are each independently an integer from between 10 and 6000. In one embodiment, the composition further comprises an agent selected from the group consisting of sunscreens, anti-aging agents, anti-acne agents, anti- wrinkle agents, spot reducers, anti-oxidants, and vitamins. In one embodiment, the composition further comprises one or more feel modifiers, tack modifiers, spreadability enhancers, diluents, adhesion modifiers, optics modifiers, particles, volatile siloxanes, emulsifiers, emollients, surfactants, thickeners, solvents, film formers, humectants, preservatives, or pigments. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity between about 150,000 and about 185,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of between about 30 and about 100 cSt or cP at about 25°C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of about 45 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized

organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of about 50 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of about 100 cSt or cP at about 25 °C. In one embodiment, the vinyl functionalized organopolysiloxane has a viscosity of about 165,000 cSt or cP at about 25 °C, and the hydride functionalized polysiloxane has a viscosity of about 500 cSt or cP at about 25 °C. In one embodiment, the vinyl

functionalized organopolysiloxane has a viscosity of about 10,000 cSt or cP at about 25 °C. In one embodiment, the composition further comprises a reinforcing constituent. In one embodiment, the reinforcing constituent is selected from the group consisting of mica, zinc oxide, titanium dioxide, aluminum oxide, clay, silica, surface treated mica, surface treated zinc oxide, surface treated titanium dioxide, surface treated aluminum oxide, surface treated clay and surface treated silica.

[0528] In one embodiment, provided herein is a method of forming a thin film on the skin of a subject, wherein the method comprises: (i) applying a composition to the skin of the subject, wherein the composition comprises (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking; and (ii) separating the encapsulating agent from the transition metal or from hydride

functionalized polysiloxane. In one embodiment, provided herein is a method of forming a thin film on the skin of a subject, wherein the method comprises: (i) applying a composition to the skin of the subject, wherein the composition comprises (a) at least one transition metal; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross- linking; and (ii) separating the encapsulating agent from the transition metal or from hydride functionalized polysiloxane.

[0529] In one embodiment, provided herein is a method of forming a thin film on the skin of a subject, wherein the method comprises: (i) applying a composition to the skin of the subject, wherein the composition comprises (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized

polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking; and (ii) separating the encapsulating agent from the transition metal or from hydride functionalized polysiloxane. In one embodiment, provided herein is a method of forming a thin film on the skin of a subject, wherein the method comprises: (i) applying a composition to the skin of the subject, wherein the composition comprises (a) at least one transition metal; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking; and (ii) separating the

encapsulating agent from the transition metal or from hydride functionalized polysiloxane. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by evaporating the encapsulating agent In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by evaporating the encapsulating agent. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by absorbing the encapsulating agent into another phase. In one embodiment, the method further comprises separating the

encapsulating agent from the hydride functionalized polysiloxane by absorbing the encapsulating agent into another phase. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by absorbing the encapsulating agent into the skin of a subject In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by absorbing the encapsulating agent into the skin of a subject In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by absorbing the encapsulating agent into another ingredients forming a complex. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by absorbing the encapsulating agent into another ingredients forming a complex. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by transforming the encapsulating agent into non-complex with the transition metal. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized

polysiloxane by transforming the encapsulating agent into non-complex with the hydride functionalized polysiloxane . In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by using heat. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized

polysiloxane by using heat In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by cooling the composition. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by cooling the composition. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by using heat generated with a blow- dry. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by using heat generated with a blow-dry. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by using ultrasound. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by using ultrasound. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by using electromagnetic waves. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by using electromagnetic waves. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by using visible light. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by using visible light. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by using ultraviolet light. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by using ultraviolet light. In one embodiment, the method further comprises separating the encapsulating agent from the transition metal by using infrared radiation. In one embodiment, the method further comprises separating the encapsulating agent from the hydride functionalized polysiloxane by using infrared radiation. In one embodiment, the composition forms a film over the skin of a subject. In one embodiment, the composition forms a film over the kerationous substrates of a subject In one embodiment, the composition forms a film over the hair of a subject In one embodiment, the composition forms a film over the mucous membrane surfaces of a subject. In one embodiment, the composition forms a film over a medical device on the skin of a subject In one embodiment, the composition forms a film over a wearable device on the skin of a subject In one embodiment, the composition forms a film over the epithelial layers of a subject. In one embodiment, the method further comprises

decomposing the encapsulating agent using visible light and freeing the transition metal. In one embodiment, the method further comprises decomposing the encapsulating agent using visible light and freeing the hydride functionalized polysiloxane.

[0530] In one embodiment, provided herein is a composition, comprising (a) platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a composition, comprising (a) platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one encapsulating agent from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to slow down cross- linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one encapsulating agent from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to prohibit cross- linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one encapsulating agent from hydride functionalized polysiloxane in the composition, wherein the composition comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one encapsulating agent from hydride functionalized polysiloxane in the composition, wherein the composition comprises (a) the platinum; (b) at least one unsaturated organopolymer; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the encapsulating agent is at a concentration sufficient to slow down the cross- linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30, 90 or 180 days or for about 1, 2 or 3 years. In one embodiment, the encapsulating agent is at a concentration sufficient to prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30, 90 or 180 days or for about 1, 2 or 3 years. In one embodiment, the encapsulating agent is at a concentration sufficient to slow down the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane at about 25 °C to about 10 %, 1 %, 0.1 %, 0.01 %, 0.001 %,

0.0001 %, 0.00001 %, 0.000001 %, or 0.0000001 % of the reaction rate of the cross-linking reaction without the encapsulating agent. In one embodiment, the encapsulating agent is at a concentration sufficient to prohibit the cross-linking reaction between the unsaturated organopolymer and the hydride functionalized polysiloxane at about 25 °C to about 10 %, 1 %, 0.1 %, 0.01 %, 0.001 %, 0.0001 %, 0.00001 %, 0.000001 %, or 0.0000001 % of the reaction rate of the cross-linking reaction without the encapsulating agent. In one embodiment, the encapsulating agent is at a concentration of about 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 99.9 % by weight of the composition. In one embodiment, the molar ratio between the encapsulating agent and the transition metal catalyst is about 10 ⁷ :1, 10 ⁶ :1, 10 ⁵ :1, 10 ⁴ :1, 10 ³ :1, 10 ² :1, 10:1, 1:1, 1:2, 1:5, or 1:10. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 107:1, 106:1, 105:1, 104:1, 103:1, 102:1, 10:1, 1:1, 1:2, 1:5, or 1:10.

[0531] In one embodiment, provided herein is a composition, comprising (a) platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a composition, comprising (a) platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) at least one encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one encapsulating agent from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one encapsulating agent from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to prohibit cross- linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one encapsulating agent from hydride functionalized polysiloxane in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the

encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross- linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method, comprising separating at least one encapsulating agent from hydride functionalized polysiloxane in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, the encapsulating agent is at a concentration sufficient to slow down the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30, 90 or 180 days or for about 1, 2 or 3 years. In one embodiment, the encapsulating agent is at a concentration sufficient to prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking at about 25 °C for about 30, 90 or 180 days or for about 1, 2 or 3 years. In one embodiment, the encapsulating agent is at a concentration sufficient to slow down the cross- linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane at about 25 °C to about 10 %, 1 %, 0.1 %, 0.01 %, 0.001 %,

0.0001 %, 0.00001 %, 0.000001 %, or 0.0000001 % of the reaction rate of the cross-linking reaction without the encapsulating agent. In one embodiment, the encapsulating agent is at a concentration sufficient to prohibit the cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane at about 25 °C to about 10 %,

1 %, 0.1 %, 0.01 %, 0.001 %, 0.0001 %, 0.00001 %, 0.000001 %, or 0.0000001 % of the reaction rate of the cross-linking reaction without the encapsulating agent In one embodiment, the encapsulating agent is at a concentration of about 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 99.9 % by weight of the composition. In one embodiment, the molar ratio between the encapsulating agent and the transition metal catalyst is about 10 ⁷ :1, 10 ⁶ :1, 10 ⁵ :1, 10 ⁴ : 1, 10 ³ :1, 10 ² :1, 10:1, 1:1, 1:2, 1:5, or 1:10. In one embodiment, the molar ratio between the encapsulating agent and the hydride functionalized polysiloxane is about 107:1, 106:1, 105:1, 104:1, 103:1, 102:1, 10:1, 1:1, 1:2, 1:5, or 1:10.

[0532] In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method that results in a separation of at least one divinyl disiloxane from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the divinyl disiloxane at a concentration sufficient to slow down cross- linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method that results in a separation of at least one encapsulating agent from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method that results in a separation of at least one encapsulating agent from platinum in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method that results in a separation of at least one encapsulating agent from hydride functionalized polysiloxane in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to slow down cross-linking reaction between the vinyl functionalized

organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking. In one embodiment, provided herein is a method of using a composition as a single formulation in a one-step method that results in a separation of at least one encapsulating agent from hydride functionalized polysiloxane in the composition, wherein the composition comprises (a) the platinum; (b) at least one vinyl functionalized organopolysiloxane; (c) at least one hydride functionalized polysiloxane; and (d) the encapsulating agent at a concentration sufficient to prohibit cross-linking reaction between the vinyl functionalized organopolysiloxane and the hydride functionalized polysiloxane, such that these components can be formulated and stored together as a mixture without significant cross-linking.

7 EXAMPLES

[0533] The testing procedures used in Examples 1, 2, 3, 4 and 5 are described as follows.

[0534] Set-to-touch time: The set-to-touch times of the tested formulations were determined in vitro by a modified ASTM D5895-03 method (“Standard Test Methods for Evaluating Drying or Curing during Film Formation of Organic Coatings using Mechanical Recorders”), as described below. These tests mimic the behavior of the tested formulation on skin (referred to herein as“Bioskin”). The test formulation was applied to a sheet of polyurethane substrate with a thickness of about 100 microns, but this thickness was then reduced quickly due to

evaporation. The test formulation was allowed to solidify on the substrate at room temperature and ambient humidity until its shine had finished decreasing, as determined by the naked eye. A sheet of porous polypropylene film (Clean & Clear Oil Control Film) (1.5 cm x 4 cm, corresponding to 0.59 inches x 1.57 inches) was then layered carefully on the surface of the test formulation without disturbing it. A weight (15 g; 1 cm wide, 2 cm long and 4.5 cm high, corresponding to 0.39 inches wide, 0.79 inches long and 1.77 inches high) was then placed on top of the polypropylene sheet so that the weight’s side defined by the weight’s length and width made contact with the sample. After two seconds, the weight was removed and the

polypropylene sheet was carefully peeled off the test formulation. Then, the polypropylene sheet was inspected visually by naked eye (i.e., without a magnifying device) to determine whether any test formulation was present on it and whether the curing film surface was damaged. This test was repeated about every 15 seconds on areas of the test formulation that had not been subjected to the afore-mentioned weight, using a new polypropylene sheet each time. The time at which no more curing film surface was damaged was observed on the polypropylene sheet was determined to be the in vitro set-to-touch time of the test formulation.

[0535] Bioskin Dry up time: The dry up times of the tested formulations were determined in vitro by a modified ASTM D5895-03 method (“Standard Test Methods for Evaluating Drying or Curing during Film Formation of Organic Coatings using Mechanical Recorders”), as described below. These tests mimic the behavior of the tested formulation on skin (i.e., Bioskin). The test formulation was applied to a sheet of polyurethane substrate with a thickness of about 100 microns, but this thickness was then reduced quickly due to evaporation. The test formulation was allowed to solidify on the substrate at room temperature and ambient humidity until its shine had finished decreasing, as determined by naked eye. A sheet of porous polypropylene film (Clean & Clear Oil Control Film) (1.5 cm x 4 cm, corresponding to 0.59 inches x 1.57 inches) was then layered carefully on the surface of the test formulation without disturbing it. A weight (15 g; 1 cm wide, 2 cm long and 4.5 cm high, corresponding to 0.39 inches wide, 0.79 inches long and 1.77 inches high) was then placed on top of the sheet so that the weight’s side defined by the weight’s length and width made contact with the sample. After two seconds, the weight was removed and the sheet was carefully peeled off the test formulation. Then, the sheet was inspected visually by naked eye (i.e., without a magnifying device) to determine whether any test formulation was present on it. This test was repeated about every 15 seconds on areas of the test formulation that had not been subjected to the afore-mentioned weight, using a new sheet each time. The time at which no more test composition is observed on the oil-absorbing paper is determined to be the Bioskin dry up time of the test formulation.

[0536] Hand Dry up time: The hand dry up time is the same as the Bioskin dry up time described above except that the test formulation is applied on the dorsal side of the hand, instead of on the Bioskin substrate.

[0537] Adhesion peel force per unit length: This test method for adhesive force was developed in accordance with ASTM C794 Adhesion-in-Peel of Elastomeric Joint Sealants. Instron 3342 single column tension/compression testing system (Instron, Norwood, MA) with 100N load cell (Instron #2519-103) mounted with extension grip geometry may be used, with polypropylene sheet of 1/32” thickness as the test substrate. Other similar equipment and other soft, flexible test substrates can also be used to measure the peeling force. The materials and application of test composition to the selected substrates are described as follows: Apply the test composition onto the substrate, then gliding the glass slide back and forth along the spacer edges to deposit a smooth and uniform layer of test composition. Allow the test composition to sit untouched over the area at room temperature and ambient humidity for 24 hours. Then, place a silicone adhesive tape (Mepitac) of 0.75” width on top of the film to fully cover the film surface on the polypropylene substrate. Allow the specimen to sit untouched over the area at room temperature and ambient humidify for 24 hours, before the measurement For each material tested, at least 3 samples are measured, and average peeling force and standard deviation of the measurements are recorded. Partially peel the silicone tape-covered test specimen at one end by hand to separate enough of the silicone tape-covered film from the polypropylene substrate for effective grip by extension grip geometry mounts of the instrument. Secure each peeling side in its own instrument grip. Make sure the strips are clamped substantially parallel to the geometry. Perform the extension test at a rate of 1 mm/s until the two peeling strips separate completely from each other. Record the peeling force vs. time data. The sample’s average peeling force (N/m) is calculated by averaging the instantaneous force (N) measured by the instrument during the experiment normalized by the sample width (0.75” or 0.019 m).

7.1 Example 1:

[0538] Step 1 A - Titration of Karstedt catalyst (Pt/DVDS) with additional divinyldisiloxane (DVDS) (with or without additional dilution from silicone fluid diluent PMX-1184). See Table lA.

[0539] Table 1A

0540] In Step 1A, all ii in a glass vial and stirred with a vortex mixer.

[0541] Step IB - Mixture of vinyl and hydride functional organopolysiloxanes (OPM-003 containing 50-75% VS165K, 5-15%XL-l 1, 5-15% R812S), with Karstedt/DVDS titration from Step 1 A. See Table IB.

[0542] Table IB

0543] In Step IB, all ingredients are added together in a glass vial and stirred with a vortex mixer. Composition AAA-034-50-B2 comprising AAA-034-50- A2 has the best stability and cure among the compositions listed in Table IB.

[0544] Step ICa - The mixture of Step 1 A and the mixture of vinyl and hydride functional organopolysiloxanes in the diluent (Step 1 Pilot A - 55% OPM-003 mixed with 45% PMX-1184 silicone fluid) with AAA-034-50- A2 - with or without other functional excipients. See Table

ICa. [0545] Table ICa

0546] In Step ICa, all ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin.

[0547] The results of Step ICa are now described:

[0548] AAA-034-50-Cla: The resulting film was thin and shiny, with a gritty texture. The film cured in 5 minutes.

[0549] AAA-034-50-C2a: The film cured in 5 minutes.

[0550] AAA-034-50-C3a: Addition of the KSG-710 resulted in a thicker film (similar to that experienced with the addition of Nylon), but also resulted in somewhat less durability. The film cured in 5 minutes.

[0551] AAA-034-50-C4a: The results are similar to that of AAA-034-50-C2a and AAA-

034-50-C3a with regard to shine and texture. The film cured in 5 minutes.

[0552] AAA-034-50-C5a: The addition of glycerol helps to smooth and soften the film somewhat, but the texture remains gritty. The film cured in 5 minutes.

[0553] AAA-034-50-C6a: The results are essentially the same as AAA-034-50-C5a. [0554] AAA-034-50-C7a: The film is dry at 5 minutes. The resulting film is cohesive with still texture.

[0555] AAA-034-50-C8a: The film is dry at 4 minutes. The resulting film is flaky upon removal with still texture.

[0556] AAA-034-50-C9a: The film is dry at 6 minutes. The resulting film is cohesive with still texture.

[0557] AAA-034-50-C10a: The film is dry at 6 minutes. The resulting film is flaky upon removal with still texture, although somewhat softer than AAA-034-50-C7a, AAA-034-50-C8a, and AAA-034-50-C9a.

7.2 Example 2:

[0558] The mixture of heterobifunctional orgopolysiloxane with AAA-034-50- A2. See

Table 2a.

[0559] Table 2a

;0560] All ingredients are added together in a glass vial and stirred with a vortex mixer.

[0561] For each of the compositions in Example 2, such compositions never set after 1 day, 7 days, and 1 month. All remained fluid after 1 month.

7.3 Example 3:

[0562] The mixture of vinyl organopolysiloxane with different size and structure with AAA- 034-50- A2 and XL-11 hydride. See Table 3a.

[0563] Table 3a

[0564] All ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin (hand) and Bioskin.

[0565] The results of Example 3 are now described:

[0566] AAA-034-50-Dla: Remains fluid after 1 week; turned to soft gel after 2 weeks. The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5.5 minutes.

[0567] AAA-034-50-D2a: A softer gel after 72 hours. The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5 minutes.

[0568] AAA-034-50-D3a: A soft gel after 72 hours. The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5.5 minutes.

[0569] AAA-034-50-D4a: A hard gel after 72 hours. The hand - dry up time is 3 minutes and the Bioskin - dry up time is 4.5 minutes.

[0570] AAA-034-50-D5a: Dries sticky; a harder gel after 72 hours. The hand - dry up time is 2 minutes and the Bioskin - dry up time is 4.5 minutes.

[0571] AAA-034-50-D6a: Dries sticky; solidified after 5.0 hours (gel). The hand - dry up time is 2.25 minutes and the Bioskin - dry up time is 7 minutes.

[0572] AAA-034-50-D7a: Solidified after 0.5 hours. The hand - dry up time is 3 minutes and the Bioskin - dry up time is 5.5 minutes. [0573] AAA-034-50-D8a: Remains fluid after 48 hours. The hand - dry up time is 4.5 minutes and the Bioskin - dry up time is 10 minutes.

[0574] AAA-034-50-D9a: Solidified after 18 hours. The hand - dry up time is 5 minutes and the Bioskin - dry up time is 9 minutes.

[0575] AAA-034-50-D10a: Solidified after 48 hours (gel). The hand - dry up time is 6 minutes and the Bioskin - dry up time is 15 minutes.

[0576] AAA-034-50-D1 la: Solidified after 48 hours (gel). The hand - dry up time is 4.5 minutes and the Bioskin - dry up time is 8 minutes.

[0577] AAA-034-50-D12a: Much thicker fluid after 48 hours. The hand - dry up time is 4 minutes and the Bioskin - dry up time is 10 minutes.

[0578] AAA-034-50-D13a: Solidified after 48 hours (gel). The hand - dry up time is 3 minutes and the Bioskin - dry up time is 8 minutes.

[0579] AAA-034-50-D14a: Remains fluid after 1 week; turned to soft gel after 2 weeks.

The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 7 minutes.

7.4 Example 4:

[0580] The mixture of branched hydride organopolysiloxane with different hydride density with AAA- 034-50- A2 and VS250 (250cSt linear vinyl terminal organopolysiloxane). See Table

4a.

[0581] Table 4a

;0582] All ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin (hand) and Bioskin.

[0583] The results of Example 4 are now described.

[0584] All compositions remained fluid after having been stored in a freezer.

[0585] AAA-034-50-Fla: The hand-dry up time is 2.5 minutes and the Bioskin-dry up time is 6 minutes.

[0586] AAA-034-50-F2a: The hand-dry up time is 4.5 minutes and the Bioskin-dry up time is 6.25 minutes.

[0587] AAA-034-50-F3a: The hand-dry up time is 4 minutes and the Bioskin-dry up time is

5 minutes.

[0588] AAA-034-50-F4a: The hand-dry up time is 6 minutes and the Bioskin-dry up time is

7 minutes.

[0589] AAA-034-50-F5a: The hand-dry up time is 9 minutes and the Bioskin-dry up time is

9 minutes.

7.5 Example 5:

[0590] Step lCb - The mixture of Step 1 A and the mixture of vinyl and hydride functional organopolysiloxanes in the diluent (Step 1 Pilot A - 55% OPM- 003 mixed with 45% PMX-1184 silicone fluid) AAA-034-50- A3 - with or without other functional excipients. See Table lCb.

[0591] Table lCb

[0592] In Step lCb, all ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin.

[0593] The results of Step lCb are now described:

[0594] AAA-034-50-Clb: The resulting film was thin and shiny, with a gritty texture. The film cured in 5 minutes and was not durable overnight.

[0595] AAA-034-50-C2b: The addition of the nylon did not help with the shine, and the texture was gritty. The film cured in 5 minutes, and showed slightly more durability than AAA- 034-50-Clb overnight.

[0596] AAA-034-50-C3b: Addition of the KSG-710 resulted in a thicker film (similar to that experienced with the addition of Nylon), but also resulted in somewhat less durability.

[0597] AAA-034-50-C4b: The results are similar to that of AAA-034-50-C2b and AAA-

034-50-C3b with regard to shine and texture. [0598] AAA-034-50-C5b: The addition of glycerol helps to smooth and soften the film somewhat, but the texture remains gritty.

[0599] AAA-034-50-C6b: The results are essentially the same as AAA-034-50-C5b.

[0600] AAA-034-50-C7b: The film is dry at 5 minutes. The resulting film is cohesive with still texture.

[0601 ] AAA-034-50-C8b: The film is dry at 4 minutes. The resulting film is flaky upon removal with still texture.

[0602] AAA-034-50-C9b: The film is dry at 6 minutes. The resulting film is cohesive with still texture.

[0603] AAA-034-50-C10b: The film is dry at 6 minutes. The resulting film is flaky upon removal with still texture, although somewhat softer than AAA-034-50-C7b, AAA-034-50-C8b, and AAA-034-50-C9b.

7.6 Example 6:

[0604] The mixture of heterobifunctional orgopolysiloxane with AAA-034-50- A3. See Table 2b.

[0605] Table 2b

[0606] All ingredients are added together in a glass vial and stirred with a vortex mixer.

[0607] For each of the compositions in Example 5, such compositions never set after 1 day, 7 days, and 1 month. All remained fluid after 1 month.

7.7 Example 7:

[0608] The mixture of vinyl organopolysiloxane with different size and structure with AAA-

034-50- A3 and XL-11 hydride. See Table 3b. [0609] Table 3b

[0610] All ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin (hand) and Bioskin.

[0611] The results of Example 7 are now described:

[0612] AAA-034-50-Dlb: Remains fluid after 1 week; turned to soft gel after 2 weeks. The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5.5 minutes.

[0613] AAA-034-50-D2b: A softer gel after 72 hours. The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5 minutes.

[0614] AAA-034-50-D3b: A soft gel after 72 hours. The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5.5 minutes.

[0615] AAA-034-50-D4b: A hard gel after 72 hours. The hand - dry up time is 3 minutes and the Bioskin - dry up time is 4.5 minutes.

[0616] AAA-034-50-D5b: Dries sticky; a harder gel after 72 hours. The hand - dry up time is 2 minutes and the Bioskin - dry up time is 4.5 minutes. [0617] AAA-034-50-D6b: Dries sticky; solidified after 5.0 hours (gel). The hand - dry up time is 2.25 minutes and the Bioskin - dry up time is 7 minutes.

[0618] AAA-034-50-D7b: Solidified after 0.5 hours. The hand - dry up time is 3 minutes and the Bioskin - dry up time is 5.5 minutes.

[0619] AAA-034-50-D8b: Remains fluid after 48 hours. The hand - dry up time is 4.5 minutes and the Bioskin - dry up time is 10 minutes.

[0620] AAA-034-50-D9b: Solidified after 18 hours. The hand - dry up time is 5 minutes and the Bioskin - dry up time is 9 minutes.

[0621] AAA-034-50-D10b: Solidified after 48 hours (gel). The hand - dry up time is 6 minutes and the Bioskin - dry up time is 15 minutes.

[0622] AAA-034-50-D1 lb: Solidified after 48 hours (gel). The hand - dry up time is 4.5 minutes and the Bioskin - dry up time is 8 minutes.

[0623] AAA-034-50-D12b: Much thicker fluid after 48 hours. The hand - dry up time is 4 minutes and the Bioskin - dry up time is 10 minutes.

[0624] AAA-034-50-D13b: Solidified after 48 hours (gel). The hand - dry up time is 3 minutes and the Bioskin - dry up time is 8 minutes.

[0625] AAA-034-50-D14b: Remains fluid after 1 week; turned to soft gel after 2 weeks.

The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 7 minutes.

7.8 Example 8:

[0626] The mixture of branched hydride organopoly siloxane with different hydride density with AAA-034-50- A3 and VS250 (250cSt linear vinyl terminal organopolysiloxane). See Table

4b.

[0627] Table 4b

[0628] All ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin (hand) and Bioskin.

[0629] The results of Example 8 are now described.

[0630] All compositions remained fluid after having been stored in a freezer.

[0631] AAA-034-50-Flb: The hand-dry up time is 2.5 minutes and the Bioskin-dry up time is 6 minutes.

[0632] AAA-034-50-F2b: The hand-dry up time is 4.5 minutes and the Bioskin-dry up time is 6.25 minutes.

[0633] AAA-034-50-F3b: The hand-dry up time is 4 minutes and the Bioskin-dry up time is

5 minutes.

[0634] AAA-034-50-F4b: The hand-dry up time is 6 minutes and the Bioskin-dry up time is

7 minutes.

[0635] AAA-034-50-F5b: The hand-dry up time is 9 minutes and the Bioskin-dry up time is

9 minutes.

7.9 Example 9:

[0636] A schematic representation of the solvent evaporation process is presented in Figure 3. In this method a water insoluble encapsulating agent is dissolved in a water immiscible volatile organic solvent, e.g., dichloromethane or chloroform or disiloxane or isododecane, into which the catalyst is also dissolved or dispersed. The resulting solution is added dropwise to a stirring aqueous solution having a suitable stabilizer to form small polymer droplets containing the encapsulated material. The core material may also be dispersed or dissolved in this aqueous solution instead. After a reasonable aging time, the droplets are hardened to produce the corresponding polymer microcapsules. This hardening process is accomplished by removal of the solvent from the polymer droplets either by solvent evaporation (by heat or reduced pressure), or by solvent extraction (with a third liquid which is a precipitant).

7.10 Example 10:

[0637] Step 1AA - Titration of Pt/hexadiene (Pt/HD) with additional hexadiene (HD) (with or without additional dilution from isododecane (IDD) diluent). See Table 1 A.

[0638] Table 5A

0639] In Step 1 AA, all ingredients for each composition are added together in a glass vial and stirred with a vortex mixer.

[0640] Step IBB - Mixture of unsaturated organopolymers and hydride functional organopolysiloxanes (OPM-001 containing 50-75% 1,4-butanediol diacrylate, 5-15%XL-ll, 5-

15% R812S), with Pt/HD titration from Step lAA. See Table 5B.

[0641] Table 5B

;0642] 9 in a glass vial and stirred with a vortex mixer. Composition AAA-034-50-BB2 comprising AAA-034-50- AA2 has the best stability and cure among the compositions listed in Table IB.

[0643] Step lCCa - The mixture of Step 1 AA and the mixture of unsaturated

organopolymers and hydride functional organopolysiloxanes in the diluent (Step 1 Pilot AA - 55% OPM-001 mixed with 45% IDD) with AAA-034-50- AA2 - with or without other functional excipients. See Table 5Ca. [0644] Table 5Ca

0645] In Step lCCa, all ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin.

[0646] The results of Step lCCa are now described:

[0647] AAA-034-50-CCla: The resulting film was thin and shiny, with a gritty texture. The film cured in 5 minutes.

[0648] AAA-034-50-CC2a: The film cured in 5 minutes.

[0649] AAA-034-50-CC3a: Addition ofthe KSG-710 resulted in a thicker film (similar to that experienced with the addition of Nylon), but also resulted in somewhat less durability. The film cured in 5 minutes.

[0650] AAA-034-50-CC4a: The results are similar to that of AAA-034-50-CC2a and AAA-

034-50-CC3a with regard to shine and texture. The film cured in 5 minutes.

[0651] AAA-034-50-CC5a: The addition of glycerol helps to smooth and soften the film somewhat, but the texture remains gritty. The film cured in 5 minutes.

[0652] AAA-034-50-CC6a: The results are essentially the same as AAA-034-50-CC5a. [0653] AAA-034-50-CC7a: The film is dry at 5 minutes. The resulting film is cohesive with still texture.

[0654] AAA-034-50-CC8a: The film is dry at 4 minutes. The resulting film is flaky upon removal with still texture.

[0655] AAA-034-50-CC9a: The film is dry at 6 minutes. The resulting film is cohesive with still texture.

[0656] AAA-034-50-CC10a: The film is dry at 6 minutes. The resulting film is flaky upon removal with still texture, although somewhat softer than AAA-034-50-CC7a, AAA-034-50- CC8a, and AAA-034-50-CC9a.

7.2 Example 11:

[0657] The mixture of heterobifunctional orgopolysiloxane with AAA-034-50- AA2. See Table 6a.

[0658] Table 6a

;0659] All ingredients are added together in a glass vial and stirred with a vortex mixer.

[0660] For each of the compositions in Example 11, such compositions never set after 1 day,

7 days, and 1 month. All remained fluid after 1 month.

7.3 Example 12:

[0661] The mixture of unsaturated organopolymers with different size and structure with AAA-034-50- AA2 and XL-11 hydride. See Table 7a.

[0662] Table 7a

Ό663] All ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin (hand) and Bioskin.

[0664] The results of Example 12 are now described:

[0665] AAA-034-50-DDla: Remains fluid after 1 week; turned to soft gel after 2 weeks.

The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5.5 minutes.

[0666] AAA-034-50-DD2a: A softer gel after 72 hours. The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5 minutes.

[0667] AAA-034-50-DD3a: A soft gel after 72 hours. The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 5.5 minutes.

[0668] AAA-034-50-DD4a: A hard gel after 72 hours. The hand - dry up time is 3 minutes and the Bioskin - dry up time is 4.5 minutes.

[0669] AAA-034-50-DD5a: Dries sticky; a harder gel after 72 hours. The hand - dry up time is 2 minutes and the Bioskin - dry up time is 4.5 minutes.

[0670] AAA-034-50-DD6a: Dries sticky; solidified after 5.0 hours (gel). The hand - dry up time is 2.25 minutes and the Bioskin - dry up time is 7 minutes. [0671] AAA-034-50-DD7a: Solidified after 0.5 hours. The hand - dry up time is 3 minutes and the Bioskin - dry up time is 5.5 minutes.

[0672] AAA-034-50-DD8a: Remains fluid after 48 hours. The hand - dry up time is 4.5 minutes and the Bioskin - dry up time is 10 minutes.

[0673] AAA-034-50-DD9a: Solidified after 18 hours. The hand - dry up time is 5 minutes and the Bioskin - dry up time is 9 minutes.

[0674] AAA-034-50-DD10a: Solidified after 48 hours (gel). The hand - dry up time is 6 minutes and the Bioskin - dry up time is 15 minutes.

[0675] AAA-034-50-DD1 la: Solidified after 48 hours (gel). The hand - dry up time is 4.5 minutes and the Bioskin - dry up time is 8 minutes.

[0676] AAA-034-50-DD12a: Much thicker fluid after 48 hours. The hand - dry up time is

4 minutes and the Bioskin - dry up time is 10 minutes.

[0677] AAA-034-50-DD13a: Solidified after 48 hours (gel). The hand - dry up time is 3 minutes and the Bioskin - dry up time is 8 minutes.

[0678] AAA-034-50-DD14a: Remains fluid after 1 week; turned to soft gel after 2 weeks.

The hand - dry up time is 2.5 minutes and the Bioskin - dry up time is 7 minutes.

7.4 Example 13:

[0679] The mixture of branched hydride organopolysiloxane with different hydride density with AAA-034-50- AA2 and VS250 (250cSt linear vinyl terminal organopolysiloxane). See Table 8a.

[0680] Table 8a

[0681] All ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin (hand) and Bioskin.

[0682] The results of Example 13 are now described.

[0683] All compositions remained fluid after having been stored in a freezer.

[0684] AAA-034-50-FFla: The hand-dry up time is 2.5 minutes and the Bioskin-dry up time is 6 minutes.

[0685] AAA-034-50-FF2a: The hand-dry up time is 4.5 minutes and the Bioskin-dry up time is 6.25 minutes.

[0686] AAA-034-50-FF3a: The hand-dry up time is 4 minutes and the Bioskin-dry up time is 5 minutes.

[0687] AAA-034-50-FF4a: The hand-dry up time is 6 minutes and the Bioskin-dry up time is 7 minutes.

[0688] AAA-034-50-FF5a: The hand-dry up time is 9 minutes and the Bioskin-dry up time is 9 minutes.

7.5 Example 14:

[0689] Step lCCb - The mixture of Step 1 A and the mixture of unsaturated organopolymers and hydride functional organopolysiloxanes in the diluent (Step 1 Pilot AA - 55% OPM- 001 mixed with 45% IDD) AAA-034-50- AA3 - with or without other functional excipients. See

Table lCCb.

[0690] Table lCCb

[0691] In Step 1CCb, all ingredients are added together in a glass vial and stirred with a vortex mixer and the resulting composition is applied to the skin.

[0692] The results of Step 1 CCb are now described:

[0693] AAA-034-50-CClb: The resulting film was thin and shiny, with a gritty texture. The film cured in 5 minutes and was not durable overnight.

[0694] AAA-034-50-CC2b: The addition of the nylon did not help with the shine, and the texture was gritty. The film cured in 5 minutes, and showed slightly more durability than AAA- 034-50-CClb overnight

[0695] AAA-034-50-CC3b: Addition of the KSG-710 resulted in a thicker film (similar to that experienced with the addition of Nylon), but also resulted in somewhat less durability.

[0696] AAA-034-50-CC4b: The results are similar to that of AAA-034-50-CC2b and AAA-

034-50-CC3b with regard to shine and texture. [0697] AAA-034-50-CC5b: The addition of glycerol helps to smooth and soften the film somewhat, but the texture remains gritty.

[0698] AAA-034-50-CC6b: The results are essentially the same as AAA-034-50-CC5b.

[0699] AAA-034-50-CC7b: The film is dry at 5 minutes. The resulting film is cohesive with still texture.

[0700] AAA-034-50-CC8b: The film is dry at 4 minutes. The resulting film is flaky upon removal with still texture.

[0701] AAA-034-50-CC9b: The film is dry at 6 minutes. The resulting film is cohesive with still texture.

[0702] AAA-034-50-CC10b: The film is dry at 6 minutes. The resulting film is flaky upon removal with still texture, although somewhat softer than AAA-034-50-CC7b, AAA-034-50- CC8b, and AAA-034-50-CC9b.

[0703] A schematic representation of the solvent evaporation process is presented in Figure 3. In this method a water insoluble encapsulating agent is dissolved in a water immiscible volatile organic solvent, e.g., dichloromethane or chloroform or disiloxane or isododecane, into which the catalyst is also dissolved or dispersed. The resulting solution is added dropwise to a stirring aqueous solution having a suitable stabilizer to form small polymer droplets containing the encapsulated material. The core material may also be dispersed or dissolved in this aqueous solution instead. After a reasonable aging time, the droplets are hardened to produce the corresponding polymer microcapsules. This hardening process is accomplished by removal of the solvent from the polymer droplets either by solvent evaporation (by heat or reduced pressure), or by solvent extraction (with a third liquid which is a precipitant).

[0704] A schematic representation of the spray drying process is presented in Figure 4. The catalyst to be encapsulated is added to the solvent (the ratio of catalyst to solvent may be optimized) and the mixture is homogenized. The encapsulating agent is added at this stage. This mixture is then fed into the spray dryer with circulating hot air and atomized, which can be made by different types of atomizers: pneumatic atomizer, pressure nozzle, spinning disk, fluid nozzle and sonic nozzle. The solvent is evaporated by hot air and the encapsulating agent encapsulates the catalyst. Small particles of the resulting microcapsules are deposited in the collection vessel where they are collected. [0705] While the present invention has been described with reference to exemplary embodiments, it is to be understood that the invention is not limited to the disclosed exemplary embodiments. The scope of the following claims is to be accorded the broadest interpretation so as to encompass all such modifications and equivalent structures and functions.